researchStatementLabel	assertType	objectURI	valueURI	label	homepage	source	dateAnnotated	whoAnnotated	evidence	evidenceRole	evidenceSource	evidenceType	evidenceStatement
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB	"05/16/2007 15:02:11
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/45	refute	http://www.ncbi.nlm.nih.gov/pubmed/9542477	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

polymorphic enzyme: NO

study duration: 4 days

population: 7 male, 3 female

ages:19-29

description:
Two randomized, double-blind, two-phase crossover studies were performed with use of an identical design, one with simvastatin (study I) and one with pravastatin (study II). In both studies, 10 healthy volunteers received either 200 mg itraconazole or placebo orally once a day for 4 days. On day 4, each subject ingested a single 40 mg dose of simvastatin (study I) or pravastatin (study II). Serum concentrations of simvastatin, simvastatin acid, pravastatin, HMG-CoA reductase inhibitors, itraconazole, and hydroxyitraconazole were determined. RESULTS: In study I, itraconazole increased the peak serum concentrations (Cmax) and the areas under the serum concentration-time curve [AUC(0-infinity)] of simvastatin and simvastatin acid at least tenfold (p < 0.001)."
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB	"05/29/2007 14:58:01
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/46	refute	http://www.ncbi.nlm.nih.gov/pubmed/9321523	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human enzymes in Supersomes

NADPH added: yes

inhibitor used: no

This study showed the formation of 3',5'-dihydrodiol, 3'-hydroxy, and 6'-exomethylene metabolites using a recombinant CYP3A4 system
"
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB	"05/29/2007 15:23:02
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/47	refute	http://www.ncbi.nlm.nih.gov/pubmed/15518608	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_Par_Grps	"Route of administration: oral

polymorphic enzyme: NO

study duration: 7 days simvastatin only, 8 days simva and clarithromycin

dose: .040g simvastatin 1xday
      .5g clarithromycin 2xday

population: 45 men and women (15 received simvastatin)

ages:18-60 

(mean AUC_i)/(mean AUC) = 219/22 

description: Clarithromycin significantly (p <0.001) increased the AUC (and C(max)) of all 3 statins, most markedly simvastatin ( approximately 10-fold increase in AUC)
"
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB	"05/16/2007 15:02:11
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/45	refute	http://www.ncbi.nlm.nih.gov/pubmed/9542477	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

polymorphic enzyme: NO

study duration: 4 days

population: 7 male, 3 female

ages:19-29

description:
Two randomized, double-blind, two-phase crossover studies were performed with use of an identical design, one with simvastatin (study I) and one with pravastatin (study II). In both studies, 10 healthy volunteers received either 200 mg itraconazole or placebo orally once a day for 4 days. On day 4, each subject ingested a single 40 mg dose of simvastatin (study I) or pravastatin (study II). Serum concentrations of simvastatin, simvastatin acid, pravastatin, HMG-CoA reductase inhibitors, itraconazole, and hydroxyitraconazole were determined. RESULTS: In study I, itraconazole increased the peak serum concentrations (Cmax) and the areas under the serum concentration-time curve [AUC(0-infinity)] of simvastatin and simvastatin acid at least tenfold (p < 0.001)."
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB	"05/29/2007 14:58:01
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/46	refute	http://www.ncbi.nlm.nih.gov/pubmed/9321523	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human enzymes in Supersomes

NADPH added: yes

inhibitor used: no

This study showed the formation of 3',5'-dihydrodiol, 3'-hydroxy, and 6'-exomethylene metabolites using a recombinant CYP3A4 system
"
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB	"05/29/2007 15:23:02
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/47	refute	http://www.ncbi.nlm.nih.gov/pubmed/15518608	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_Par_Grps	"Route of administration: oral

polymorphic enzyme: NO

study duration: 7 days simvastatin only, 8 days simva and clarithromycin

dose: .040g simvastatin 1xday
      .5g clarithromycin 2xday

population: 45 men and women (15 received simvastatin)

ages:18-60 

(mean AUC_i)/(mean AUC) = 219/22 

description: Clarithromycin significantly (p <0.001) increased the AUC (and C(max)) of all 3 statins, most markedly simvastatin ( approximately 10-fold increase in AUC)
"
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB	"05/16/2007 15:02:11
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/45	refute	http://www.ncbi.nlm.nih.gov/pubmed/9542477	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

polymorphic enzyme: NO

study duration: 4 days

population: 7 male, 3 female

ages:19-29

description:
Two randomized, double-blind, two-phase crossover studies were performed with use of an identical design, one with simvastatin (study I) and one with pravastatin (study II). In both studies, 10 healthy volunteers received either 200 mg itraconazole or placebo orally once a day for 4 days. On day 4, each subject ingested a single 40 mg dose of simvastatin (study I) or pravastatin (study II). Serum concentrations of simvastatin, simvastatin acid, pravastatin, HMG-CoA reductase inhibitors, itraconazole, and hydroxyitraconazole were determined. RESULTS: In study I, itraconazole increased the peak serum concentrations (Cmax) and the areas under the serum concentration-time curve [AUC(0-infinity)] of simvastatin and simvastatin acid at least tenfold (p < 0.001)."
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB	"05/29/2007 14:58:01
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/46	refute	http://www.ncbi.nlm.nih.gov/pubmed/9321523	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human enzymes in Supersomes

NADPH added: yes

inhibitor used: no

This study showed the formation of 3',5'-dihydrodiol, 3'-hydroxy, and 6'-exomethylene metabolites using a recombinant CYP3A4 system
"
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB	"05/29/2007 15:23:02
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/47	refute	http://www.ncbi.nlm.nih.gov/pubmed/15518608	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_Par_Grps	"Route of administration: oral

polymorphic enzyme: NO

study duration: 7 days simvastatin only, 8 days simva and clarithromycin

dose: .040g simvastatin 1xday
      .5g clarithromycin 2xday

population: 45 men and women (15 received simvastatin)

ages:18-60 

(mean AUC_i)/(mean AUC) = 219/22 

description: Clarithromycin significantly (p <0.001) increased the AUC (and C(max)) of all 3 statins, most markedly simvastatin ( approximately 10-fold increase in AUC)
"
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB	"05/16/2007 15:02:11
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/45	refute	http://www.ncbi.nlm.nih.gov/pubmed/9542477	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

polymorphic enzyme: NO

study duration: 4 days

population: 7 male, 3 female

ages:19-29

description:
Two randomized, double-blind, two-phase crossover studies were performed with use of an identical design, one with simvastatin (study I) and one with pravastatin (study II). In both studies, 10 healthy volunteers received either 200 mg itraconazole or placebo orally once a day for 4 days. On day 4, each subject ingested a single 40 mg dose of simvastatin (study I) or pravastatin (study II). Serum concentrations of simvastatin, simvastatin acid, pravastatin, HMG-CoA reductase inhibitors, itraconazole, and hydroxyitraconazole were determined. RESULTS: In study I, itraconazole increased the peak serum concentrations (Cmax) and the areas under the serum concentration-time curve [AUC(0-infinity)] of simvastatin and simvastatin acid at least tenfold (p < 0.001)."
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB	"05/29/2007 14:58:01
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/46	refute	http://www.ncbi.nlm.nih.gov/pubmed/9321523	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human enzymes in Supersomes

NADPH added: yes

inhibitor used: no

This study showed the formation of 3',5'-dihydrodiol, 3'-hydroxy, and 6'-exomethylene metabolites using a recombinant CYP3A4 system
"
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB	"05/29/2007 15:23:02
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/47	refute	http://www.ncbi.nlm.nih.gov/pubmed/15518608	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_Par_Grps	"Route of administration: oral

polymorphic enzyme: NO

study duration: 7 days simvastatin only, 8 days simva and clarithromycin

dose: .040g simvastatin 1xday
      .5g clarithromycin 2xday

population: 45 men and women (15 received simvastatin)

ages:18-60 

(mean AUC_i)/(mean AUC) = 219/22 

description: Clarithromycin significantly (p <0.001) increased the AUC (and C(max)) of all 3 statins, most markedly simvastatin ( approximately 10-fold increase in AUC)
"
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB	"05/16/2007 15:02:11
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/45	refute	http://www.ncbi.nlm.nih.gov/pubmed/9542477	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

polymorphic enzyme: NO

study duration: 4 days

population: 7 male, 3 female

ages:19-29

description:
Two randomized, double-blind, two-phase crossover studies were performed with use of an identical design, one with simvastatin (study I) and one with pravastatin (study II). In both studies, 10 healthy volunteers received either 200 mg itraconazole or placebo orally once a day for 4 days. On day 4, each subject ingested a single 40 mg dose of simvastatin (study I) or pravastatin (study II). Serum concentrations of simvastatin, simvastatin acid, pravastatin, HMG-CoA reductase inhibitors, itraconazole, and hydroxyitraconazole were determined. RESULTS: In study I, itraconazole increased the peak serum concentrations (Cmax) and the areas under the serum concentration-time curve [AUC(0-infinity)] of simvastatin and simvastatin acid at least tenfold (p < 0.001)."
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB	"05/29/2007 14:58:01
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/46	refute	http://www.ncbi.nlm.nih.gov/pubmed/9321523	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human enzymes in Supersomes

NADPH added: yes

inhibitor used: no

This study showed the formation of 3',5'-dihydrodiol, 3'-hydroxy, and 6'-exomethylene metabolites using a recombinant CYP3A4 system
"
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB	"05/29/2007 15:23:02
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/47	refute	http://www.ncbi.nlm.nih.gov/pubmed/15518608	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_Par_Grps	"Route of administration: oral

polymorphic enzyme: NO

study duration: 7 days simvastatin only, 8 days simva and clarithromycin

dose: .040g simvastatin 1xday
      .5g clarithromycin 2xday

population: 45 men and women (15 received simvastatin)

ages:18-60 

(mean AUC_i)/(mean AUC) = 219/22 

description: Clarithromycin significantly (p <0.001) increased the AUC (and C(max)) of all 3 statins, most markedly simvastatin ( approximately 10-fold increase in AUC)
"
nefazodone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006121	N-demethyldesacetyl-diltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2d6.html	DIKB				refute			
nefazodone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006121	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2d6.html	DIKB				refute			
nefazodone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006121	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2d6.html	DIKB				refute			
nefazodone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006121	desacetyldiltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2d6.html	DIKB				refute			
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB	"09/25/2007 07:52:24
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/66	refute	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"Enzyme system: human liver microsomes

NADPH added: yes
inhibitor used: itraconazole

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
itraconazole effected a dramatic decrease in the formation of both metabolites from both lactone and acid forms of atorvastatin"
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB	"09/25/2007 08:33:11
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/67	refute	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human CYP3A4 enzymes in insect microsomes

NADPH added: yes
substrate used: atorvastatin acid and lactone

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
This enzyme system catalyzed the above reactions with Km values ranging from 1.4micM/L for atorvastatin lactone--&gt;para-hydroxy-atorvastatin to 29.7micM/L for the atorvastatin acid--&gt;ortho-hydroxy-atorvastatin

"
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB	"09/27/2007 10:18:37
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/68	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/8a201c80-a51d-4c1c-963b-488c071908c0	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	&quot;In vitro studies suggest the importance of atorvastatin metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of atorvastatin in humans following coadministration with erythromycin, a known inhibitor of this isozyme&quot;
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB	"09/25/2007 07:52:24
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/66	refute	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"Enzyme system: human liver microsomes

NADPH added: yes
inhibitor used: itraconazole

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
itraconazole effected a dramatic decrease in the formation of both metabolites from both lactone and acid forms of atorvastatin"
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB	"09/25/2007 08:33:11
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/67	refute	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human CYP3A4 enzymes in insect microsomes

NADPH added: yes
substrate used: atorvastatin acid and lactone

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
This enzyme system catalyzed the above reactions with Km values ranging from 1.4micM/L for atorvastatin lactone--&gt;para-hydroxy-atorvastatin to 29.7micM/L for the atorvastatin acid--&gt;ortho-hydroxy-atorvastatin

"
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB	"09/27/2007 10:18:37
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/68	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/8a201c80-a51d-4c1c-963b-488c071908c0	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	&quot;In vitro studies suggest the importance of atorvastatin metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of atorvastatin in humans following coadministration with erythromycin, a known inhibitor of this isozyme&quot;
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB	"09/25/2007 07:52:24
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/66	refute	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"Enzyme system: human liver microsomes

NADPH added: yes
inhibitor used: itraconazole

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
itraconazole effected a dramatic decrease in the formation of both metabolites from both lactone and acid forms of atorvastatin"
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB	"09/25/2007 08:33:11
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/67	refute	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human CYP3A4 enzymes in insect microsomes

NADPH added: yes
substrate used: atorvastatin acid and lactone

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
This enzyme system catalyzed the above reactions with Km values ranging from 1.4micM/L for atorvastatin lactone--&gt;para-hydroxy-atorvastatin to 29.7micM/L for the atorvastatin acid--&gt;ortho-hydroxy-atorvastatin

"
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB	"09/27/2007 10:18:37
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/68	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/8a201c80-a51d-4c1c-963b-488c071908c0	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	&quot;In vitro studies suggest the importance of atorvastatin metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of atorvastatin in humans following coadministration with erythromycin, a known inhibitor of this isozyme&quot;
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB	"09/25/2007 07:52:24
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/66	refute	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"Enzyme system: human liver microsomes

NADPH added: yes
inhibitor used: itraconazole

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
itraconazole effected a dramatic decrease in the formation of both metabolites from both lactone and acid forms of atorvastatin"
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB	"09/25/2007 08:33:11
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/67	refute	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human CYP3A4 enzymes in insect microsomes

NADPH added: yes
substrate used: atorvastatin acid and lactone

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
This enzyme system catalyzed the above reactions with Km values ranging from 1.4micM/L for atorvastatin lactone--&gt;para-hydroxy-atorvastatin to 29.7micM/L for the atorvastatin acid--&gt;ortho-hydroxy-atorvastatin

"
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB	"09/27/2007 10:18:37
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/68	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/8a201c80-a51d-4c1c-963b-488c071908c0	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	&quot;In vitro studies suggest the importance of atorvastatin metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of atorvastatin in humans following coadministration with erythromycin, a known inhibitor of this isozyme&quot;
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB	"09/25/2007 07:52:24
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/66	refute	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"Enzyme system: human liver microsomes

NADPH added: yes
inhibitor used: itraconazole

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
itraconazole effected a dramatic decrease in the formation of both metabolites from both lactone and acid forms of atorvastatin"
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB	"09/25/2007 08:33:11
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/67	refute	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human CYP3A4 enzymes in insect microsomes

NADPH added: yes
substrate used: atorvastatin acid and lactone

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
This enzyme system catalyzed the above reactions with Km values ranging from 1.4micM/L for atorvastatin lactone--&gt;para-hydroxy-atorvastatin to 29.7micM/L for the atorvastatin acid--&gt;ortho-hydroxy-atorvastatin

"
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB	"09/27/2007 10:18:37
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/68	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/8a201c80-a51d-4c1c-963b-488c071908c0	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	&quot;In vitro studies suggest the importance of atorvastatin metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of atorvastatin in humans following coadministration with erythromycin, a known inhibitor of this isozyme&quot;
alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB	"06/26/2007 07:11:48
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/122	refute	http://www.ncbi.nlm.nih.gov/pubmed/12124305	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human enzymes in Supersomes

NADPH added: yes

inhibitor used: no

This study showed the formation of both 1'-OH-triazolam and  4-OH-triazolam in a recombinant cyp3a4 Supersome system"
alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB	"06/26/2007 07:39:29
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/123	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/b5e516a0-d0f4-4613-ab56-b1bb440fcb78	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
&quot;Alprazolam is extensively metabolized in humans, primarily by cytochrome P450 3A4 (CYP3A4), to two major metabolites in the plasma: 4-hydroxyalprazolam and alpha-hydroxyalprazolam.&quot;"
alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB	"07/02/2007 10:51:34
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/124	refute	http://www.ncbi.nlm.nih.gov/pubmed/10548453	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes (p. 394 `chemical inhibition`

inhibitor used: 

reaction: alprazolam --&gt; 4-OH-alprazolam
          alprazolam --&gt; 1'-OH-alprazolam

Quote: 

&quot;Co-incubation of human liver microsomes with the prototypic 3A4 inhibitor, troleandomycin, ( &gt; 50microM) resulted in no detectable formation of 1'-OH-alprazolam and 4-OH-alprazolam&quot;"
alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB	"06/26/2007 07:11:48
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/122	refute	http://www.ncbi.nlm.nih.gov/pubmed/12124305	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human enzymes in Supersomes

NADPH added: yes

inhibitor used: no

This study showed the formation of both 1'-OH-triazolam and  4-OH-triazolam in a recombinant cyp3a4 Supersome system"
alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB	"06/26/2007 07:39:29
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/123	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/b5e516a0-d0f4-4613-ab56-b1bb440fcb78	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
&quot;Alprazolam is extensively metabolized in humans, primarily by cytochrome P450 3A4 (CYP3A4), to two major metabolites in the plasma: 4-hydroxyalprazolam and alpha-hydroxyalprazolam.&quot;"
alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB	"07/02/2007 10:51:34
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/124	refute	http://www.ncbi.nlm.nih.gov/pubmed/10548453	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes (p. 394 `chemical inhibition`

inhibitor used: 

reaction: alprazolam --&gt; 4-OH-alprazolam
          alprazolam --&gt; 1'-OH-alprazolam

Quote: 

&quot;Co-incubation of human liver microsomes with the prototypic 3A4 inhibitor, troleandomycin, ( &gt; 50microM) resulted in no detectable formation of 1'-OH-alprazolam and 4-OH-alprazolam&quot;"
alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB	"06/26/2007 07:11:48
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/122	refute	http://www.ncbi.nlm.nih.gov/pubmed/12124305	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human enzymes in Supersomes

NADPH added: yes

inhibitor used: no

This study showed the formation of both 1'-OH-triazolam and  4-OH-triazolam in a recombinant cyp3a4 Supersome system"
alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB	"06/26/2007 07:39:29
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/123	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/b5e516a0-d0f4-4613-ab56-b1bb440fcb78	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
&quot;Alprazolam is extensively metabolized in humans, primarily by cytochrome P450 3A4 (CYP3A4), to two major metabolites in the plasma: 4-hydroxyalprazolam and alpha-hydroxyalprazolam.&quot;"
alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB	"07/02/2007 10:51:34
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/124	refute	http://www.ncbi.nlm.nih.gov/pubmed/10548453	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes (p. 394 `chemical inhibition`

inhibitor used: 

reaction: alprazolam --&gt; 4-OH-alprazolam
          alprazolam --&gt; 1'-OH-alprazolam

Quote: 

&quot;Co-incubation of human liver microsomes with the prototypic 3A4 inhibitor, troleandomycin, ( &gt; 50microM) resulted in no detectable formation of 1'-OH-alprazolam and 4-OH-alprazolam&quot;"
alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB	"06/26/2007 07:11:48
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/122	refute	http://www.ncbi.nlm.nih.gov/pubmed/12124305	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human enzymes in Supersomes

NADPH added: yes

inhibitor used: no

This study showed the formation of both 1'-OH-triazolam and  4-OH-triazolam in a recombinant cyp3a4 Supersome system"
alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB	"06/26/2007 07:39:29
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/123	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/b5e516a0-d0f4-4613-ab56-b1bb440fcb78	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
&quot;Alprazolam is extensively metabolized in humans, primarily by cytochrome P450 3A4 (CYP3A4), to two major metabolites in the plasma: 4-hydroxyalprazolam and alpha-hydroxyalprazolam.&quot;"
alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB	"07/02/2007 10:51:34
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/124	refute	http://www.ncbi.nlm.nih.gov/pubmed/10548453	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes (p. 394 `chemical inhibition`

inhibitor used: 

reaction: alprazolam --&gt; 4-OH-alprazolam
          alprazolam --&gt; 1'-OH-alprazolam

Quote: 

&quot;Co-incubation of human liver microsomes with the prototypic 3A4 inhibitor, troleandomycin, ( &gt; 50microM) resulted in no detectable formation of 1'-OH-alprazolam and 4-OH-alprazolam&quot;"
alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB	"06/26/2007 07:11:48
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/122	refute	http://www.ncbi.nlm.nih.gov/pubmed/12124305	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human enzymes in Supersomes

NADPH added: yes

inhibitor used: no

This study showed the formation of both 1'-OH-triazolam and  4-OH-triazolam in a recombinant cyp3a4 Supersome system"
alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB	"06/26/2007 07:39:29
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/123	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/b5e516a0-d0f4-4613-ab56-b1bb440fcb78	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
&quot;Alprazolam is extensively metabolized in humans, primarily by cytochrome P450 3A4 (CYP3A4), to two major metabolites in the plasma: 4-hydroxyalprazolam and alpha-hydroxyalprazolam.&quot;"
alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB	"07/02/2007 10:51:34
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/124	refute	http://www.ncbi.nlm.nih.gov/pubmed/10548453	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes (p. 394 `chemical inhibition`

inhibitor used: 

reaction: alprazolam --&gt; 4-OH-alprazolam
          alprazolam --&gt; 1'-OH-alprazolam

Quote: 

&quot;Co-incubation of human liver microsomes with the prototypic 3A4 inhibitor, troleandomycin, ( &gt; 50microM) resulted in no detectable formation of 1'-OH-alprazolam and 4-OH-alprazolam&quot;"
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	N-demethyldesacetyl-diltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB	"05/05/2009 17:43:52
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/159	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.2 Inhibitors of CYP2D6

Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine. Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) [see Warnings and Precautions (5.10)]."
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	N-demethyldesacetyl-diltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB	"06/20/2009 13:36:32
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/160	refute	http://www.ncbi.nlm.nih.gov/pubmed/12621382	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"

route of administration: oral

study duration: &quot;In study 2, there were 2 study periods separated by a least 4 days. In period 1, subjects received 40 mg duloxetine every day for 5 days. Blood samples for the measurement of duloxetine plasma concentrations were taken immediately before duloxetine dosing on days 3 4, and 5 and at 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours after dosing on day 5. In period 2, subjects received 20 mg paroxetine every day for 20 days Beginning on day 12 of this period, subjects again received duloxetine 40 mg every day for 5 days and samples were taken as in period 1, except that additional samples were taken 96 and 120 hours after the &amp;#64257;nal duloxetine dose. On the &amp;#64257;nal day of duloxetine dosing in each period, subjects fasted from midnigh until 4 hours after dosing. All doses of study drugs were supervised by study site personnel. &quot;

population: 12 male; 11 of 12 were of Chinese or Malay decent NOTE: only 10 completed the study

tested for known CYP450 polymorphisms? yes but exact genotype not mentioned only that all were genotypically CYP2D6 extensive metabolizers.

ages: 21 - 27

description:
&quot;Paroxetine increased the maximum plasma concentration of duloxetine and the area under the concentration-time curve at steady state 1.6-fold.&quot;

"
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB	"05/05/2009 17:43:52
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/159	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.2 Inhibitors of CYP2D6

Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine. Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) [see Warnings and Precautions (5.10)]."
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB	"06/20/2009 13:36:32
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/160	refute	http://www.ncbi.nlm.nih.gov/pubmed/12621382	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"

route of administration: oral

study duration: &quot;In study 2, there were 2 study periods separated by a least 4 days. In period 1, subjects received 40 mg duloxetine every day for 5 days. Blood samples for the measurement of duloxetine plasma concentrations were taken immediately before duloxetine dosing on days 3 4, and 5 and at 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours after dosing on day 5. In period 2, subjects received 20 mg paroxetine every day for 20 days Beginning on day 12 of this period, subjects again received duloxetine 40 mg every day for 5 days and samples were taken as in period 1, except that additional samples were taken 96 and 120 hours after the &amp;#64257;nal duloxetine dose. On the &amp;#64257;nal day of duloxetine dosing in each period, subjects fasted from midnigh until 4 hours after dosing. All doses of study drugs were supervised by study site personnel. &quot;

population: 12 male; 11 of 12 were of Chinese or Malay decent NOTE: only 10 completed the study

tested for known CYP450 polymorphisms? yes but exact genotype not mentioned only that all were genotypically CYP2D6 extensive metabolizers.

ages: 21 - 27

description:
&quot;Paroxetine increased the maximum plasma concentration of duloxetine and the area under the concentration-time curve at steady state 1.6-fold.&quot;

"
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB	"05/05/2009 17:43:52
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/159	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.2 Inhibitors of CYP2D6

Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine. Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) [see Warnings and Precautions (5.10)]."
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB	"06/20/2009 13:36:32
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/160	refute	http://www.ncbi.nlm.nih.gov/pubmed/12621382	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"

route of administration: oral

study duration: &quot;In study 2, there were 2 study periods separated by a least 4 days. In period 1, subjects received 40 mg duloxetine every day for 5 days. Blood samples for the measurement of duloxetine plasma concentrations were taken immediately before duloxetine dosing on days 3 4, and 5 and at 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours after dosing on day 5. In period 2, subjects received 20 mg paroxetine every day for 20 days Beginning on day 12 of this period, subjects again received duloxetine 40 mg every day for 5 days and samples were taken as in period 1, except that additional samples were taken 96 and 120 hours after the &amp;#64257;nal duloxetine dose. On the &amp;#64257;nal day of duloxetine dosing in each period, subjects fasted from midnigh until 4 hours after dosing. All doses of study drugs were supervised by study site personnel. &quot;

population: 12 male; 11 of 12 were of Chinese or Malay decent NOTE: only 10 completed the study

tested for known CYP450 polymorphisms? yes but exact genotype not mentioned only that all were genotypically CYP2D6 extensive metabolizers.

ages: 21 - 27

description:
&quot;Paroxetine increased the maximum plasma concentration of duloxetine and the area under the concentration-time curve at steady state 1.6-fold.&quot;

"
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	desacetyldiltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB	"05/05/2009 17:43:52
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/159	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.2 Inhibitors of CYP2D6

Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine. Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) [see Warnings and Precautions (5.10)]."
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	desacetyldiltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB	"06/20/2009 13:36:32
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/160	refute	http://www.ncbi.nlm.nih.gov/pubmed/12621382	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"

route of administration: oral

study duration: &quot;In study 2, there were 2 study periods separated by a least 4 days. In period 1, subjects received 40 mg duloxetine every day for 5 days. Blood samples for the measurement of duloxetine plasma concentrations were taken immediately before duloxetine dosing on days 3 4, and 5 and at 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours after dosing on day 5. In period 2, subjects received 20 mg paroxetine every day for 20 days Beginning on day 12 of this period, subjects again received duloxetine 40 mg every day for 5 days and samples were taken as in period 1, except that additional samples were taken 96 and 120 hours after the &amp;#64257;nal duloxetine dose. On the &amp;#64257;nal day of duloxetine dosing in each period, subjects fasted from midnigh until 4 hours after dosing. All doses of study drugs were supervised by study site personnel. &quot;

population: 12 male; 11 of 12 were of Chinese or Malay decent NOTE: only 10 completed the study

tested for known CYP450 polymorphisms? yes but exact genotype not mentioned only that all were genotypically CYP2D6 extensive metabolizers.

ages: 21 - 27

description:
&quot;Paroxetine increased the maximum plasma concentration of duloxetine and the area under the concentration-time curve at steady state 1.6-fold.&quot;

"
nefazodone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp3a4.html	DIKB	"02/13/2010 09:12:03
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/175	refute	http://www.ncbi.nlm.nih.gov/pubmed/11872324	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: ketoconazole

reaction: nefazodone --&gt; OH-NEF and nefazodone --&gt; mCPP

Quote: 
Incubations of human liver microsomes with NEF and
the CYP3A4 inhibitor ketoconazole resulted in a concentration-dependent inhibition of the formation of mCPP and OH-NEF (Fig. 3).



"
nefazodone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp3a4.html	DIKB	"02/13/2010 09:12:03
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/175	refute	http://www.ncbi.nlm.nih.gov/pubmed/11872324	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: ketoconazole

reaction: nefazodone --&gt; OH-NEF and nefazodone --&gt; mCPP

Quote: 
Incubations of human liver microsomes with NEF and
the CYP3A4 inhibitor ketoconazole resulted in a concentration-dependent inhibition of the formation of mCPP and OH-NEF (Fig. 3).



"
nefazodone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp3a4.html	DIKB	"02/13/2010 09:12:03
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/175	refute	http://www.ncbi.nlm.nih.gov/pubmed/11872324	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: ketoconazole

reaction: nefazodone --&gt; OH-NEF and nefazodone --&gt; mCPP

Quote: 
Incubations of human liver microsomes with NEF and
the CYP3A4 inhibitor ketoconazole resulted in a concentration-dependent inhibition of the formation of mCPP and OH-NEF (Fig. 3).



"
nefazodone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp3a4.html	DIKB	"02/13/2010 09:12:03
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/175	refute	http://www.ncbi.nlm.nih.gov/pubmed/11872324	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: ketoconazole

reaction: nefazodone --&gt; OH-NEF and nefazodone --&gt; mCPP

Quote: 
Incubations of human liver microsomes with NEF and
the CYP3A4 inhibitor ketoconazole resulted in a concentration-dependent inhibition of the formation of mCPP and OH-NEF (Fig. 3).



"
nefazodone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp3a4.html	DIKB	"02/13/2010 09:12:03
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/175	refute	http://www.ncbi.nlm.nih.gov/pubmed/11872324	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: ketoconazole

reaction: nefazodone --&gt; OH-NEF and nefazodone --&gt; mCPP

Quote: 
Incubations of human liver microsomes with NEF and
the CYP3A4 inhibitor ketoconazole resulted in a concentration-dependent inhibition of the formation of mCPP and OH-NEF (Fig. 3).



"
modafinil_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00745	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/modafinil_substrate_of_cyp3a4.html	DIKB	"09/24/2009 12:45:45
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/187	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e16c26ad-7bc2-d155-3a5d-da83ad6492c8.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Drug-Drug Interactions:

Based on in vitro data, modafinil is metabolized partially by the 3A isoform subfamily of hepatic cytochrome P450 (CYP3A4). I"
modafinil_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00745	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/modafinil_substrate_of_cyp3a4.html	DIKB	"09/24/2009 12:45:45
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/187	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e16c26ad-7bc2-d155-3a5d-da83ad6492c8.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Drug-Drug Interactions:

Based on in vitro data, modafinil is metabolized partially by the 3A isoform subfamily of hepatic cytochrome P450 (CYP3A4). I"
modafinil_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00745	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/modafinil_substrate_of_cyp3a4.html	DIKB	"09/24/2009 12:45:45
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/187	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e16c26ad-7bc2-d155-3a5d-da83ad6492c8.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Drug-Drug Interactions:

Based on in vitro data, modafinil is metabolized partially by the 3A isoform subfamily of hepatic cytochrome P450 (CYP3A4). I"
modafinil_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00745	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/modafinil_substrate_of_cyp3a4.html	DIKB	"09/24/2009 12:45:45
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/187	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e16c26ad-7bc2-d155-3a5d-da83ad6492c8.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Drug-Drug Interactions:

Based on in vitro data, modafinil is metabolized partially by the 3A isoform subfamily of hepatic cytochrome P450 (CYP3A4). I"
modafinil_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00745	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/modafinil_substrate_of_cyp3a4.html	DIKB	"09/24/2009 12:45:45
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/187	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e16c26ad-7bc2-d155-3a5d-da83ad6492c8.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Drug-Drug Interactions:

Based on in vitro data, modafinil is metabolized partially by the 3A isoform subfamily of hepatic cytochrome P450 (CYP3A4). I"
lovastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00227	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lovastatin_substrate_of_cyp3a4.html	DIKB	"09/28/2007 14:01:54
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/192	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/d3620ebe-87e1-4a93-96cc-ff20ddbb30b2	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"&quot;Potent inhibitors of CYP3A4: Lovastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of cytochrome P450 3A4 (CYP3A4). When lovastatin is used with a potent inhibitor of CYP3A4, elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of lovastatin.&quot;
"
lovastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00227	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lovastatin_substrate_of_cyp3a4.html	DIKB	"10/29/2007 13:18:39
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/193	refute	http://www.ncbi.nlm.nih.gov/pubmed/8689812	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

study duration: 4 days pretreatment with 200mg oral itraconazole; a single, oral, 40mg dose of lovastatin on day 4

population: 12
male: 5
female: 7 (2 on contraceptive steroids)

ages: 20-29

AUC_i/AUC: 546/15 = &gt;36.4
NOTE: AUC of lovastatin w/ placebo could not be measured but was known to be &lt; 15ng/ml*h"
lovastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00227	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lovastatin_substrate_of_cyp3a4.html	DIKB	"09/28/2007 14:01:54
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/192	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/d3620ebe-87e1-4a93-96cc-ff20ddbb30b2	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"&quot;Potent inhibitors of CYP3A4: Lovastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of cytochrome P450 3A4 (CYP3A4). When lovastatin is used with a potent inhibitor of CYP3A4, elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of lovastatin.&quot;
"
lovastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00227	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lovastatin_substrate_of_cyp3a4.html	DIKB	"10/29/2007 13:18:39
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/193	refute	http://www.ncbi.nlm.nih.gov/pubmed/8689812	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

study duration: 4 days pretreatment with 200mg oral itraconazole; a single, oral, 40mg dose of lovastatin on day 4

population: 12
male: 5
female: 7 (2 on contraceptive steroids)

ages: 20-29

AUC_i/AUC: 546/15 = &gt;36.4
NOTE: AUC of lovastatin w/ placebo could not be measured but was known to be &lt; 15ng/ml*h"
lovastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00227	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lovastatin_substrate_of_cyp3a4.html	DIKB	"09/28/2007 14:01:54
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/192	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/d3620ebe-87e1-4a93-96cc-ff20ddbb30b2	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"&quot;Potent inhibitors of CYP3A4: Lovastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of cytochrome P450 3A4 (CYP3A4). When lovastatin is used with a potent inhibitor of CYP3A4, elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of lovastatin.&quot;
"
lovastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00227	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lovastatin_substrate_of_cyp3a4.html	DIKB	"10/29/2007 13:18:39
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/193	refute	http://www.ncbi.nlm.nih.gov/pubmed/8689812	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

study duration: 4 days pretreatment with 200mg oral itraconazole; a single, oral, 40mg dose of lovastatin on day 4

population: 12
male: 5
female: 7 (2 on contraceptive steroids)

ages: 20-29

AUC_i/AUC: 546/15 = &gt;36.4
NOTE: AUC of lovastatin w/ placebo could not be measured but was known to be &lt; 15ng/ml*h"
lovastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00227	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lovastatin_substrate_of_cyp3a4.html	DIKB	"09/28/2007 14:01:54
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/192	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/d3620ebe-87e1-4a93-96cc-ff20ddbb30b2	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"&quot;Potent inhibitors of CYP3A4: Lovastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of cytochrome P450 3A4 (CYP3A4). When lovastatin is used with a potent inhibitor of CYP3A4, elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of lovastatin.&quot;
"
lovastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00227	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lovastatin_substrate_of_cyp3a4.html	DIKB	"10/29/2007 13:18:39
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/193	refute	http://www.ncbi.nlm.nih.gov/pubmed/8689812	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

study duration: 4 days pretreatment with 200mg oral itraconazole; a single, oral, 40mg dose of lovastatin on day 4

population: 12
male: 5
female: 7 (2 on contraceptive steroids)

ages: 20-29

AUC_i/AUC: 546/15 = &gt;36.4
NOTE: AUC of lovastatin w/ placebo could not be measured but was known to be &lt; 15ng/ml*h"
lovastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00227	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lovastatin_substrate_of_cyp3a4.html	DIKB	"09/28/2007 14:01:54
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/192	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/d3620ebe-87e1-4a93-96cc-ff20ddbb30b2	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"&quot;Potent inhibitors of CYP3A4: Lovastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of cytochrome P450 3A4 (CYP3A4). When lovastatin is used with a potent inhibitor of CYP3A4, elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of lovastatin.&quot;
"
lovastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00227	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lovastatin_substrate_of_cyp3a4.html	DIKB	"10/29/2007 13:18:39
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/193	refute	http://www.ncbi.nlm.nih.gov/pubmed/8689812	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

study duration: 4 days pretreatment with 200mg oral itraconazole; a single, oral, 40mg dose of lovastatin on day 4

population: 12
male: 5
female: 7 (2 on contraceptive steroids)

ages: 20-29

AUC_i/AUC: 546/15 = &gt;36.4
NOTE: AUC of lovastatin w/ placebo could not be measured but was known to be &lt; 15ng/ml*h"
eszopiclone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_substrate_of_cyp3a4.html	DIKB	"09/23/2009 15:48:01
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/225	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes."
eszopiclone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_substrate_of_cyp3a4.html	DIKB	"09/23/2009 16:09:10
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/226	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Drugs That Inhibit CYP3A4 (Ketoconazole)

CYP3A4 is a major metabolic pathway for elimination of eszopiclone. The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days. Cmax and t1/2 were increased 1.4-fold and 1.3-fold, respectively. Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly."
eszopiclone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_substrate_of_cyp3a4.html	DIKB	"09/23/2009 15:48:01
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/225	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes."
eszopiclone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_substrate_of_cyp3a4.html	DIKB	"09/23/2009 16:09:10
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/226	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Drugs That Inhibit CYP3A4 (Ketoconazole)

CYP3A4 is a major metabolic pathway for elimination of eszopiclone. The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days. Cmax and t1/2 were increased 1.4-fold and 1.3-fold, respectively. Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly."
eszopiclone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_substrate_of_cyp3a4.html	DIKB	"09/23/2009 15:48:01
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/225	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes."
eszopiclone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_substrate_of_cyp3a4.html	DIKB	"09/23/2009 16:09:10
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/226	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Drugs That Inhibit CYP3A4 (Ketoconazole)

CYP3A4 is a major metabolic pathway for elimination of eszopiclone. The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days. Cmax and t1/2 were increased 1.4-fold and 1.3-fold, respectively. Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly."
eszopiclone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_substrate_of_cyp3a4.html	DIKB	"09/23/2009 15:48:01
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/225	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes."
eszopiclone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_substrate_of_cyp3a4.html	DIKB	"09/23/2009 16:09:10
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/226	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Drugs That Inhibit CYP3A4 (Ketoconazole)

CYP3A4 is a major metabolic pathway for elimination of eszopiclone. The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days. Cmax and t1/2 were increased 1.4-fold and 1.3-fold, respectively. Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly."
eszopiclone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_substrate_of_cyp3a4.html	DIKB	"09/23/2009 15:48:01
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/225	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes."
eszopiclone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_substrate_of_cyp3a4.html	DIKB	"09/23/2009 16:09:10
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/226	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Drugs That Inhibit CYP3A4 (Ketoconazole)

CYP3A4 is a major metabolic pathway for elimination of eszopiclone. The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days. Cmax and t1/2 were increased 1.4-fold and 1.3-fold, respectively. Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly."
escitalopram_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp3a4.html	DIKB	"06/12/2009 19:11:52
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/233	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

reaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram

Quote:

Chemical Inhibition of CT and DCT Biotransformation in
Microsomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by
ketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.
"
escitalopram_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp3a4.html	DIKB	"06/12/2009 19:11:52
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/233	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

reaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram

Quote:

Chemical Inhibition of CT and DCT Biotransformation in
Microsomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by
ketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.
"
escitalopram_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp3a4.html	DIKB	"06/12/2009 19:11:52
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/233	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

reaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram

Quote:

Chemical Inhibition of CT and DCT Biotransformation in
Microsomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by
ketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.
"
escitalopram_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp3a4.html	DIKB	"06/12/2009 19:11:52
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/233	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

reaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram

Quote:

Chemical Inhibition of CT and DCT Biotransformation in
Microsomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by
ketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.
"
escitalopram_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp3a4.html	DIKB	"06/12/2009 19:11:52
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/233	refute	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

reaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram

Quote:

Chemical Inhibition of CT and DCT Biotransformation in
Microsomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by
ketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.
"
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	N-demethyldesacetyl-diltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB	"05/15/2009 11:01:27
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/319	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/883b5d43-0339-7dc1-f775-93791fb9b978	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Pharmacokinetic-related Interactions

Clozapine is a substrate for many CYP 450 isozymes, in particular 1A2, 2D6, and 3A4. The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized. Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes."
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	N-demethyldesacetyl-diltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB	"06/20/2009 14:35:57
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/320	refute	http://www.ncbi.nlm.nih.gov/pubmed/11147928	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"
Route of administration: oral

study duration: three weeks

population: 17 patients stabilized on clozapine, eight of which received sertraline for an additional three weeks

ages: 29 - 55


Quote:

The effect of paroxetine or sertraline on steady-state plasma concentrations of clozapine and its major metabolites was studied in 17 patients with schizophrenia or schizoaffective disorder stabilized on clozapine therapy (200-400 mg/day). In order to treat negative symptomatology or concomitant depression, 9 patients received additional paroxetine (20-40mg/day) and 8 patients sertraline (50-100 mg/day). After 3 weeks of paroxetine administration, mean plasma concentrations of clozapine and norclozapine increased significantly by 31% (p&lt;0.01) and by 20% (p&lt;0.05), respectively, while levels of clozapine N-oxide remained almost unchanged. The mean plasma norclozapine/clozapine and clozapine N-oxide/clozapine ratios were not modified during paroxetine treatment. No significant changes in plasma concentrations of clozapine and its major metabolites were observed after 3 weeks of combined therapy with sertraline."
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB	"05/15/2009 11:01:27
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/319	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/883b5d43-0339-7dc1-f775-93791fb9b978	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Pharmacokinetic-related Interactions

Clozapine is a substrate for many CYP 450 isozymes, in particular 1A2, 2D6, and 3A4. The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized. Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes."
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB	"06/20/2009 14:35:57
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/320	refute	http://www.ncbi.nlm.nih.gov/pubmed/11147928	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"
Route of administration: oral

study duration: three weeks

population: 17 patients stabilized on clozapine, eight of which received sertraline for an additional three weeks

ages: 29 - 55


Quote:

The effect of paroxetine or sertraline on steady-state plasma concentrations of clozapine and its major metabolites was studied in 17 patients with schizophrenia or schizoaffective disorder stabilized on clozapine therapy (200-400 mg/day). In order to treat negative symptomatology or concomitant depression, 9 patients received additional paroxetine (20-40mg/day) and 8 patients sertraline (50-100 mg/day). After 3 weeks of paroxetine administration, mean plasma concentrations of clozapine and norclozapine increased significantly by 31% (p&lt;0.01) and by 20% (p&lt;0.05), respectively, while levels of clozapine N-oxide remained almost unchanged. The mean plasma norclozapine/clozapine and clozapine N-oxide/clozapine ratios were not modified during paroxetine treatment. No significant changes in plasma concentrations of clozapine and its major metabolites were observed after 3 weeks of combined therapy with sertraline."
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB	"05/15/2009 11:01:27
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/319	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/883b5d43-0339-7dc1-f775-93791fb9b978	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Pharmacokinetic-related Interactions

Clozapine is a substrate for many CYP 450 isozymes, in particular 1A2, 2D6, and 3A4. The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized. Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes."
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB	"06/20/2009 14:35:57
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/320	refute	http://www.ncbi.nlm.nih.gov/pubmed/11147928	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"
Route of administration: oral

study duration: three weeks

population: 17 patients stabilized on clozapine, eight of which received sertraline for an additional three weeks

ages: 29 - 55


Quote:

The effect of paroxetine or sertraline on steady-state plasma concentrations of clozapine and its major metabolites was studied in 17 patients with schizophrenia or schizoaffective disorder stabilized on clozapine therapy (200-400 mg/day). In order to treat negative symptomatology or concomitant depression, 9 patients received additional paroxetine (20-40mg/day) and 8 patients sertraline (50-100 mg/day). After 3 weeks of paroxetine administration, mean plasma concentrations of clozapine and norclozapine increased significantly by 31% (p&lt;0.01) and by 20% (p&lt;0.05), respectively, while levels of clozapine N-oxide remained almost unchanged. The mean plasma norclozapine/clozapine and clozapine N-oxide/clozapine ratios were not modified during paroxetine treatment. No significant changes in plasma concentrations of clozapine and its major metabolites were observed after 3 weeks of combined therapy with sertraline."
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	desacetyldiltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB	"05/15/2009 11:01:27
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/319	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/883b5d43-0339-7dc1-f775-93791fb9b978	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Pharmacokinetic-related Interactions

Clozapine is a substrate for many CYP 450 isozymes, in particular 1A2, 2D6, and 3A4. The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized. Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes."
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	desacetyldiltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB	"06/20/2009 14:35:57
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/320	refute	http://www.ncbi.nlm.nih.gov/pubmed/11147928	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"
Route of administration: oral

study duration: three weeks

population: 17 patients stabilized on clozapine, eight of which received sertraline for an additional three weeks

ages: 29 - 55


Quote:

The effect of paroxetine or sertraline on steady-state plasma concentrations of clozapine and its major metabolites was studied in 17 patients with schizophrenia or schizoaffective disorder stabilized on clozapine therapy (200-400 mg/day). In order to treat negative symptomatology or concomitant depression, 9 patients received additional paroxetine (20-40mg/day) and 8 patients sertraline (50-100 mg/day). After 3 weeks of paroxetine administration, mean plasma concentrations of clozapine and norclozapine increased significantly by 31% (p&lt;0.01) and by 20% (p&lt;0.05), respectively, while levels of clozapine N-oxide remained almost unchanged. The mean plasma norclozapine/clozapine and clozapine N-oxide/clozapine ratios were not modified during paroxetine treatment. No significant changes in plasma concentrations of clozapine and its major metabolites were observed after 3 weeks of combined therapy with sertraline."
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB				support			
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB				support			
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB				support			
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB				support			
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB				support			
nefazodone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006121	N-demethyldesacetyl-diltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2d6.html	DIKB	02/12/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/50	support	http://www.ncbi.nlm.nih.gov/pubmed/11872324	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid for CYP1A2 and CYP2D6; recombinant human enzymes in baculovirus-infected insect cells for CYP2C8, CYP2C9, and CYP2C19
NADPH added:yes

inhibitor used: no

When NEF or OH-NEF was incubated with microsomes from cells transfected with human cDNA for one of CYP1A1, CYP1A2, CYP2A6, CYP2D6, CYP3A4, CYP2C8, CYP2C9 arg, CYP2C9 cys, or CYP2C19, metabolite formation was seen with the CYP3A4 incubations only (Table 4)."
nefazodone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006121	N-demethyldesacetyl-diltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2d6.html	DIKB	"02/12/2010 13:56:37
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/51	support	http://www.ncbi.nlm.nih.gov/pubmed/11872324	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: quinidine

reaction: nefazodone --&gt; OH-NEF ; nefazodone --&gt; mCPP

Quote: 
Incubations of human liver microsomes with NEF and the CYP3A4 inhibitor ketoconazole resulted in a concentration-dependent inhibition of the formation of mCPP and OH-NEF (Fig. 3). Incubations of human liver microsomes with NEF and the CYP2D6 inhibitor quinidine did not affect the production of OH-NEF and mCPP. Incubations of OH-NEF with the CYP3A4 inhibitor ketoconazole resulted in the inhibition of metabolite formation, and incubations with the CYP2D6 inhibitor quinidine did not, similar to what was found with NEF metabolism (data not presented).



"
nefazodone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006121	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2d6.html	DIKB	02/12/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/50	support	http://www.ncbi.nlm.nih.gov/pubmed/11872324	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid for CYP1A2 and CYP2D6; recombinant human enzymes in baculovirus-infected insect cells for CYP2C8, CYP2C9, and CYP2C19
NADPH added:yes

inhibitor used: no

When NEF or OH-NEF was incubated with microsomes from cells transfected with human cDNA for one of CYP1A1, CYP1A2, CYP2A6, CYP2D6, CYP3A4, CYP2C8, CYP2C9 arg, CYP2C9 cys, or CYP2C19, metabolite formation was seen with the CYP3A4 incubations only (Table 4)."
nefazodone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006121	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2d6.html	DIKB	"02/12/2010 13:56:37
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/51	support	http://www.ncbi.nlm.nih.gov/pubmed/11872324	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: quinidine

reaction: nefazodone --&gt; OH-NEF ; nefazodone --&gt; mCPP

Quote: 
Incubations of human liver microsomes with NEF and the CYP3A4 inhibitor ketoconazole resulted in a concentration-dependent inhibition of the formation of mCPP and OH-NEF (Fig. 3). Incubations of human liver microsomes with NEF and the CYP2D6 inhibitor quinidine did not affect the production of OH-NEF and mCPP. Incubations of OH-NEF with the CYP3A4 inhibitor ketoconazole resulted in the inhibition of metabolite formation, and incubations with the CYP2D6 inhibitor quinidine did not, similar to what was found with NEF metabolism (data not presented).



"
nefazodone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006121	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2d6.html	DIKB	02/12/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/50	support	http://www.ncbi.nlm.nih.gov/pubmed/11872324	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid for CYP1A2 and CYP2D6; recombinant human enzymes in baculovirus-infected insect cells for CYP2C8, CYP2C9, and CYP2C19
NADPH added:yes

inhibitor used: no

When NEF or OH-NEF was incubated with microsomes from cells transfected with human cDNA for one of CYP1A1, CYP1A2, CYP2A6, CYP2D6, CYP3A4, CYP2C8, CYP2C9 arg, CYP2C9 cys, or CYP2C19, metabolite formation was seen with the CYP3A4 incubations only (Table 4)."
nefazodone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006121	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2d6.html	DIKB	"02/12/2010 13:56:37
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/51	support	http://www.ncbi.nlm.nih.gov/pubmed/11872324	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: quinidine

reaction: nefazodone --&gt; OH-NEF ; nefazodone --&gt; mCPP

Quote: 
Incubations of human liver microsomes with NEF and the CYP3A4 inhibitor ketoconazole resulted in a concentration-dependent inhibition of the formation of mCPP and OH-NEF (Fig. 3). Incubations of human liver microsomes with NEF and the CYP2D6 inhibitor quinidine did not affect the production of OH-NEF and mCPP. Incubations of OH-NEF with the CYP3A4 inhibitor ketoconazole resulted in the inhibition of metabolite formation, and incubations with the CYP2D6 inhibitor quinidine did not, similar to what was found with NEF metabolism (data not presented).



"
nefazodone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006121	desacetyldiltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2d6.html	DIKB	02/12/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/50	support	http://www.ncbi.nlm.nih.gov/pubmed/11872324	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid for CYP1A2 and CYP2D6; recombinant human enzymes in baculovirus-infected insect cells for CYP2C8, CYP2C9, and CYP2C19
NADPH added:yes

inhibitor used: no

When NEF or OH-NEF was incubated with microsomes from cells transfected with human cDNA for one of CYP1A1, CYP1A2, CYP2A6, CYP2D6, CYP3A4, CYP2C8, CYP2C9 arg, CYP2C9 cys, or CYP2C19, metabolite formation was seen with the CYP3A4 incubations only (Table 4)."
nefazodone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006121	desacetyldiltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2d6.html	DIKB	"02/12/2010 13:56:37
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/51	support	http://www.ncbi.nlm.nih.gov/pubmed/11872324	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: quinidine

reaction: nefazodone --&gt; OH-NEF ; nefazodone --&gt; mCPP

Quote: 
Incubations of human liver microsomes with NEF and the CYP3A4 inhibitor ketoconazole resulted in a concentration-dependent inhibition of the formation of mCPP and OH-NEF (Fig. 3). Incubations of human liver microsomes with NEF and the CYP2D6 inhibitor quinidine did not affect the production of OH-NEF and mCPP. Incubations of OH-NEF with the CYP3A4 inhibitor ketoconazole resulted in the inhibition of metabolite formation, and incubations with the CYP2D6 inhibitor quinidine did not, similar to what was found with NEF metabolism (data not presented).



"
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB				support			
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB				support			
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB				support			
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB				support			
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB				support			
alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB				support			
alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB				support			
alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB				support			
alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB				support			
alprazolam_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp3a4.html	DIKB				support			
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	N-demethyldesacetyl-diltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB				support			
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB				support			
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB				support			
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	desacetyldiltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB				support			
nefazodone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp3a4.html	DIKB				support			
nefazodone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp3a4.html	DIKB				support			
nefazodone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp3a4.html	DIKB				support			
nefazodone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp3a4.html	DIKB				support			
nefazodone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp3a4.html	DIKB				support			
modafinil_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00745	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/modafinil_substrate_of_cyp3a4.html	DIKB				support			
modafinil_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00745	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/modafinil_substrate_of_cyp3a4.html	DIKB				support			
modafinil_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00745	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/modafinil_substrate_of_cyp3a4.html	DIKB				support			
modafinil_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00745	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/modafinil_substrate_of_cyp3a4.html	DIKB				support			
modafinil_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00745	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/modafinil_substrate_of_cyp3a4.html	DIKB				support			
lovastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00227	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lovastatin_substrate_of_cyp3a4.html	DIKB				support			
lovastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00227	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lovastatin_substrate_of_cyp3a4.html	DIKB				support			
lovastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00227	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lovastatin_substrate_of_cyp3a4.html	DIKB				support			
lovastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00227	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lovastatin_substrate_of_cyp3a4.html	DIKB				support			
lovastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00227	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lovastatin_substrate_of_cyp3a4.html	DIKB				support			
eszopiclone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_substrate_of_cyp3a4.html	DIKB				support			
eszopiclone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_substrate_of_cyp3a4.html	DIKB				support			
eszopiclone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_substrate_of_cyp3a4.html	DIKB				support			
eszopiclone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_substrate_of_cyp3a4.html	DIKB				support			
eszopiclone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_substrate_of_cyp3a4.html	DIKB				support			
escitalopram_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp3a4.html	DIKB				support			
escitalopram_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp3a4.html	DIKB				support			
escitalopram_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp3a4.html	DIKB				support			
escitalopram_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp3a4.html	DIKB				support			
escitalopram_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp3a4.html	DIKB				support			
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	N-demethyldesacetyl-diltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB				support			
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB				support			
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB				support			
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	desacetyldiltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB				support			
voriconazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_substrate_of_cyp3a4.html	DIKB				support			
voriconazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_substrate_of_cyp3a4.html	DIKB				support			
voriconazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_substrate_of_cyp3a4.html	DIKB				support			
voriconazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_substrate_of_cyp3a4.html	DIKB				support			
voriconazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_substrate_of_cyp3a4.html	DIKB				support			
clozapine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp3a4.html	DIKB				support			
clozapine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp3a4.html	DIKB				support			
clozapine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp3a4.html	DIKB				support			
clozapine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp3a4.html	DIKB				support			
clozapine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp3a4.html	DIKB				support			
escitalopram_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006121	N-demethyldesacetyl-diltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp2d6.html	DIKB				support			
escitalopram_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006121	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp2d6.html	DIKB				support			
escitalopram_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006121	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp2d6.html	DIKB				support			
escitalopram_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006121	desacetyldiltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp2d6.html	DIKB				support			
rabeprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01129	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rabeprazole_substrate_of_cyp3a4.html	DIKB				support			
rabeprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01129	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rabeprazole_substrate_of_cyp3a4.html	DIKB				support			
rabeprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01129	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rabeprazole_substrate_of_cyp3a4.html	DIKB				support			
rabeprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01129	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rabeprazole_substrate_of_cyp3a4.html	DIKB				support			
rabeprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01129	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rabeprazole_substrate_of_cyp3a4.html	DIKB				support			
risperidone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00734	http://purl.obolibrary.org/obo/PR_000006121	N-demethyldesacetyl-diltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/risperidone_substrate_of_cyp2d6.html	DIKB				support			
risperidone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00734	http://purl.obolibrary.org/obo/PR_000006121	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/risperidone_substrate_of_cyp2d6.html	DIKB				support			
risperidone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00734	http://purl.obolibrary.org/obo/PR_000006121	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/risperidone_substrate_of_cyp2d6.html	DIKB				support			
risperidone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00734	http://purl.obolibrary.org/obo/PR_000006121	desacetyldiltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/risperidone_substrate_of_cyp2d6.html	DIKB				support			
pantoprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00213	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/pantoprazole_substrate_of_cyp3a4.html	DIKB				support			
pantoprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00213	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/pantoprazole_substrate_of_cyp3a4.html	DIKB				support			
pantoprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00213	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/pantoprazole_substrate_of_cyp3a4.html	DIKB				support			
pantoprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00213	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/pantoprazole_substrate_of_cyp3a4.html	DIKB				support			
pantoprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00213	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/pantoprazole_substrate_of_cyp3a4.html	DIKB				support			
venlafaxine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006121	N-demethyldesacetyl-diltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_substrate_of_cyp2d6.html	DIKB				support			
venlafaxine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006121	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_substrate_of_cyp2d6.html	DIKB				support			
venlafaxine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006121	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_substrate_of_cyp2d6.html	DIKB				support			
venlafaxine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006121	desacetyldiltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_substrate_of_cyp2d6.html	DIKB				support			
aripiprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp3a4.html	DIKB				support			
aripiprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp3a4.html	DIKB				support			
aripiprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp3a4.html	DIKB				support			
aripiprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp3a4.html	DIKB				support			
aripiprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp3a4.html	DIKB				support			
clarithromycin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006130	reduced-haloperidol	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_substrate_of_cyp3a4.html	DIKB				support			
clarithromycin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_substrate_of_cyp3a4.html	DIKB				support			
clarithromycin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_substrate_of_cyp3a4.html	DIKB				support			
clarithromycin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-lovastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_substrate_of_cyp3a4.html	DIKB				support			
clarithromycin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006130	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_substrate_of_cyp3a4.html	DIKB				support			
perphenazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006121	N-demethyldesacetyl-diltiazem	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_substrate_of_cyp2d6.html	DIKB				support			
perphenazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006121	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_substrate_of_cyp2d6.html	DIKB				support			
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB				refute			
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB				refute			
tamoxifen_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00675	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/tamoxifen_substrate_of_cyp2d6.html	DIKB				refute			
aripiprazole_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2d6.html	DIKB				refute			
venlafaxine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_substrate_of_cyp2d6.html	DIKB				refute			
ziprasidone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_substrate_of_cyp2d6.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/657	refute	http://www.ncbi.nlm.nih.gov/pubmed/10771452	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"

Enzyme system: For CYP1A2 - recombinant CYP450 enzymes expressed in an human lymphoblastoid cell system. For CYP2C9, 2C19, and 2D6 - recombinant CYP450 enzymes expressed in insect cells

NADPH added: yes

reaction: 1) ziprasidone --&gt; ziprasidone sulphoxide 
          2) ziprasidone --&gt; ziprasidone sulphone 

Quote: 
&quot;The ability of specific CYP isoforms to metabolize
ziprasidone was determined using recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. H.p.l.c.-radioactivity profiles of ziprasidone metabolites following incubation of [14C]-ziprasidone or [3H]-ziprasidone with CYP3A4 are shown in Figure 5(a) and (b), respectively. CYP3A4 catalysed the formation of the N-dealkylated metabolite (M5), as well as ziprasidone sulphone (M8) and ziprasidone sulphoxide (M10). These oxidative metabolites were not detected in incubations containing recombinant CYP1A2, CYP2C9, CYP2C19 or CYP2D6.&quot;

"
atorvastatin_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp2d6.html	DIKB	"01/14/2008 12:55:21
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/786	refute	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human CYP2D6 enzymes in insect microsomes

NADPH added: yes
substrate used: atorvastatin acid and lactone

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
This enzyme system FAILED TO catalyze the above reactions to any measurable extent "
clarithromycin_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_substrate_of_cyp2d6.html	DIKB	"01/14/2008 13:20:24
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/824	refute	http://www.ncbi.nlm.nih.gov/pubmed/9152603	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes
NADPH added: yes

inhibitor used: quinidine
reaction:
clarithromycin --&gt; 14-(R)-hydroxylase-clarithromycin clarithromycin --&gt; 14-N-demethylase-clarithromycin

description: clarithromycin oxidative metabolism was only very slightly affected by the addition of the selective inhibitor"
escitalopram_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp2d6.html	DIKB				refute			
nefazodone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2d6.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/879	refute	http://www.ncbi.nlm.nih.gov/pubmed/11872324	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid for CYP1A2 and CYP2D6; recombinant human enzymes in baculovirus-infected insect cells for CYP2C8, CYP2C9, and CYP2C19
NADPH added:yes

inhibitor used: no

When NEF or OH-NEF was incubated with microsomes from cells transfected with human cDNA for one of CYP1A1, CYP1A2, CYP2A6, CYP2D6, CYP3A4, CYP2C8, CYP2C9 arg, CYP2C9 cys, or CYP2C19, metabolite formation was seen with the CYP3A4 incubations only (Table 4)."
nefazodone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2d6.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/880	refute	http://www.ncbi.nlm.nih.gov/pubmed/11872324	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: quinidine

reaction: nefazodone --&gt; OH-NEF ; nefazodone --&gt; mCPP

Quote: 
Incubations of human liver microsomes with NEF and the CYP3A4 inhibitor ketoconazole resulted in a concentration-dependent inhibition of the formation of mCPP and OH-NEF (Fig. 3). Incubations of human liver microsomes with NEF and the CYP2D6 inhibitor quinidine did not affect the production of OH-NEF and mCPP. Incubations of OH-NEF with the CYP3A4 inhibitor ketoconazole resulted in the inhibition of metabolite formation, and incubations with the CYP2D6 inhibitor quinidine did not, similar to what was found with NEF metabolism (data not presented).



"
paroxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00715	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paroxetine_substrate_of_cyp2d6.html	DIKB				refute			
thioridazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00679	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/thioridazine_substrate_of_cyp2d6.html	DIKB				refute			
zaleplon_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00962	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zaleplon_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1142	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/71be4cb7-a42f-43be-9b9b-f090edb2fd21	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Paroxetine

Coadministration of a single dose of zaleplon 20 mg and paroxetine 20 mg daily for 7 days did not produce any interaction on psychomotor performance. Additionally, paroxetine did not alter the pharmacokinetics of zaleplon, reflecting the absence of a role of CYP2D6 in zaleplon's metabolism. 

"
olanzapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00334	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/olanzapine_substrate_of_cyp2d6.html	DIKB				refute			
risperidone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00734	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/risperidone_substrate_of_cyp2d6.html	DIKB				refute			
ranolazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00243	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ranolazine_substrate_of_cyp2d6.html	DIKB				refute			
mirtazapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp2d6.html	DIKB				refute			
cinacalcet_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_substrate_of_cyp2d6.html	DIKB				refute			
perphenazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_substrate_of_cyp2d6.html	DIKB				refute			
fluvoxamine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00176	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvoxamine_substrate_of_cyp2d6.html	DIKB				refute			
fluoxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00472	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluoxetine_substrate_of_cyp2d6.html	DIKB				refute			
clozapine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp3a4.html	DIKB				refute			
aripiprazole_substrate_of_cyp2b6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006116	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2b6.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/16	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
aripiprazole_substrate_of_cyp2b6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006116	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2b6.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/16	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
citalopram_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_substrate_of_cyp3a4.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/20	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Ketoconazole

Combined administration of citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram."
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB				refute			
celecoxib_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006120	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_substrate_of_cyp2c9.html	DIKB				refute			
celecoxib_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006120	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_substrate_of_cyp2c9.html	DIKB				refute			
celecoxib_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006120	clarithromycin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_substrate_of_cyp2c9.html	DIKB				refute			
voriconazole_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006118	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_substrate_of_cyp2c19.html	DIKB				refute			
voriconazole_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006118	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_substrate_of_cyp2c19.html	DIKB				refute			
quetiapine_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006102	alprazolam	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp1a2.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/136	refute	http://www.ncbi.nlm.nih.gov/pubmed/16390352	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid
NADPH added: not explicitly mentioned but assumed

inhibitor used: no

Quetiapine metabolites were not detected after 1-h incubations of quetiapine with microsomes from vector-control lymphoblastoid cell lines or those that expressed CYP1A2, CYP2C9, CYP2C19 or CYP2E1. In contrast, metabolite profles produced when quetiapine was incubated in human liver microsomes (Figure 2A) were similar to those produced by expressed CYP3A4 (Figure 2B). Quetiapine sulfoxide was the major metabolite formed during incubations with expressed CYP3A4."
quetiapine_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006102	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp1a2.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/136	refute	http://www.ncbi.nlm.nih.gov/pubmed/16390352	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid
NADPH added: not explicitly mentioned but assumed

inhibitor used: no

Quetiapine metabolites were not detected after 1-h incubations of quetiapine with microsomes from vector-control lymphoblastoid cell lines or those that expressed CYP1A2, CYP2C9, CYP2C19 or CYP2E1. In contrast, metabolite profles produced when quetiapine was incubated in human liver microsomes (Figure 2A) were similar to those produced by expressed CYP3A4 (Figure 2B). Quetiapine sulfoxide was the major metabolite formed during incubations with expressed CYP3A4."
quetiapine_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006102	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp1a2.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/136	refute	http://www.ncbi.nlm.nih.gov/pubmed/16390352	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid
NADPH added: not explicitly mentioned but assumed

inhibitor used: no

Quetiapine metabolites were not detected after 1-h incubations of quetiapine with microsomes from vector-control lymphoblastoid cell lines or those that expressed CYP1A2, CYP2C9, CYP2C19 or CYP2E1. In contrast, metabolite profles produced when quetiapine was incubated in human liver microsomes (Figure 2A) were similar to those produced by expressed CYP3A4 (Figure 2B). Quetiapine sulfoxide was the major metabolite formed during incubations with expressed CYP3A4."
quetiapine_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006102	clarithromycin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp1a2.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/136	refute	http://www.ncbi.nlm.nih.gov/pubmed/16390352	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid
NADPH added: not explicitly mentioned but assumed

inhibitor used: no

Quetiapine metabolites were not detected after 1-h incubations of quetiapine with microsomes from vector-control lymphoblastoid cell lines or those that expressed CYP1A2, CYP2C9, CYP2C19 or CYP2E1. In contrast, metabolite profles produced when quetiapine was incubated in human liver microsomes (Figure 2A) were similar to those produced by expressed CYP3A4 (Figure 2B). Quetiapine sulfoxide was the major metabolite formed during incubations with expressed CYP3A4."
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	zaleplon	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB				refute			
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	asenapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB				refute			
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	nefazodone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB				refute			
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	clarithromycin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB				refute			
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	desvenlafaxine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB				refute			
pantoprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00213	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/pantoprazole_substrate_of_cyp3a4.html	DIKB				refute			
alprazolam_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006102	alprazolam	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp1a2.html	DIKB	"01/14/2008 13:22:18
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/173	refute	http://www.ncbi.nlm.nih.gov/pubmed/10548453	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes

inhibitor used: alpha-napthoflavone

reaction: alprazolam --&gt; 4-OH-alprazolam
alprazolam --&gt; 1'-OH-alprazolam

Inhibition of CYP1A2 by in vitro selective inhibitor alpha-napthoflavone had no effect on the transformation of alprazolam to its two major metabolites

NOTE: the use of a NADPH generating system is inferred from paragraph 2 of p. 934 &quot;Alprazolam hydrozylase assay&quot; "
alprazolam_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006102	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp1a2.html	DIKB	"01/14/2008 13:22:18
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/173	refute	http://www.ncbi.nlm.nih.gov/pubmed/10548453	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes

inhibitor used: alpha-napthoflavone

reaction: alprazolam --&gt; 4-OH-alprazolam
alprazolam --&gt; 1'-OH-alprazolam

Inhibition of CYP1A2 by in vitro selective inhibitor alpha-napthoflavone had no effect on the transformation of alprazolam to its two major metabolites

NOTE: the use of a NADPH generating system is inferred from paragraph 2 of p. 934 &quot;Alprazolam hydrozylase assay&quot; "
alprazolam_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006102	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp1a2.html	DIKB	"01/14/2008 13:22:18
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/173	refute	http://www.ncbi.nlm.nih.gov/pubmed/10548453	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes

inhibitor used: alpha-napthoflavone

reaction: alprazolam --&gt; 4-OH-alprazolam
alprazolam --&gt; 1'-OH-alprazolam

Inhibition of CYP1A2 by in vitro selective inhibitor alpha-napthoflavone had no effect on the transformation of alprazolam to its two major metabolites

NOTE: the use of a NADPH generating system is inferred from paragraph 2 of p. 934 &quot;Alprazolam hydrozylase assay&quot; "
alprazolam_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006102	clarithromycin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp1a2.html	DIKB	"01/14/2008 13:22:18
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/173	refute	http://www.ncbi.nlm.nih.gov/pubmed/10548453	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes

inhibitor used: alpha-napthoflavone

reaction: alprazolam --&gt; 4-OH-alprazolam
alprazolam --&gt; 1'-OH-alprazolam

Inhibition of CYP1A2 by in vitro selective inhibitor alpha-napthoflavone had no effect on the transformation of alprazolam to its two major metabolites

NOTE: the use of a NADPH generating system is inferred from paragraph 2 of p. 934 &quot;Alprazolam hydrozylase assay&quot; "
fluvastatin_substrate_of_cyp2c8	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01095	http://purl.obolibrary.org/obo/PR_000006119	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvastatin_substrate_of_cyp2c8.html	DIKB				refute			
fluvastatin_substrate_of_cyp2c8	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01095	http://purl.obolibrary.org/obo/PR_000006119	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvastatin_substrate_of_cyp2c8.html	DIKB				refute			
aripiprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp3a4.html	DIKB				refute			
ziprasidone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_substrate_of_cyp3a4.html	DIKB				refute			
rabeprazole_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01129	http://purl.obolibrary.org/obo/PR_000006118	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rabeprazole_substrate_of_cyp2c19.html	DIKB				refute			
rabeprazole_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01129	http://purl.obolibrary.org/obo/PR_000006118	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rabeprazole_substrate_of_cyp2c19.html	DIKB				refute			
escitalopram_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006118	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp2c19.html	DIKB				refute			
escitalopram_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006118	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp2c19.html	DIKB				refute			
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB				refute			
sertraline_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01104	http://purl.obolibrary.org/obo/PR_000006118	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/sertraline_substrate_of_cyp2c19.html	DIKB				refute			
sertraline_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01104	http://purl.obolibrary.org/obo/PR_000006118	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/sertraline_substrate_of_cyp2c19.html	DIKB				refute			
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	zaleplon	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB				refute			
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	asenapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB				refute			
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	nefazodone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB				refute			
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	clarithromycin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB				refute			
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	desvenlafaxine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB				refute			
citalopram_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006118	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_substrate_of_cyp2c19.html	DIKB				refute			
citalopram_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006118	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_substrate_of_cyp2c19.html	DIKB				refute			
atorvastatin_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006120	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp2c9.html	DIKB	"01/14/2008 13:46:45
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/382	refute	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human CYP2C9 enzymes in insect microsomes

NADPH added: yes
substrate used: atorvastatin acid and lactone

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
This enzyme system FAILED TO catalyze the above reactions to any measurable extent "
atorvastatin_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006120	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp2c9.html	DIKB	"01/14/2008 13:46:45
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/382	refute	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human CYP2C9 enzymes in insect microsomes

NADPH added: yes
substrate used: atorvastatin acid and lactone

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
This enzyme system FAILED TO catalyze the above reactions to any measurable extent "
atorvastatin_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006120	clarithromycin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp2c9.html	DIKB	"01/14/2008 13:46:45
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/382	refute	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human CYP2C9 enzymes in insect microsomes

NADPH added: yes
substrate used: atorvastatin acid and lactone

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
This enzyme system FAILED TO catalyze the above reactions to any measurable extent "
quetiapine_substrate_of_cyp2e1	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006122	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp2e1.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/393	refute	http://www.ncbi.nlm.nih.gov/pubmed/16390352	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid
NADPH added: not explicitly mentioned but assumed

inhibitor used: no

Quetiapine metabolites were not detected after 1-h incubations of quetiapine with microsomes from vector-control lymphoblastoid cell lines or those that expressed CYP1A2, CYP2C9, CYP2C19 or CYP2E1. In contrast, metabolite profles produced when quetiapine was incubated in human liver microsomes (Figure 2A) were similar to those produced by expressed CYP3A4 (Figure 2B). Quetiapine sulfoxide was the major metabolite formed during incubations with expressed CYP3A4."
quetiapine_substrate_of_cyp2e1	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006122	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp2e1.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/393	refute	http://www.ncbi.nlm.nih.gov/pubmed/16390352	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid
NADPH added: not explicitly mentioned but assumed

inhibitor used: no

Quetiapine metabolites were not detected after 1-h incubations of quetiapine with microsomes from vector-control lymphoblastoid cell lines or those that expressed CYP1A2, CYP2C9, CYP2C19 or CYP2E1. In contrast, metabolite profles produced when quetiapine was incubated in human liver microsomes (Figure 2A) were similar to those produced by expressed CYP3A4 (Figure 2B). Quetiapine sulfoxide was the major metabolite formed during incubations with expressed CYP3A4."
mirtazapine_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006118	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp2c19.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/406	refute	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid cells
NADPH added:yes

inhibitor used: no

Table 2 shows that CYP2C19, CYP2B6, CYP2A6, AND CYP3E1 each contributed less than 1% to the formation of metabolites by the three metabolic pathways examined. NOTE: Formation of MIR-N+-glucuronide, a metabolite found in significant concentrations in humans, was not examined however, this metabolite is likely the product of the either the dirct glucuronidation of mirtazapine or a metabolite produced by the three pathways examined. "
mirtazapine_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006118	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp2c19.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/406	refute	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid cells
NADPH added:yes

inhibitor used: no

Table 2 shows that CYP2C19, CYP2B6, CYP2A6, AND CYP3E1 each contributed less than 1% to the formation of metabolites by the three metabolic pathways examined. NOTE: Formation of MIR-N+-glucuronide, a metabolite found in significant concentrations in humans, was not examined however, this metabolite is likely the product of the either the dirct glucuronidation of mirtazapine or a metabolite produced by the three pathways examined. "
perphenazine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_substrate_of_cyp3a4.html	DIKB				refute			
aripiprazole_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006120	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2c9.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/430	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
aripiprazole_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006120	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2c9.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/430	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
aripiprazole_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006120	clarithromycin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2c9.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/430	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. Aripiprazole also does not undergo direct glucuronidation. This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
fluvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01095	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvastatin_substrate_of_cyp3a4.html	DIKB				refute			
zafirlukast_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006120	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_substrate_of_cyp2c9.html	DIKB				refute			
zafirlukast_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006120	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_substrate_of_cyp2c9.html	DIKB				refute			
zafirlukast_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006120	clarithromycin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_substrate_of_cyp2c9.html	DIKB				refute			
atorvastatin_substrate_of_cyp1a1	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006101	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp1a1.html	DIKB	"01/14/2008 13:23:51
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/454	refute	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human CYP1A1 enzymes in insect microsomes

NADPH added: yes
substrate used: atorvastatin acid and lactone

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
This enzyme system FAILED TO catalyze the above reactions to any measurable extent "
atorvastatin_substrate_of_cyp1a1	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006101	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp1a1.html	DIKB	"01/14/2008 13:23:51
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/454	refute	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human CYP1A1 enzymes in insect microsomes

NADPH added: yes
substrate used: atorvastatin acid and lactone

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
This enzyme system FAILED TO catalyze the above reactions to any measurable extent "
clarithromycin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_substrate_of_cyp3a4.html	DIKB				refute			
mirtazapine_substrate_of_cyp2a6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006114	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp2a6.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/460	refute	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid cells
NADPH added:yes

inhibitor used: no

Table 2 shows that CYP2C19, CYP2B6, CYP2A6, AND CYP3E1 each contributed less than 1% to the formation of metabolites by the three metabolic pathways examined. NOTE: Formation of MIR-N+-glucuronide, a metabolite found in significant concentrations in humans, was not examined however, this metabolite is likely the product of the either the dirct glucuronidation of mirtazapine or a metabolite produced by the three pathways examined. "
mirtazapine_substrate_of_cyp2a6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006114	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp2a6.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/460	refute	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid cells
NADPH added:yes

inhibitor used: no

Table 2 shows that CYP2C19, CYP2B6, CYP2A6, AND CYP3E1 each contributed less than 1% to the formation of metabolites by the three metabolic pathways examined. NOTE: Formation of MIR-N+-glucuronide, a metabolite found in significant concentrations in humans, was not examined however, this metabolite is likely the product of the either the dirct glucuronidation of mirtazapine or a metabolite produced by the three pathways examined. "
diltiazem_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00343	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/diltiazem_substrate_of_cyp3a4.html	DIKB				refute			
quetiapine_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006118	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp2c19.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/469	refute	http://www.ncbi.nlm.nih.gov/pubmed/16390352	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid
NADPH added: not explicitly mentioned but assumed

inhibitor used: no

Quetiapine metabolites were not detected after 1-h incubations of quetiapine with microsomes from vector-control lymphoblastoid cell lines or those that expressed CYP1A2, CYP2C9, CYP2C19 or CYP2E1. In contrast, metabolite profles produced when quetiapine was incubated in human liver microsomes (Figure 2A) were similar to those produced by expressed CYP3A4 (Figure 2B). Quetiapine sulfoxide was the major metabolite formed during incubations with expressed CYP3A4."
quetiapine_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006118	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp2c19.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/469	refute	http://www.ncbi.nlm.nih.gov/pubmed/16390352	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid
NADPH added: not explicitly mentioned but assumed

inhibitor used: no

Quetiapine metabolites were not detected after 1-h incubations of quetiapine with microsomes from vector-control lymphoblastoid cell lines or those that expressed CYP1A2, CYP2C9, CYP2C19 or CYP2E1. In contrast, metabolite profles produced when quetiapine was incubated in human liver microsomes (Figure 2A) were similar to those produced by expressed CYP3A4 (Figure 2B). Quetiapine sulfoxide was the major metabolite formed during incubations with expressed CYP3A4."
rosuvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01098	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosuvastatin_substrate_of_cyp3a4.html	DIKB	"01/14/2008 13:14:22
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/492	refute	http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3249	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
&quot;Cytochrome P450 3A4: In vitro and in vivo data indicate that rosuvastatin clearance is not dependent on metabolism by cytochrome P450 3A4 to a clinically significant extent. This has been confirmed in studies with known cytochrome P450 3A4 inhibitors (ketoconazole, erythromycin, itraconazole).

Ketoconazole: Coadministration of ketoconazole (200 mg twice daily for 7 days) with rosuvastatin (80 mg) resulted in no change in plasma concentrations of rosuvastatin.

Erythromycin: Coadministration of erythromycin (500 mg four times daily for 7 days) with rosuvastatin (80 mg) decreased AUC and Cmax of rosuvastatin by 20% and 31%, respectively. These reductions are not considered clinically significant.&quot;"
tamoxifen_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00675	http://purl.obolibrary.org/obo/PR_000006121	zaleplon	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/tamoxifen_substrate_of_cyp2d6.html	DIKB				refute			
tamoxifen_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00675	http://purl.obolibrary.org/obo/PR_000006121	asenapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/tamoxifen_substrate_of_cyp2d6.html	DIKB				refute			
tamoxifen_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00675	http://purl.obolibrary.org/obo/PR_000006121	nefazodone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/tamoxifen_substrate_of_cyp2d6.html	DIKB				refute			
tamoxifen_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00675	http://purl.obolibrary.org/obo/PR_000006121	clarithromycin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/tamoxifen_substrate_of_cyp2d6.html	DIKB				refute			
tamoxifen_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00675	http://purl.obolibrary.org/obo/PR_000006121	desvenlafaxine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/tamoxifen_substrate_of_cyp2d6.html	DIKB				refute			
zolpidem_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00425	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zolpidem_substrate_of_cyp3a4.html	DIKB				refute			
ziprasidone_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006118	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_substrate_of_cyp2c19.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/533	refute	http://www.ncbi.nlm.nih.gov/pubmed/10771452	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"

Enzyme system: For CYP1A2 - recombinant CYP450 enzymes expressed in an human lymphoblastoid cell system. For CYP2C9, 2C19, and 2D6 - recombinant CYP450 enzymes expressed in insect cells

NADPH added: yes

reaction: 1) ziprasidone --&gt; ziprasidone sulphoxide 
          2) ziprasidone --&gt; ziprasidone sulphone 

Quote: 
&quot;The ability of specific CYP isoforms to metabolize
ziprasidone was determined using recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. H.p.l.c.-radioactivity profiles of ziprasidone metabolites following incubation of [14C]-ziprasidone or [3H]-ziprasidone with CYP3A4 are shown in Figure 5(a) and (b), respectively. CYP3A4 catalysed the formation of the N-dealkylated metabolite (M5), as well as ziprasidone sulphone (M8) and ziprasidone sulphoxide (M10). These oxidative metabolites were not detected in incubations containing recombinant CYP1A2, CYP2C9, CYP2C19 or CYP2D6.&quot;

"
ziprasidone_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006118	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_substrate_of_cyp2c19.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/533	refute	http://www.ncbi.nlm.nih.gov/pubmed/10771452	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"

Enzyme system: For CYP1A2 - recombinant CYP450 enzymes expressed in an human lymphoblastoid cell system. For CYP2C9, 2C19, and 2D6 - recombinant CYP450 enzymes expressed in insect cells

NADPH added: yes

reaction: 1) ziprasidone --&gt; ziprasidone sulphoxide 
          2) ziprasidone --&gt; ziprasidone sulphone 

Quote: 
&quot;The ability of specific CYP isoforms to metabolize
ziprasidone was determined using recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. H.p.l.c.-radioactivity profiles of ziprasidone metabolites following incubation of [14C]-ziprasidone or [3H]-ziprasidone with CYP3A4 are shown in Figure 5(a) and (b), respectively. CYP3A4 catalysed the formation of the N-dealkylated metabolite (M5), as well as ziprasidone sulphone (M8) and ziprasidone sulphoxide (M10). These oxidative metabolites were not detected in incubations containing recombinant CYP1A2, CYP2C9, CYP2C19 or CYP2D6.&quot;

"
mirtazapine_substrate_of_cyp2e1	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006122	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp2e1.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/618	refute	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid cells
NADPH added:yes

inhibitor used: no

Table 2 shows that CYP2C19, CYP2B6, CYP2A6, AND CYP3E1 each contributed less than 1% to the formation of metabolites by the three metabolic pathways examined. NOTE: Formation of MIR-N+-glucuronide, a metabolite found in significant concentrations in humans, was not examined however, this metabolite is likely the product of the either the dirct glucuronidation of mirtazapine or a metabolite produced by the three pathways examined. "
mirtazapine_substrate_of_cyp2e1	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006122	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp2e1.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/618	refute	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"Enzyme system: recombinant human enzymes in human lymphoblastoid cells
NADPH added:yes

inhibitor used: no

Table 2 shows that CYP2C19, CYP2B6, CYP2A6, AND CYP3E1 each contributed less than 1% to the formation of metabolites by the three metabolic pathways examined. NOTE: Formation of MIR-N+-glucuronide, a metabolite found in significant concentrations in humans, was not examined however, this metabolite is likely the product of the either the dirct glucuronidation of mirtazapine or a metabolite produced by the three pathways examined. "
aripiprazole_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006121	zaleplon	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2d6.html	DIKB				refute			
aripiprazole_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006121	asenapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2d6.html	DIKB				refute			
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/149	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/883b5d43-0339-7dc1-f775-93791fb9b978	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Pharmacokinetic-related Interactions

Clozapine is a substrate for many CYP 450 isozymes, in particular 1A2, 2D6, and 3A4. The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized. Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes."
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/150	support	http://www.ncbi.nlm.nih.gov/pubmed/11147928	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"
Route of administration: oral

study duration: three weeks

population: 17 patients stabilized on clozapine, eight of which received sertraline for an additional three weeks

ages: 29 - 55


Quote:

The effect of paroxetine or sertraline on steady-state plasma concentrations of clozapine and its major metabolites was studied in 17 patients with schizophrenia or schizoaffective disorder stabilized on clozapine therapy (200-400 mg/day). In order to treat negative symptomatology or concomitant depression, 9 patients received additional paroxetine (20-40mg/day) and 8 patients sertraline (50-100 mg/day). After 3 weeks of paroxetine administration, mean plasma concentrations of clozapine and norclozapine increased significantly by 31% (p&lt;0.01) and by 20% (p&lt;0.05), respectively, while levels of clozapine N-oxide remained almost unchanged. The mean plasma norclozapine/clozapine and clozapine N-oxide/clozapine ratios were not modified during paroxetine treatment. No significant changes in plasma concentrations of clozapine and its major metabolites were observed after 3 weeks of combined therapy with sertraline."
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/333	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.2 Inhibitors of CYP2D6

Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine. Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) [see Warnings and Precautions (5.10)]."
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/334	support	http://www.ncbi.nlm.nih.gov/pubmed/12621382	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"

route of administration: oral

study duration: &quot;In study 2, there were 2 study periods separated by a least 4 days. In period 1, subjects received 40 mg duloxetine every day for 5 days. Blood samples for the measurement of duloxetine plasma concentrations were taken immediately before duloxetine dosing on days 3 4, and 5 and at 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours after dosing on day 5. In period 2, subjects received 20 mg paroxetine every day for 20 days Beginning on day 12 of this period, subjects again received duloxetine 40 mg every day for 5 days and samples were taken as in period 1, except that additional samples were taken 96 and 120 hours after the &amp;#64257;nal duloxetine dose. On the &amp;#64257;nal day of duloxetine dosing in each period, subjects fasted from midnigh until 4 hours after dosing. All doses of study drugs were supervised by study site personnel. &quot;

population: 12 male; 11 of 12 were of Chinese or Malay decent NOTE: only 10 completed the study

tested for known CYP450 polymorphisms? yes but exact genotype not mentioned only that all were genotypically CYP2D6 extensive metabolizers.

ages: 21 - 27

description:
&quot;Paroxetine increased the maximum plasma concentration of duloxetine and the area under the concentration-time curve at steady state 1.6-fold.&quot;

"
tamoxifen_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00675	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/tamoxifen_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/503	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/407a372d-4448-4d53-afd4-eb0e74bbc336	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism

Tamoxifen is extensively metabolized after oral administration. N-desmethyl tamoxifen is the major metabolite found in patientsâ€™ plasma. The biological activity of N-desmethyl tamoxifen appears to be similar to that of tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. Tamoxifen is a substrate of cytochrome P-450 3A, 2C9 and 2D6, and an inhibitor of P-glycoprotein."
aripiprazole_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2d6.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/629	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Both CYP3A4 and CYP2D6 are responsible for aripiprazole metabolism. Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.

Ketoconazole and Other CYP3A4 Inhibitors

Coadministration of ketoconazole (200 mg/day for 14 days) with a 15 mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively. The effect of a higher ketoconazole dose (400 mg/day) has not been studied. When ketoconazole is given concomitantly with aripiprazole, the aripiprazole dose should be reduced to one-half of its normal dose. Other strong inhibitors of CYP3A4 (itraconazole) would be expected to have similar effects and need similar dose reductions; moderate inhibitors (erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the aripiprazole dose should be increased.

Quinidine and Other CYP2D6 Inhibitors

Coadministration of a 10 mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydro-aripiprazole, by 35%. Aripiprazole dose should be reduced to one-half of its normal dose when quinidine is given concomitantly with aripiprazole. Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be expected to have similar effects and should lead to similar dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, the aripiprazole dose should be increased. When adjunctive ABILIFY is administered to patients with Major Depressive Disorder, ABILIFY should be administered without dosage adjustment as specified in DOSAGE AND ADMINISTRATION (2.3).

Carbamazepine and Other CYP3A4 Inducers

Coadministration of carbamazepine (200 mg twice daily), a potent CYP3A4 inducer, with aripiprazole (30 mg/day) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole. When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled. Additional dose increases should be based on clinical evaluation. When carbamazepine is withdrawn from the combination therapy, the aripiprazole dose should be reduced."
venlafaxine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/645	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drugs that Inhibit Cytochrome P450 Isoenzymes

CYP2D6 Inhibitors: In vitro and in vivo studies indicate that venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6, the isoenzyme that is responsible for the genetic polymorphism seen in the metabolism of many antidepressants. Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism and venlafaxine. However, although imipramine partially inhibited the CYP2D6-mediated metabolism of venlafaxine, resulting in higher plasma concentrations of venlafaxine and lower plasma concentrations of ODV, the total concentration of active compounds (venlafaxine plus ODV) was not affected. Additionally, in a clinical study involving CYP2D6-poor and -extensive metabolizers, the total concentration of active compounds (venlafaxine plus ODV), was similar in the two metabolizer groups. Therefore, no dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor.

"
venlafaxine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/646	support	http://www.ncbi.nlm.nih.gov/pubmed/10192828	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: paroxetine

reaction: venlafaxine --&gt; O-desmethylvenlafaxine

Quote: 
&quot;All six SSRIs inhibited the formation of ODV with PX being the most potent and DES being the least potent (Table 3).&quot;

K_i for paroxetine vs O-desmethylvenlafaxine formation: 0.17micM"
venlafaxine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/647	support	http://www.ncbi.nlm.nih.gov/pubmed/10192828	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"

Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: quinidine

reaction: venlafaxine --&gt; O-desmethylvenlafaxine

Quote: 
&quot;All six SSRIs [including quinidine] inhibited the formation of ODV with PX being the most potent and DES being the least potent (Table 3).&quot;

K_i for quinidine vs O-desmethylvenlafaxine formation: 0.04micM"
ziprasidone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_substrate_of_cyp2d6.html	DIKB				support			
atorvastatin_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp2d6.html	DIKB				support			
clarithromycin_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_substrate_of_cyp2d6.html	DIKB				support			
escitalopram_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/834	support	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

reaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram

Quote:

Chemical Inhibition of CT and DCT Biotransformation in
Microsomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by
ketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.
"
nefazodone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01149	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/nefazodone_substrate_of_cyp2d6.html	DIKB				support			
paroxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00715	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paroxetine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1072	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/08320ea3-8f93-6f04-5d1c-f69af3eb5a81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
&quot;Paroxetine is extensively metabolized and the metabolites are considered to be inactive. Nonlinearity in pharmacokinetics is observed with increasing doses. Paroxetine metabolism is mediated in part by CYP2D6, and the metabolites are primarily excreted in the urine and to some extent in the feces.&quot;"
thioridazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00679	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/thioridazine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1118	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	thioridizine is listed in table 4 (p21) as a CYP2D6 substrate with a narrow therapeutic range
thioridazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00679	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/thioridazine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1119	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/56b3f4c2-52af-4947-b225-6808ae9f26f5	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
&quot;Drugs That Inhibit Cytochrome P450 2D6

In a study of 19 healthy male subjects, which included 6 slow and 13 rapid hydroxylators of debrisoquin, a single 25 mg oral dose of thioridazine produced a 2.4-fold higher Cmax and a 4.5-fold higher AUC for thioridazine in the slow hydroxylators compared to rapid hydroxylators. The rate of debrisoquin hydroxylation is felt to depend on the level of cytochrome P450 2D6 isozyme activity. Thus, this study suggests that drugs that inhibit P450 2D6 or the presence of reduced activity levels of this isozyme will produce elevated plasma levels of thioridazine. Therefore, the co-administration of drugs that inhibit P450 2D6 with thioridazine and the use of thioridazine in patients known to have reduced activity of P450 2D6 are contraindicated.&quot;"
zaleplon_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00962	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zaleplon_substrate_of_cyp2d6.html	DIKB				support			
olanzapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00334	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/olanzapine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1149	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/d5051fbc-846b-4946-82df-341fb1216341	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
&quot;Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. The magnitude of the impact of this factor is small in comparison to the overall variability between individuals, and therefore dose modification is not routinely recommended. When using ZYPREXA and fluoxetine in combination, also refer to the Drug Interactions section of the package insert for Symbyax.&quot;"
risperidone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00734	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/risperidone_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1189	support	http://www.ncbi.nlm.nih.gov/pubmed/7690693	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_CT_PK_Phenotype	"
route of administration: oral

study duration: single dose

population: 12 males, phenotyped using dextromethorphan (9 2D6 EMs, 2 PMs, 1 IM)

ages: 24 (SD:6) 

Quote:
The pharmacokinetics of a novel antipsychotic agent, risperidone, and the prolactin response were studied in 12 dextromethorphan-phenotyped healthy men after administration of 1 mg risperidone intravenously, intramuscularly, and orally. The formation of the equipotent major metabolite, 9-hydroxyrisperidone, exhibited CYP2D6-related polymorphism. The plasma area under the concentration-time curve from time zero to infinity ratio of 9-hydroxyrisperidone to risperidone averaged 3 (intravenous and intramuscular) and 6 (oral administration) in the extensive metabolizers and 0.2 in the poor metabolizers"
risperidone_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00734	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/risperidone_substrate_of_cyp2d6.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1190	support	http://www.ncbi.nlm.nih.gov/pubmed/10048600	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: not mentioned but acceptable methods assumed

inhibitor used: quinidine

reaction: risperidone 9-hydroxylation

NOTE: experiment used 100micM of risperidone which is likely well above C_max based on PMID 7690693

Quote: 
risperidone was incubated with human liver microsomes in the presence of different concentrations of   inhibitors of CYP enzymes. Both quinidine (inhibitor of CYP2D6) and ketoconazole (inhibitor of CYP3A) inhibited the formation of 9-hydroxyrisperidone in a concentration-dependent manner (Fig. 4).



"
ranolazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00243	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ranolazine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1218	support	http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10bd89e9-2d00-430c-8f55-81a37fed5fab	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
CYP2D6 Inhibitors

The potent CYP2D6 inhibitor, paroxetine (20 mg once daily), increases ranolazine concentrations 1.2-fold. No dose adjustment of Ranexa is required in patients treated with CYP2D6 inhibitors."
mirtazapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp2d6.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1317	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/31f48378-27db-424f-a4c5-82584a553c35	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
&quot;Mirtazapine is extensively metabolized after oral administration. Major pathways of biotransformation are demethylation and hydroxylation followed by glucuronide conjugation. In vitro data from human liver microsomes indicate that cytochrome 2D6 and 1A2 are involved in the formation of the 8-hydroxy metabolite of mirtazapine, whereas cytochrome 3A is considered to be responsible for the formation of the N-desmethyl and N-oxide metabolite.&quot;"
mirtazapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_substrate_of_cyp2d6.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1318	support	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: quinidine

reaction: mirtazapine 8-hydroxylation (25 and 250 micM) 

Quote: 
Incubations of MIR with human liver microsomes resulted in the formation of OHM, DMM, and MIR-N-
oxide (Fig. 1). Quinidine (5 micM) and alpha-naphthoflavone (0.5 micM),specific inhibitors of CYP2D6 and CYP1A2, respectively, partially inhibited MIR-hydroxylation. Ketoconazole (1 micM), a specific inhibitor of CYP3A4, inhibited MIR-N-demethylation and MIR-N-oxidation. 

NOTE: lowest MIR concentration tested was 25 micM

"
cinacalcet_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_substrate_of_cyp2d6.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1437	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism and Excretion

Cinacalcet is metabolized by multiple enzymes, primarily CYP3A4, CYP2D6 and CYP1A2."
perphenazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_substrate_of_cyp2d6.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1441	support	http://www.ncbi.nlm.nih.gov/pubmed/11136295	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: ketoconazole

reaction: perphenazine N-dealkylation

Quote: 
To identify the human cytochrome P450 (CYP) isoforms mediating the N-dealkylation of the antipsychotic drug perphenazine in vitro and estimate the relative contributions of the CYP isoforms involved. METHODS: cDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction... Ketoconazole inhibition of N-dealkylation mediated by a mixed HLM indicated that CYP3A4 accounted for about 40% of perphenazine N-dealkylation at therapeutically relevant concentrations.The contribution of the CYP isoforms 1A2, 2C19 and 2D6 amounted to 20-25% each as measured by the percentage inhibition obtained by addition of furafylline, fluvoxamine or quinidine, respectively.

"
perphenazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_substrate_of_cyp2d6.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1442	support	http://www.ncbi.nlm.nih.gov/pubmed/11136295	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human CYP enzymes in baculovirus-infected insect cells

NADPH added: yes 

Quote:
cDNA-expressed CYP isoforms were used to identify the isoforms that are able to mediate the N-dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the N-dealkylation reaction. RESULTS: CYP isoforms 1A2, 3A4, 2C8, 2C9, 2C18, 2C19 and 2D6 were able to mediate the N-dealkylation of perphenazine. Reaction velocities and their relative abundance in HLM suggested that CYP1A2, 3A4, 2C19 and 2D6 were the most important contributors to N-dealkylation. Apparent Km values of CYP1A2 and CYP2D6 were in the range 1-2 microM, and Km values of CYP2C19 and CYP3A4 were 14 microM and 7.9 microM, respectively."
perphenazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_substrate_of_cyp2d6.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1443	support	http://www.ncbi.nlm.nih.gov/pubmed/9333110	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
route of administration: oral

study duration: single dose of perphenazine (0.11 mg/kg orally) or placebo following a randomized double-blind design. Perphenazine plasma concentrations and effects were assessed for a period of 8 hours. Subsequently, subjects were treated with a standard therapeutic dose of paroxetine (20 mg/day orally) for 10 days and test sessions with perphenazine and placebo were repeated.

population: 8 adults (5 female, 3 male); all CYP2D6 EMs as determined by the dextromethorphan metabolite ration

ages: 21 - 49

Description: 
Paroxetine treatment resulted in a twofold to 21-fold decrease in CYP2D6 activity (p &lt; 0.001). After pretreatment with paroxetine, perphenazine peak plasma concentrations increased twofold to 13-fold (p &lt; 0.01). This was associated with a significant increase in central nervous system side effects of perphenazine, including oversedation, extrapyramidal symptoms, and impairment of psychomotor performance and memory (p &lt; 0.05). 
"
perphenazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_substrate_of_cyp2d6.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1444	support	http://www.ncbi.nlm.nih.gov/pubmed/17429316	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_CT_PK_Genotype	"

route of administration: oral

study duration: single-dose of perphenazine (0.1mg/kg)

population: 22 healthy, non-smoking, adult males of chinese ancestry

tested for known CYP450 polymorphisms? yes...&quot;DNA samples from all participants were genotyped for
CYP2D6*10 and CYP2D6*5 using a nested and allele-
specific PCR-restriction fragment length polymorphism
analysis as described previously [34,35]. Alleles not being CYP2D6*5 or CYP2D6*10 were called CYP2D6*1. Geno-
typing for these three alleles has been shown in the past to be adequate for a reliable determination of CYP2D6 genotypes in Asians [8,15,34,35]. The invest igators did not have access to data on CYP2D6 genotype during ascertainment of the pharmacological phenotypes (i.e. perphenazine and prolactin concentration data); genotyping was also performed blind to the prolactin or plasma concentration data.&quot;

ages: 21 - 50

description:
&quot;In volunteers with CYP2D6*10/CYP2D6*10 genotype, the mean area under curve (AUC0-6) for perphenazine concentration was 2.9-fold higher than those who carry the CYP2D6*1 allele (P&lt;0.01).&quot;

"
perphenazine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_substrate_of_cyp2d6.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1445	support	http://www.ncbi.nlm.nih.gov/pubmed/8689810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_CT_PK_Genotype	"
route of administration: oral

study duration: During a 1-year period a blood sample was taken for genotyping together with blood for serum monitoring. Blood samples were taken from 151 patients

population: patients undergoing therapeutic drug monitoring of orally-administered perphenazine. The analysis included 56 EMs and 3 PMs taking a drug that could potentially affect perphenazine metabolism, 32 EMs and 6 PMs taking a no drug known to affect perphenazine metabolism. All PMs were grouped for analysis since they did not carry a functional CYP2D6 allele.

tested for known CYP450 polymorphisms? yes, genotyping found 142 CYP2D6 extensive metabolizers (EM) and 9 poor metabolizers (PM)

ages: 12 - 75; median of 38 years

description:
The poor metabolizer group had the highest median steady-state serum concentration value (0.195 nmol/L per milligram), which was about twice the value of the extensive metablolizer group without potentially interacting medicine (0.098 nmol/L per milligram; p &lt; 0.01)

"
fluvoxamine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00176	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvoxamine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1451	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/53664f8d-3a93-9f2b-daee-380707e4062c	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Approximately 7% of the normal population has a genetic defect that leads to reduced levels of activity of cytochrome P450IID6 isozyme. Such individuals have been referred to as &quot;poor metabolizers&quot; (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants. While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in thirteen PM subjects demonstrated altered pharmacokinetic properties compared to sixteen &quot;extensive metabolizers&quot; (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group. This suggests that fluvoxamine is metabolized, at least in part, by IID6 isozyme. Caution is indicated in patients known to have reduced levels of P450IID6 activity and those receiving concomitant drugs known to inhibit this isozyme (e.g., quinidine).
fluvoxamine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00176	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvoxamine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1452	support	http://www.ncbi.nlm.nih.gov/pubmed/8823236	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_CT_PK_Phenotype	"
route of administration: oral

study duration: single 50mg dose fluvoxamine 

population: 7 male and 7 female; 10 CYP2D6 EMs and four PMs according to debrisoquine metabolism. 5 EMs smoked during the study as did 3 PMs

ages: 25 - 49

Description: 
Compared with nonsmoking extensive metabolizers, nonsmoking poor metabolizers had a statistically significant (p = 0.02, Mann-Whitney U test) about twofold higher maximum plasma concentration, longer half-life, and fivefold lower oral clearance of fluvoxamine.
"
fluoxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00472	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluoxetine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1525	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5f356c1b-96bd-4ef1-960c-91cf4905e6b1	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Variability in metabolism ï¿½ A subset (about 7%) of the population has reduced activity of the drug metabolizing enzyme cytochrome P450 2D6 (CYP2D6). Such individuals are referred to as ï¿½poor metabolizersï¿½ of drugs such as debrisoquin, dextromethorphan, and the TCAs. In a study involving labeled and unlabeled enantiomers administered as a racemate, these individuals metabolized Sï¿½fluoxetine at a slower rate and thus achieved higher concentrations of Sï¿½fluoxetine. Consequently, concentrations of Sï¿½norfluoxetine at steady state were lower. The metabolism of Rï¿½fluoxetine in these poor metabolizers appears normal. When compared with normal metabolizers, the total sum at steady state of the plasma concentrations of the 4 active enantiomers was not significantly greater among poor metabolizers. Thus, the net pharmacodynamic activities were essentially the same. Alternative, nonsaturable pathways (nonï¿½2D6) also contribute to the metabolism of fluoxetine. This explains how fluoxetine achieves a steadyï¿½state concentration rather than increasing without limit.
fluoxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00472	http://purl.obolibrary.org/obo/PR_000006121	clozapine-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluoxetine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1526	support	http://www.ncbi.nlm.nih.gov/pubmed/8941024	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_CT_PK_Phenotype	"

route of administration: oral

study duration: 

population: 20 healthy, non-smoking, males

tested for known CYP450 polymorphisms? Yes, using debrisoquin / 4-hydroxydebrisoquin metabolite ratio; 10 were CYP2D6 EMs and 10 PMs

ages: 18 - 32

description:

&quot;Poor metabolizers had significantly greater fluoxetine peak plasma concentrations (Cmax; increases 57%), area under the concentration versus time curve (AUCzero--&gt;infinity; increases 290%), and terminal elimination half-life (increases 216%) compared with extensive metabolizers. The total amount of fluoxetine excreted in the urine during 8 days was almost three times higher in poor metabolizers than in extensive metabolizers (719 versus 225 micrograms; p &lt; 0.05), whereas the total amount of norfluoxetine excreted in urine of poor metabolizers was about half of that of extensive metabolizers (524 versus 1047 micrograms; p &lt; 0.05). Norfluoxetine Cmax and AUCzero--&gt;t were significantly smaller in poor metabolizers (decreases 55% and decreases 53%, respectively), and the partial metabolic clearance of fluoxetine into norfluoxetine was 10 times smaller in this group (4.3 +/- 1.9 versus 0.4 +/- 0.1 L/hr; p &lt; 0.05).&quot;

"
clozapine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/6	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/883b5d43-0339-7dc1-f775-93791fb9b978	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Pharmacokinetic-related Interactions

Clozapine is a substrate for many CYP 450 isozymes, in particular 1A2, 2D6, and 3A4. The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized. Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes."
clozapine_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp3a4.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/7	support	http://www.ncbi.nlm.nih.gov/pubmed/9384460	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: ketoconazole

reaction: clozapine demethylation and N-oxidation

Quote: 
Ketconazole inhibited [clozapine] demethylation by 28+/-20% and 68+/-15% at 0.2 and 2 micM, respectively... CLZ-NO formation was inhibited by ketoconazole by 41+/-14% and 51+/-13% at 0.2 and 2 micM, respectively. 


"
aripiprazole_substrate_of_cyp2b6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006116	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2b6.html	DIKB				support			
aripiprazole_substrate_of_cyp2b6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006116	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp2b6.html	DIKB				support			
citalopram_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_substrate_of_cyp3a4.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/21	support	http://www.ncbi.nlm.nih.gov/pubmed/10494454	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes:

NADPH added: yes

inhibitor used: ketoconazole

reaction: citalopram --&gt; desmethylcitalopram

Quote: 
Ketoconazole produced concentration-dependent inhibition of DCT formation (Figure 4). The mean (+/-SE) IC50 values for ketoconazole were 0.81 (+/-.24) micM/L at
CT = 10 micM/L, and 1.54 (+/-.35) micM/L CT = 100 micM/L; these values were not significantly different.



"
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/25	support	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"Enzyme system: human liver microsomes

NADPH added: yes
inhibitor used: itraconazole

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
itraconazole effected a dramatic decrease in the formation of both metabolites from both lactone and acid forms of atorvastatin"
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/26	support	http://www.ncbi.nlm.nih.gov/pubmed/11038166	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human CYP3A4 enzymes in insect microsomes

NADPH added: yes
substrate used: atorvastatin acid and lactone

reaction:
atorvastatin acid--&gt;ortho-hydroxy-atorvastatin
atorvastatin lactone--&gt;ortho-hydroxy-atorvastatin
atorvastatin acid--&gt;para-hydroxy-atorvastatin
atorvastatin lactone--&gt;para-hydroxy-atorvastatin

description:
This enzyme system catalyzed the above reactions with Km values ranging from 1.4micM/L for atorvastatin lactone--&gt;para-hydroxy-atorvastatin to 29.7micM/L for the atorvastatin acid--&gt;ortho-hydroxy-atorvastatin

"
atorvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/27	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/8a201c80-a51d-4c1c-963b-488c071908c0	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	&quot;In vitro studies suggest the importance of atorvastatin metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of atorvastatin in humans following coadministration with erythromycin, a known inhibitor of this isozyme&quot;
celecoxib_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006120	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_substrate_of_cyp2c9.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/75	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism: Celecoxib metabolism is primarily mediated via CYP2C9. Three metabolites, a primary alcohol, the corresponding carboxylic acid and its glucuronide conjugate, have been identified in human plasma. These metabolites are inactive as COX-1 or COX-2 inhibitors.

CYP2C9 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity, such as those homozygous for the CYP2C9*2 and CYP2C9*3 polymorphisms. Limited data from 4 published reports that included a total of 8 subjects with the homozygous CYP2C9*3/*3 genotype showed celecoxib systemic levels that were 3- to 7-fold higher in these subjects compared to subjects with CYP2C9*1/*1 or *I/*3 genotypes. The pharmacokinetics of celecoxib have not been evaluated in subjects with other CYP2C9 polymorphisms, such as *2, *5, *6, *9 and *11. It is estimated that the frequency of the homozygous *3/*3 genotype is 0.3% to 1.0% in various ethnic groups. "
celecoxib_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006120	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_substrate_of_cyp2c9.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/75	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism: Celecoxib metabolism is primarily mediated via CYP2C9. Three metabolites, a primary alcohol, the corresponding carboxylic acid and its glucuronide conjugate, have been identified in human plasma. These metabolites are inactive as COX-1 or COX-2 inhibitors.

CYP2C9 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity, such as those homozygous for the CYP2C9*2 and CYP2C9*3 polymorphisms. Limited data from 4 published reports that included a total of 8 subjects with the homozygous CYP2C9*3/*3 genotype showed celecoxib systemic levels that were 3- to 7-fold higher in these subjects compared to subjects with CYP2C9*1/*1 or *I/*3 genotypes. The pharmacokinetics of celecoxib have not been evaluated in subjects with other CYP2C9 polymorphisms, such as *2, *5, *6, *9 and *11. It is estimated that the frequency of the homozygous *3/*3 genotype is 0.3% to 1.0% in various ethnic groups. "
celecoxib_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006120	clarithromycin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_substrate_of_cyp2c9.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/75	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism: Celecoxib metabolism is primarily mediated via CYP2C9. Three metabolites, a primary alcohol, the corresponding carboxylic acid and its glucuronide conjugate, have been identified in human plasma. These metabolites are inactive as COX-1 or COX-2 inhibitors.

CYP2C9 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity, such as those homozygous for the CYP2C9*2 and CYP2C9*3 polymorphisms. Limited data from 4 published reports that included a total of 8 subjects with the homozygous CYP2C9*3/*3 genotype showed celecoxib systemic levels that were 3- to 7-fold higher in these subjects compared to subjects with CYP2C9*1/*1 or *I/*3 genotypes. The pharmacokinetics of celecoxib have not been evaluated in subjects with other CYP2C9 polymorphisms, such as *2, *5, *6, *9 and *11. It is estimated that the frequency of the homozygous *3/*3 genotype is 0.3% to 1.0% in various ethnic groups. "
voriconazole_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006118	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_substrate_of_cyp2c19.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/107	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism

In vitro studies showed that voriconazole is metabolized by the human hepatic cytochrome P450 enzymes, CYP2C19, CYP2C9 and CYP3A4 "
voriconazole_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006118	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_substrate_of_cyp2c19.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/107	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Metabolism

In vitro studies showed that voriconazole is metabolized by the human hepatic cytochrome P450 enzymes, CYP2C19, CYP2C9 and CYP3A4 "
quetiapine_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006102	alprazolam	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp1a2.html	DIKB				support			
quetiapine_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006102	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp1a2.html	DIKB				support			
quetiapine_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006102	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp1a2.html	DIKB				support			
quetiapine_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006102	clarithromycin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_substrate_of_cyp1a2.html	DIKB				support			
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	zaleplon	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/149	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/883b5d43-0339-7dc1-f775-93791fb9b978	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Pharmacokinetic-related Interactions

Clozapine is a substrate for many CYP 450 isozymes, in particular 1A2, 2D6, and 3A4. The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized. Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes."
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	zaleplon	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/150	support	http://www.ncbi.nlm.nih.gov/pubmed/11147928	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"
Route of administration: oral

study duration: three weeks

population: 17 patients stabilized on clozapine, eight of which received sertraline for an additional three weeks

ages: 29 - 55


Quote:

The effect of paroxetine or sertraline on steady-state plasma concentrations of clozapine and its major metabolites was studied in 17 patients with schizophrenia or schizoaffective disorder stabilized on clozapine therapy (200-400 mg/day). In order to treat negative symptomatology or concomitant depression, 9 patients received additional paroxetine (20-40mg/day) and 8 patients sertraline (50-100 mg/day). After 3 weeks of paroxetine administration, mean plasma concentrations of clozapine and norclozapine increased significantly by 31% (p&lt;0.01) and by 20% (p&lt;0.05), respectively, while levels of clozapine N-oxide remained almost unchanged. The mean plasma norclozapine/clozapine and clozapine N-oxide/clozapine ratios were not modified during paroxetine treatment. No significant changes in plasma concentrations of clozapine and its major metabolites were observed after 3 weeks of combined therapy with sertraline."
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	asenapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/149	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/883b5d43-0339-7dc1-f775-93791fb9b978	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Pharmacokinetic-related Interactions

Clozapine is a substrate for many CYP 450 isozymes, in particular 1A2, 2D6, and 3A4. The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized. Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes."
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	asenapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/150	support	http://www.ncbi.nlm.nih.gov/pubmed/11147928	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"
Route of administration: oral

study duration: three weeks

population: 17 patients stabilized on clozapine, eight of which received sertraline for an additional three weeks

ages: 29 - 55


Quote:

The effect of paroxetine or sertraline on steady-state plasma concentrations of clozapine and its major metabolites was studied in 17 patients with schizophrenia or schizoaffective disorder stabilized on clozapine therapy (200-400 mg/day). In order to treat negative symptomatology or concomitant depression, 9 patients received additional paroxetine (20-40mg/day) and 8 patients sertraline (50-100 mg/day). After 3 weeks of paroxetine administration, mean plasma concentrations of clozapine and norclozapine increased significantly by 31% (p&lt;0.01) and by 20% (p&lt;0.05), respectively, while levels of clozapine N-oxide remained almost unchanged. The mean plasma norclozapine/clozapine and clozapine N-oxide/clozapine ratios were not modified during paroxetine treatment. No significant changes in plasma concentrations of clozapine and its major metabolites were observed after 3 weeks of combined therapy with sertraline."
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	nefazodone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/149	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/883b5d43-0339-7dc1-f775-93791fb9b978	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Pharmacokinetic-related Interactions

Clozapine is a substrate for many CYP 450 isozymes, in particular 1A2, 2D6, and 3A4. The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized. Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes."
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	nefazodone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/150	support	http://www.ncbi.nlm.nih.gov/pubmed/11147928	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"
Route of administration: oral

study duration: three weeks

population: 17 patients stabilized on clozapine, eight of which received sertraline for an additional three weeks

ages: 29 - 55


Quote:

The effect of paroxetine or sertraline on steady-state plasma concentrations of clozapine and its major metabolites was studied in 17 patients with schizophrenia or schizoaffective disorder stabilized on clozapine therapy (200-400 mg/day). In order to treat negative symptomatology or concomitant depression, 9 patients received additional paroxetine (20-40mg/day) and 8 patients sertraline (50-100 mg/day). After 3 weeks of paroxetine administration, mean plasma concentrations of clozapine and norclozapine increased significantly by 31% (p&lt;0.01) and by 20% (p&lt;0.05), respectively, while levels of clozapine N-oxide remained almost unchanged. The mean plasma norclozapine/clozapine and clozapine N-oxide/clozapine ratios were not modified during paroxetine treatment. No significant changes in plasma concentrations of clozapine and its major metabolites were observed after 3 weeks of combined therapy with sertraline."
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	clarithromycin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/149	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/883b5d43-0339-7dc1-f775-93791fb9b978	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Pharmacokinetic-related Interactions

Clozapine is a substrate for many CYP 450 isozymes, in particular 1A2, 2D6, and 3A4. The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized. Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes."
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	clarithromycin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/150	support	http://www.ncbi.nlm.nih.gov/pubmed/11147928	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"
Route of administration: oral

study duration: three weeks

population: 17 patients stabilized on clozapine, eight of which received sertraline for an additional three weeks

ages: 29 - 55


Quote:

The effect of paroxetine or sertraline on steady-state plasma concentrations of clozapine and its major metabolites was studied in 17 patients with schizophrenia or schizoaffective disorder stabilized on clozapine therapy (200-400 mg/day). In order to treat negative symptomatology or concomitant depression, 9 patients received additional paroxetine (20-40mg/day) and 8 patients sertraline (50-100 mg/day). After 3 weeks of paroxetine administration, mean plasma concentrations of clozapine and norclozapine increased significantly by 31% (p&lt;0.01) and by 20% (p&lt;0.05), respectively, while levels of clozapine N-oxide remained almost unchanged. The mean plasma norclozapine/clozapine and clozapine N-oxide/clozapine ratios were not modified during paroxetine treatment. No significant changes in plasma concentrations of clozapine and its major metabolites were observed after 3 weeks of combined therapy with sertraline."
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	desvenlafaxine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/149	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/883b5d43-0339-7dc1-f775-93791fb9b978	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Pharmacokinetic-related Interactions

Clozapine is a substrate for many CYP 450 isozymes, in particular 1A2, 2D6, and 3A4. The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized. Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes."
clozapine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006121	desvenlafaxine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/150	support	http://www.ncbi.nlm.nih.gov/pubmed/11147928	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"
Route of administration: oral

study duration: three weeks

population: 17 patients stabilized on clozapine, eight of which received sertraline for an additional three weeks

ages: 29 - 55


Quote:

The effect of paroxetine or sertraline on steady-state plasma concentrations of clozapine and its major metabolites was studied in 17 patients with schizophrenia or schizoaffective disorder stabilized on clozapine therapy (200-400 mg/day). In order to treat negative symptomatology or concomitant depression, 9 patients received additional paroxetine (20-40mg/day) and 8 patients sertraline (50-100 mg/day). After 3 weeks of paroxetine administration, mean plasma concentrations of clozapine and norclozapine increased significantly by 31% (p&lt;0.01) and by 20% (p&lt;0.05), respectively, while levels of clozapine N-oxide remained almost unchanged. The mean plasma norclozapine/clozapine and clozapine N-oxide/clozapine ratios were not modified during paroxetine treatment. No significant changes in plasma concentrations of clozapine and its major metabolites were observed after 3 weeks of combined therapy with sertraline."
pantoprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00213	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/pantoprazole_substrate_of_cyp3a4.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/157	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/742ca9f4-9fba-44d4-29a8-1fe3a04f1af6	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"

Metabolism

Pantoprazole is extensively metabolized in the liver through the cytochrome P450 (CYP) system. Pantoprazole metabolism is independent of the route of administration (intravenous or oral). The main metabolic pathway is demethylation, by CYP2C19, with subsequent sulfation; other metabolic pathways include oxidation by CYP3A4. There is no evidence that any of the pantoprazole metabolites have significant pharmacologic activity. "
alprazolam_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006102	alprazolam	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp1a2.html	DIKB				support			
alprazolam_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006102	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp1a2.html	DIKB				support			
alprazolam_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006102	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp1a2.html	DIKB				support			
alprazolam_substrate_of_cyp1a2	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00404	http://purl.obolibrary.org/obo/PR_000006102	clarithromycin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/alprazolam_substrate_of_cyp1a2.html	DIKB				support			
fluvastatin_substrate_of_cyp2c8	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01095	http://purl.obolibrary.org/obo/PR_000006119	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvastatin_substrate_of_cyp2c8.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/198	support	http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3237	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"&quot;
Fluvastatin is metabolized in the liver, primarily via hydroxylation of the indole ring at the 5- and 6-positions. N-dealkylation and beta-oxidation of the side-chain also occurs. The hydroxy metabolites have some pharmacologic activity, but do not circulate in the blood. Both enantiomers of fluvastatin are metabolized in a similar manner.

      In vitro studies demonstrated that fluvastatin undergoes oxidative metabolism, predominantly via 2C9 isozyme systems (75%). Other isozymes that contribute to fluvastatin metabolism are 2C8 (~5%) and 3A4 (~20%).&quot;"
fluvastatin_substrate_of_cyp2c8	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01095	http://purl.obolibrary.org/obo/PR_000006119	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvastatin_substrate_of_cyp2c8.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/198	support	http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3237	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"&quot;
Fluvastatin is metabolized in the liver, primarily via hydroxylation of the indole ring at the 5- and 6-positions. N-dealkylation and beta-oxidation of the side-chain also occurs. The hydroxy metabolites have some pharmacologic activity, but do not circulate in the blood. Both enantiomers of fluvastatin are metabolized in a similar manner.

      In vitro studies demonstrated that fluvastatin undergoes oxidative metabolism, predominantly via 2C9 isozyme systems (75%). Other isozymes that contribute to fluvastatin metabolism are 2C8 (~5%) and 3A4 (~20%).&quot;"
aripiprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/241	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Both CYP3A4 and CYP2D6 are responsible for aripiprazole metabolism. Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.

Ketoconazole and Other CYP3A4 Inhibitors

Coadministration of ketoconazole (200 mg/day for 14 days) with a 15 mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively. The effect of a higher ketoconazole dose (400 mg/day) has not been studied. When ketoconazole is given concomitantly with aripiprazole, the aripiprazole dose should be reduced to one-half of its normal dose. Other strong inhibitors of CYP3A4 (itraconazole) would be expected to have similar effects and need similar dose reductions; moderate inhibitors (erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the aripiprazole dose should be increased.

Quinidine and Other CYP2D6 Inhibitors

Coadministration of a 10 mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydro-aripiprazole, by 35%. Aripiprazole dose should be reduced to one-half of its normal dose when quinidine is given concomitantly with aripiprazole. Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be expected to have similar effects and should lead to similar dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, the aripiprazole dose should be increased. When adjunctive ABILIFY is administered to patients with Major Depressive Disorder, ABILIFY should be administered without dosage adjustment as specified in DOSAGE AND ADMINISTRATION (2.3).

Carbamazepine and Other CYP3A4 Inducers

Coadministration of carbamazepine (200 mg twice daily), a potent CYP3A4 inducer, with aripiprazole (30 mg/day) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole. When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled. Additional dose increases should be based on clinical evaluation. When carbamazepine is withdrawn from the combination therapy, the aripiprazole dose should be reduced."
aripiprazole_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_substrate_of_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/242	support	http://www.ncbi.nlm.nih.gov/pubmed/15770075	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"Route of administration: oral

study duration: Two phases : Phase I - a single dose of aripiprazole; Phase II - 7 days pre-treatment with ITZ, single dose of aripiprazole with ITZ, then ITZ alone or 14 more days; a 35 day washout between Phase I and II

population: 24 healthy adult Japanese males

meean age (SD): 23.2 (2.4)

AUC_i/AUC (336hr): 1075/736 = 1.48

Description:
The objective of the present study was to investigate the influence of itraconazole (hereafter referred to as ITZ) co-administration (CYP3A4 inhibition) on the pharmacokinetics of ARIPIPRAZOLE administered to 24 healthy adult male volunteers in a fasting condition. The influence of CYP3A4 inhibition was also examined by CYP2D6 genotype. All subjects were administered a single oral dose of ARIPIPRAZOLE alone in Period I and a single oral dose of ARIPIPRAZOLE following administration of ITZ at 100 mg/day for 7 consecutive days in Period II. The pharmacokinetic parameters of ARIPIPRAZOLE and its main metabolite OPC-14857 were determined. Co-administration of ITZ increased the Cmax, AUC336 hr, and t1/2,z of ARIPIPRAZOLE and OPC-14857 by 19.4%, 48.0%, and 18.6% and by 18.6%, 38.8%, and 53.4%, respectively. By co-administration of ITZ, the CL/F of ARIPIPRAZOLE in extensive metabolizers was decreased by 26.6%, with an even greater decrease (47.3%) in intermediate metabolizers. For the co-administration period, the CL/F of ARIPIPRAZOLE in intermediate metabolizers was about half of that in extensive metabolizers. For Cmax, there was no significant difference between extensive metabolizers and intermediate metabolizers, and the percent change by co-administration of ITZ was less than 20% in both extensive metabolizers and intermediate metabolizers. For OPC-14857, the t(max) in intermediate metabolizers was longer than that in extensive metabolizers, with the difference being amplified by co-administration of ITZ. The AUC336 hr showed similar increases by co-administration of ITZ in all genotypes. The urinary 6beta-hydroxycortisol/cortisol concentration ratio following ITZ administration for 7 consecutive days was about half of that before the start of ITZ administration, indicating that CYP3A4 metabolic activity was inhibited by administration of ITZ. The influence of CYP3A4 inhibition on the pharmacokinetics of ARIPIPRAZOLE was not considered to be clinically significant. On the other hand, definite differences in pharmacokinetics were observed between CYP2D6 genotypes. "
ziprasidone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_substrate_of_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/247	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism and Elimination

... In vitro studies using human liver microsomes and recombinant enzymes indicate that CYP3A4 is the major CYP contributing to the oxidative metabolism of ziprasidone. CYP1A2 may contribute to a much lesser extent. Based on in vivo abundance of excretory metabolites, less than one-third of ziprasidone metabolic clearance is mediated by cytochrome P450 catalyzed oxidation and approximately two-thirds via reduction by aldehyde oxidase. There are no known clinically relevant inhibitors or inducers of aldehyde oxidase."
ziprasidone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_substrate_of_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/248	support	http://www.ncbi.nlm.nih.gov/pubmed/10771452	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"

Enzyme system: For CYP1A2 - recombinant CYP450 enzymes expressed in an human lymphoblastoid cell system. For CYP2C9, 2C19,2D6, and 3A4 - recombinant CYP450 enzymes expressed in insect cells

NADPH added: yes

reaction: 1) ziprasidone --&gt; ziprasidone sulphoxide 
          2) ziprasidone --&gt; ziprasidone sulphone 

Quote: 
&quot;The ability of specific CYP isoforms to metabolize
ziprasidone was determined using recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. H.p.l.c.-radioactivity profiles of ziprasidone metabolites following incubation of [14C]-ziprasidone or [3H]-ziprasidone with CYP3A4 are shown in Figure 5(a) and (b), respectively. CYP3A4 catalysed the formation of the N-dealkylated metabolite (M5), as well as ziprasidone sulphone (M8) and ziprasidone sulphoxide (M10). These oxidative metabolites were not detected in incubations containing recombinant CYP1A2, CYP2C9, CYP2C19 or CYP2D6.&quot;

"
ziprasidone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_substrate_of_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/249	support	http://www.ncbi.nlm.nih.gov/pubmed/10771452	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes

inhibitor used: ketoconazole

reaction: 1) ziprasidone --&gt; ziprasidone sulphoxide/sulphone
2) ziprasidone --&gt; oxindole acetic acid

Quote: 
Inhibition of metabolite formation by each inhibitor is
summarized in Table 2. Ketoconazole (10micM) inhibited
the formation of ziprasidone sulphoxide (sulphoxide and
sulphone) by 79% and oxindole acetic acid N-dealkylated
product) completely. Sulphaphenazole an furafylline did
not inhibit the formation of ziprasidone sulphoxide. The formation of oxindole acetic acid was inhibited (~50%) by furafylline. The formation of ziprasidone metabolites was not inhibited by quinidine but rather increased.


"
ziprasidone_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_substrate_of_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/250	support	http://www.ncbi.nlm.nih.gov/pubmed/10771458	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"

route of administration: oral

study duration: 

population: 14 healthy, non-smoking, adults (6 male, 8 female); only 13 completed the study

tested for known CYP450 polymorphisms? 

ages: 18 - 45

description:
&quot;Co-administration of ziprasidone with ketoconazole was associated with a modest increase in ziprasidone exposure; mean ziprasidone AUC(0,infinity) increased by 33%, from 899 ng ml(-1) h with placebo to 1199 ng ml(-1) h with ketoconazole. Mean Cmax increased by 34%, from 89 ng ml(-1) to 119 ng ml(-1), respectively. The treatment effect on both of these parameters was statistically significant (P&lt;0.02).&quot;
"
rabeprazole_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01129	http://purl.obolibrary.org/obo/PR_000006118	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rabeprazole_substrate_of_cyp2c19.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/281	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5d103551-978f-472a-9c62-51e6e4dea068	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
7.5 Drugs metabolized by CYP2C19

In a clinical study in Japan evaluating rabeprazole in patients categorized by CYP2C19 genotype (n=6 per genotype category), gastric acid suppression was higher in poor metabolizers as compared to extensive metabolizers. This could be due to higher rabeprazole plasma levels in poor metabolizers. Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied."
rabeprazole_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01129	http://purl.obolibrary.org/obo/PR_000006118	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rabeprazole_substrate_of_cyp2c19.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/281	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5d103551-978f-472a-9c62-51e6e4dea068	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
7.5 Drugs metabolized by CYP2C19

In a clinical study in Japan evaluating rabeprazole in patients categorized by CYP2C19 genotype (n=6 per genotype category), gastric acid suppression was higher in poor metabolizers as compared to extensive metabolizers. This could be due to higher rabeprazole plasma levels in poor metabolizers. Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied."
escitalopram_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006118	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp2c19.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/285	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.18 CYP3A4 and -2C19 Inhibitors

In vitro studies indicated that CYP3A4 and -2C19 are the primary enzymes involved in the metabolism of escitalopram. However, coadministration of escitalopram (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram. Because escitalopram is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease escitalopram clearance.

"
escitalopram_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006118	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp2c19.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/286	support	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

reaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram

Quote:

Chemical Inhibition of CT and DCT Biotransformation in
Microsomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by
ketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.
"
escitalopram_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006118	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp2c19.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/285	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.18 CYP3A4 and -2C19 Inhibitors

In vitro studies indicated that CYP3A4 and -2C19 are the primary enzymes involved in the metabolism of escitalopram. However, coadministration of escitalopram (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram. Because escitalopram is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease escitalopram clearance.

"
escitalopram_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006118	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_substrate_of_cyp2c19.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/286	support	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Microsome_Chem	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

reaction: R- and S-citalopram --&gt; R- and S- demethylcitalopram

Quote:

Chemical Inhibition of CT and DCT Biotransformation in
Microsomes. At 10micM R- or S-CT, ketoconazole reduced reaction velocity to 55 to 60% of control, quinidine to 80% of control, and omeprazole to 80 to 85% of control (Fig. 6). When the R- and S-CT concentration was increased to 100 M, the degree of inhibition by
ketoconazole increased, while inhibition by quinidine decreased (Fig. 6). These findings are consistent with the data from heterologously expressed CYP isoforms.
"
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/313	support	http://www.ncbi.nlm.nih.gov/pubmed/9542477	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

polymorphic enzyme: NO

study duration: 4 days

population: 7 male, 3 female

ages:19-29

description:
Two randomized, double-blind, two-phase crossover studies were performed with use of an identical design, one with simvastatin (study I) and one with pravastatin (study II). In both studies, 10 healthy volunteers received either 200 mg itraconazole or placebo orally once a day for 4 days. On day 4, each subject ingested a single 40 mg dose of simvastatin (study I) or pravastatin (study II). Serum concentrations of simvastatin, simvastatin acid, pravastatin, HMG-CoA reductase inhibitors, itraconazole, and hydroxyitraconazole were determined. RESULTS: In study I, itraconazole increased the peak serum concentrations (Cmax) and the areas under the serum concentration-time curve [AUC(0-infinity)] of simvastatin and simvastatin acid at least tenfold (p < 0.001)."
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/314	support	http://www.ncbi.nlm.nih.gov/pubmed/9321523	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_ID_Cyp450_Hum_Recom	"
Enzyme system: recombinant human enzymes in Supersomes

NADPH added: yes

inhibitor used: no

This study showed the formation of 3',5'-dihydrodiol, 3'-hydroxy, and 6'-exomethylene metabolites using a recombinant CYP3A4 system
"
simvastatin_substrate_of_cyp3a4	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00641	http://purl.obolibrary.org/obo/PR_000006130	rosuvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/simvastatin_substrate_of_cyp3a4.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/315	support	http://www.ncbi.nlm.nih.gov/pubmed/15518608	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_Par_Grps	"Route of administration: oral

polymorphic enzyme: NO

study duration: 7 days simvastatin only, 8 days simva and clarithromycin

dose: .040g simvastatin 1xday
      .5g clarithromycin 2xday

population: 45 men and women (15 received simvastatin)

ages:18-60 

(mean AUC_i)/(mean AUC) = 219/22 

description: Clarithromycin significantly (p <0.001) increased the AUC (and C(max)) of all 3 statins, most markedly simvastatin ( approximately 10-fold increase in AUC)
"
sertraline_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01104	http://purl.obolibrary.org/obo/PR_000006118	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/sertraline_substrate_of_cyp2c19.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/332	support	http://www.ncbi.nlm.nih.gov/pubmed/11452243	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_CT_PK_Genotype	"

route of administration: oral

study duration: single dose of 100 mg sertraline 

population: 12 healthy Chinese male, non-smokers

tested for known CYP450 polymorphisms? Patients were genotyped for CYP2C19 polymorphisms and also phenotyped using the omeprazole/5-hydroxy-omeprazole metabolic ratio. 6 extensive metabolizers (EM) and 6 poor metabolizers (PM) were chosen using stratified random selection from a pool of 66 EMs and 11 PMs.

ages: 19 - 22 years

description:
The poor metabolizers had a 41% increase in sertraline AUC(0-inf) (983.6 ï¿½ 199.3 micg ï¿½ h/L versus 697.6 ï¿½ 133.0 mcg ï¿½ h/L; P &lt; .05) and a 51% increase in sertraline terminal elimination half-life (t_1/2) (35.5 ï¿½ 5.6 hours 2 versus 23.5 ï¿½ 4.4 hours; P &lt; .01) compared with extensive metabolizers. The oral clearance (CL_oral) of sertraline in poor metabolizers was significantly lower than that in extensive metabolizers (105.3 ï¿½ 19.4 L/h versus 148.4 ï¿½ 28.6 L/h; P &lt; .05). The AUC0-144 and Cmax of desmethylsertraline in poor metabolizers were significantly lower than the values in extensive metabolizers (627.6 ï¿½ 203.8 ï¿½g ï¿½ h/L versus 972.1 ï¿½ 270.3 ï¿½g ï¿½ h/L; P &lt; .05; 23.6 ï¿½ 6.5 nmol/L versus 32.4 ï¿½ 8.2 nmol/L; P &lt; .01; respectively). In addition, desmethylsertraline Tmax (time to reach Cmax) in poor metabolizers was markedly higher than that in extensive metabolizers (70.0 ï¿½ 24.5 hours versus 26.4 ï¿½ 5.4 hours; P &lt; .01). 


"
sertraline_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01104	http://purl.obolibrary.org/obo/PR_000006118	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/sertraline_substrate_of_cyp2c19.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/332	support	http://www.ncbi.nlm.nih.gov/pubmed/11452243	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_CT_PK_Genotype	"

route of administration: oral

study duration: single dose of 100 mg sertraline 

population: 12 healthy Chinese male, non-smokers

tested for known CYP450 polymorphisms? Patients were genotyped for CYP2C19 polymorphisms and also phenotyped using the omeprazole/5-hydroxy-omeprazole metabolic ratio. 6 extensive metabolizers (EM) and 6 poor metabolizers (PM) were chosen using stratified random selection from a pool of 66 EMs and 11 PMs.

ages: 19 - 22 years

description:
The poor metabolizers had a 41% increase in sertraline AUC(0-inf) (983.6 ï¿½ 199.3 micg ï¿½ h/L versus 697.6 ï¿½ 133.0 mcg ï¿½ h/L; P &lt; .05) and a 51% increase in sertraline terminal elimination half-life (t_1/2) (35.5 ï¿½ 5.6 hours 2 versus 23.5 ï¿½ 4.4 hours; P &lt; .01) compared with extensive metabolizers. The oral clearance (CL_oral) of sertraline in poor metabolizers was significantly lower than that in extensive metabolizers (105.3 ï¿½ 19.4 L/h versus 148.4 ï¿½ 28.6 L/h; P &lt; .05). The AUC0-144 and Cmax of desmethylsertraline in poor metabolizers were significantly lower than the values in extensive metabolizers (627.6 ï¿½ 203.8 ï¿½g ï¿½ h/L versus 972.1 ï¿½ 270.3 ï¿½g ï¿½ h/L; P &lt; .05; 23.6 ï¿½ 6.5 nmol/L versus 32.4 ï¿½ 8.2 nmol/L; P &lt; .01; respectively). In addition, desmethylsertraline Tmax (time to reach Cmax) in poor metabolizers was markedly higher than that in extensive metabolizers (70.0 ï¿½ 24.5 hours versus 26.4 ï¿½ 5.4 hours; P &lt; .01). 


"
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	zaleplon	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/333	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.2 Inhibitors of CYP2D6

Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine. Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) [see Warnings and Precautions (5.10)]."
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	zaleplon	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/334	support	http://www.ncbi.nlm.nih.gov/pubmed/12621382	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"

route of administration: oral

study duration: &quot;In study 2, there were 2 study periods separated by a least 4 days. In period 1, subjects received 40 mg duloxetine every day for 5 days. Blood samples for the measurement of duloxetine plasma concentrations were taken immediately before duloxetine dosing on days 3 4, and 5 and at 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours after dosing on day 5. In period 2, subjects received 20 mg paroxetine every day for 20 days Beginning on day 12 of this period, subjects again received duloxetine 40 mg every day for 5 days and samples were taken as in period 1, except that additional samples were taken 96 and 120 hours after the &amp;#64257;nal duloxetine dose. On the &amp;#64257;nal day of duloxetine dosing in each period, subjects fasted from midnigh until 4 hours after dosing. All doses of study drugs were supervised by study site personnel. &quot;

population: 12 male; 11 of 12 were of Chinese or Malay decent NOTE: only 10 completed the study

tested for known CYP450 polymorphisms? yes but exact genotype not mentioned only that all were genotypically CYP2D6 extensive metabolizers.

ages: 21 - 27

description:
&quot;Paroxetine increased the maximum plasma concentration of duloxetine and the area under the concentration-time curve at steady state 1.6-fold.&quot;

"
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	asenapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/333	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.2 Inhibitors of CYP2D6

Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine. Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) [see Warnings and Precautions (5.10)]."
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	asenapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/334	support	http://www.ncbi.nlm.nih.gov/pubmed/12621382	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"

route of administration: oral

study duration: &quot;In study 2, there were 2 study periods separated by a least 4 days. In period 1, subjects received 40 mg duloxetine every day for 5 days. Blood samples for the measurement of duloxetine plasma concentrations were taken immediately before duloxetine dosing on days 3 4, and 5 and at 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours after dosing on day 5. In period 2, subjects received 20 mg paroxetine every day for 20 days Beginning on day 12 of this period, subjects again received duloxetine 40 mg every day for 5 days and samples were taken as in period 1, except that additional samples were taken 96 and 120 hours after the &amp;#64257;nal duloxetine dose. On the &amp;#64257;nal day of duloxetine dosing in each period, subjects fasted from midnigh until 4 hours after dosing. All doses of study drugs were supervised by study site personnel. &quot;

population: 12 male; 11 of 12 were of Chinese or Malay decent NOTE: only 10 completed the study

tested for known CYP450 polymorphisms? yes but exact genotype not mentioned only that all were genotypically CYP2D6 extensive metabolizers.

ages: 21 - 27

description:
&quot;Paroxetine increased the maximum plasma concentration of duloxetine and the area under the concentration-time curve at steady state 1.6-fold.&quot;

"
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	nefazodone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/333	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.2 Inhibitors of CYP2D6

Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine. Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) [see Warnings and Precautions (5.10)]."
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	nefazodone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/334	support	http://www.ncbi.nlm.nih.gov/pubmed/12621382	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"

route of administration: oral

study duration: &quot;In study 2, there were 2 study periods separated by a least 4 days. In period 1, subjects received 40 mg duloxetine every day for 5 days. Blood samples for the measurement of duloxetine plasma concentrations were taken immediately before duloxetine dosing on days 3 4, and 5 and at 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours after dosing on day 5. In period 2, subjects received 20 mg paroxetine every day for 20 days Beginning on day 12 of this period, subjects again received duloxetine 40 mg every day for 5 days and samples were taken as in period 1, except that additional samples were taken 96 and 120 hours after the &amp;#64257;nal duloxetine dose. On the &amp;#64257;nal day of duloxetine dosing in each period, subjects fasted from midnigh until 4 hours after dosing. All doses of study drugs were supervised by study site personnel. &quot;

population: 12 male; 11 of 12 were of Chinese or Malay decent NOTE: only 10 completed the study

tested for known CYP450 polymorphisms? yes but exact genotype not mentioned only that all were genotypically CYP2D6 extensive metabolizers.

ages: 21 - 27

description:
&quot;Paroxetine increased the maximum plasma concentration of duloxetine and the area under the concentration-time curve at steady state 1.6-fold.&quot;

"
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	clarithromycin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/333	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.2 Inhibitors of CYP2D6

Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine. Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) [see Warnings and Precautions (5.10)]."
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	clarithromycin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/334	support	http://www.ncbi.nlm.nih.gov/pubmed/12621382	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"

route of administration: oral

study duration: &quot;In study 2, there were 2 study periods separated by a least 4 days. In period 1, subjects received 40 mg duloxetine every day for 5 days. Blood samples for the measurement of duloxetine plasma concentrations were taken immediately before duloxetine dosing on days 3 4, and 5 and at 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours after dosing on day 5. In period 2, subjects received 20 mg paroxetine every day for 20 days Beginning on day 12 of this period, subjects again received duloxetine 40 mg every day for 5 days and samples were taken as in period 1, except that additional samples were taken 96 and 120 hours after the &amp;#64257;nal duloxetine dose. On the &amp;#64257;nal day of duloxetine dosing in each period, subjects fasted from midnigh until 4 hours after dosing. All doses of study drugs were supervised by study site personnel. &quot;

population: 12 male; 11 of 12 were of Chinese or Malay decent NOTE: only 10 completed the study

tested for known CYP450 polymorphisms? yes but exact genotype not mentioned only that all were genotypically CYP2D6 extensive metabolizers.

ages: 21 - 27

description:
&quot;Paroxetine increased the maximum plasma concentration of duloxetine and the area under the concentration-time curve at steady state 1.6-fold.&quot;

"
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	desvenlafaxine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/333	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.2 Inhibitors of CYP2D6

Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine. Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) [see Warnings and Precautions (5.10)]."
duloxetine_substrate_of_cyp2d6	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006121	desvenlafaxine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_substrate_of_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/334	support	http://www.ncbi.nlm.nih.gov/pubmed/12621382	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"

route of administration: oral

study duration: &quot;In study 2, there were 2 study periods separated by a least 4 days. In period 1, subjects received 40 mg duloxetine every day for 5 days. Blood samples for the measurement of duloxetine plasma concentrations were taken immediately before duloxetine dosing on days 3 4, and 5 and at 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours after dosing on day 5. In period 2, subjects received 20 mg paroxetine every day for 20 days Beginning on day 12 of this period, subjects again received duloxetine 40 mg every day for 5 days and samples were taken as in period 1, except that additional samples were taken 96 and 120 hours after the &amp;#64257;nal duloxetine dose. On the &amp;#64257;nal day of duloxetine dosing in each period, subjects fasted from midnigh until 4 hours after dosing. All doses of study drugs were supervised by study site personnel. &quot;

population: 12 male; 11 of 12 were of Chinese or Malay decent NOTE: only 10 completed the study

tested for known CYP450 polymorphisms? yes but exact genotype not mentioned only that all were genotypically CYP2D6 extensive metabolizers.

ages: 21 - 27

description:
&quot;Paroxetine increased the maximum plasma concentration of duloxetine and the area under the concentration-time curve at steady state 1.6-fold.&quot;

"
citalopram_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006118	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_substrate_of_cyp2c19.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/362	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro studies using human liver microsomes indicated that CYP3A4 and CYP2C19 are the primary isozymes involved in the N-demethylation of citalopram.
citalopram_substrate_of_cyp2c19	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006118	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_substrate_of_cyp2c19.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/362	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro studies using human liver microsomes indicated that CYP3A4 and CYP2C19 are the primary isozymes involved in the N-demethylation of citalopram.
atorvastatin_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006120	aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp2c9.html	DIKB				support			
atorvastatin_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006120	iloperidone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp2c9.html	DIKB				support			
atorvastatin_substrate_of_cyp2c9	substrate_of	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006120	clarithromycin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_substrate_of_cyp2c9.html	DIKB				support			
mirtazapine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_inhibits_cyp2c9.html	DIKB				refute			
mirtazapine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_inhibits_cyp2c9.html	DIKB				refute			
fluconazole_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00196	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluconazole_inhibits_cyp2c9.html	DIKB	"09/27/2007 11:44:51
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/37	refute	http://www.ncbi.nlm.nih.gov/pubmed/8801057	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"
Route of administration: fluconazole oral; warfarin - IV

study duration: phase 1 - 8 days of .75mg/kg warfarin alone; phase 2 (21 days later) 14 days of .75mg/kg q.d. AND 400mg q.d. of fluconazole

population: 6 male

ages: 23-29

description: 
formation of 6- and 7-OH-(s)-warfarin decreased by 70%; this reaction is considered primarily catalyzed by CYP2C9. There was also a notable increase in AUC of (S)-warfarin (mean AUC_i/AUC=7.633)"
fluconazole_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00196	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluconazole_inhibits_cyp2c9.html	DIKB	"06/30/2009 13:32:26
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/38	refute	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	'The FDA recommends this as a CYP2C9 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19'
fluconazole_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00196	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluconazole_inhibits_cyp2c9.html	DIKB	"09/27/2007 11:44:51
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/37	refute	http://www.ncbi.nlm.nih.gov/pubmed/8801057	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_NR	"
Route of administration: fluconazole oral; warfarin - IV

study duration: phase 1 - 8 days of .75mg/kg warfarin alone; phase 2 (21 days later) 14 days of .75mg/kg q.d. AND 400mg q.d. of fluconazole

population: 6 male

ages: 23-29

description: 
formation of 6- and 7-OH-(s)-warfarin decreased by 70%; this reaction is considered primarily catalyzed by CYP2C9. There was also a notable increase in AUC of (S)-warfarin (mean AUC_i/AUC=7.633)"
fluconazole_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00196	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluconazole_inhibits_cyp2c9.html	DIKB	"06/30/2009 13:32:26
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/38	refute	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	'The FDA recommends this as a CYP2C9 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19'
quetiapine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp3a4.html	DIKB				refute			
zafirlukast_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_inhibits_cyp3a4.html	DIKB	09/24/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/85	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5550433b-8c9c-4378-058f-6bb724c4f18c	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Zafirlukast is extensively metabolized. The most common metabolic products are hydroxylated metabolites which are excreted in the feces. The metabolites of zafirlukast identified in plasma are at least 90 times less potent as LTD4 receptor antagonists than zafirlukast in a standard in vitro test of activity. In vitro studies using human liver microsomes showed that the hydroxylated metabolites of zafirlukast excreted in the feces are formed through the cytochrome P450 2C9 (CYP2C9) pathway. Additional in vitro studies utilizing human liver microsomes show that zafirlukast inhibits the cytochrome P450 CYP3A4 and CYP2C9 isoenzymes at concentrations close to the clinically achieved total plasma concentrations"
ritonavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp3a4.html	DIKB	"06/30/2009 14:06:14
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/87	refute	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19'
ritonavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp3a4.html	DIKB	"01/11/2010 17:43:46
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/88	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2849298e-de6e-47bb-8194-56e075b33fc3	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions

Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) both in vitro and in vivo. Ritonavir also inhibits CYP2D6 in vitro, but to a lesser extent than CYP3A. Co-administration of ritonavir and drugs primarily metabolized by CYP3A or CYP2D6 may result in increased plasma concentrations of other drugs that could increase or prolong its therapeutic and adverse effects "
ritonavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp3a4.html	DIKB	"01/11/2010 17:52:19
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/89	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2849298e-de6e-47bb-8194-56e075b33fc3	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Table 3 shows that the AUC of sildenafil increased 11-fold in the presence of ritonavir
duloxetine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp2c19.html	DIKB				refute			
duloxetine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp2c19.html	DIKB				refute			
paliperidone_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp3a4.html	DIKB				refute			
verapamil_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00661	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/verapamil_inhibits_cyp3a4.html	DIKB	"06/30/2009 14:26:54
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/113	refute	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;moderate&quot; CYP3A inhibitor in vivo in it most recent guidance document. See Table 5, p22
erythromycin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00199	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/erythromycin_inhibits_cyp3a4.html	DIKB	"06/25/2007 13:47:05
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/140	refute	http://www.ncbi.nlm.nih.gov/pubmed/9757151	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

study duration: 1 day pre-treatment with erythromycin 500mg 2x/day

population: 12 healthy adults 
male: 6
female: 6
ages: 21-39 years

AUC_i/AUC: 20.9/5.5

Quote:
In a randomized, double-blind, 5-trial clinical pharmacokinetic-pharmacodynamic study, 12 volunteers received 0.125 mg triazolam orally, together with placebo, azithromycin, erythromycin, or clarithromycin. In a fifth trial they received placebo plus placebo...Apparent oral clearance was significantly reduced (P < .05) during erythromycin and clarithromycin trials (146 and 95 mL/min). Peak plasma concentration was correspondingly increased, and elimination half-life was prolonged. The effects of triazolam on dynamic measures were nearly identical when triazolam was given with placebo or azithromycin, but benzodiazepine agonist effects were enhanced during erythromycin and clarithromycin trials."
erythromycin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00199	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/erythromycin_inhibits_cyp3a4.html	DIKB	"10/16/2007 09:38:08
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/141	refute	http://www.ncbi.nlm.nih.gov/pubmed/8720318	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

study duration: 4 days pre-treatment with erythromycin 500mg 3x/day; 5th day patients in the treatment arm received a single 15mg oral dose of MDZ

population: 12 healthy adults
male: 4
female: 8
ages: 24-53 years

AUC_i/AUC: 662.71/173.77 ng*hr/ml = 3.814

NOTE: AUC values  appear to be 0-24 hour 

Quote:
&quot;The pharmacokinetic and pharmacodynamic interaction between azithromycin (CAS 83905-01-5), an azalide antibiotic, and midazolam (CAS 59467-70-8), a short-acting hypnotic agent, was investigated in an open, three-way cross-over study, including erythromycin (CAS 114-07-8) as a positive control. Twelve healthy male and female subjects had standard doses of azithromycin (500 mg o.d. over 3 days), or erythromycin (500 mg t.i.d. over 5 days), or no pretreatment. On the day of the last dose, they ingested 15 mg midazolam. Blood samples were collected and psychometric tests performed. Erythromycin pretreatment (E) significantly changed the pharmacokinetics of midazolam compared to control (C), whereas azithromycin (A) had no such effect. The parameters are summarized as follows: area under the concentration-time curve, AUC (C) 173.8 h.ng.ml-1 vs. (E) 662.7 h.ng.ml-1*+ and (A) 220.0 h.ng.ml-1; concentration maxima (C) 67.2 ng.ml-1 vs. (E) 182.3 ng.ml-1*+ and (A) 86.7 ng.ml-1; elimination half-life (C) 2.21 h vs. (E) 4.85 h* and (A) 2.41 h (* p &lt; 0.05 vs. (C), +p &lt; 0.05 vs. (A)). Pharmacodynamic tests (digit symbol substitution test; critical flicker fusion test; subjective analog scale for rating of alertness; duration of sleep) consistently showed significant differences after erythromycin pretreatment compared to control, but not after azithromycin. Erythromycin, but not azithromycin, causes clinically significant changes in the pharmacokinetics and pharmacodynamics of midazolam.&quot;"
montelukast_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp2c19.html	DIKB				refute			
montelukast_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp2c19.html	DIKB				refute			
cinacalcet_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp2c19.html	DIKB				refute			
cinacalcet_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp2c19.html	DIKB				refute			
escitalopram_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp2c19.html	DIKB				refute			
escitalopram_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp2c19.html	DIKB				refute			
citalopram_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp2c9.html	DIKB				refute			
citalopram_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp2c9.html	DIKB				refute			
celecoxib_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp3a4.html	DIKB				refute			
duloxetine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp3a4.html	DIKB				refute			
fluconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00196	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluconazole_inhibits_cyp3a4.html	DIKB	"10/22/2007 13:08:14
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/251	refute	http://www.ncbi.nlm.nih.gov/pubmed/8904618	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

study duration: four phase crossover study; each phase consisted of four days pre-treatment with placebo or fluconazole (50,100, or 200mg), on day four 0.25mg of triazolam was administered

population: 8 healthy adults 
male:3
female:5

ages: 20-32

AUC_i/AUC (0-inf): 
50mg fluconazole = 1.63
100mg fluconazole = 2.05
200mg fluconazole = 4.42

description: 
"
fluconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00196	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluconazole_inhibits_cyp3a4.html	DIKB	"12/10/2007 15:42:25
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/252	refute	http://www.ncbi.nlm.nih.gov/pubmed/16172184	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

study duration: 4-way crossover; subjects received oral fluconazole (100, 200, or 400mg) or placebo;  2 hours later a single dose of MDZ (1mg IV or oral depending on the study arm) was given followed 30 minutes later by 4mg IV of ondansetron, followed by 15ug/kg of IV alfentanil (one arm) or 40mcg oral alfentanil.

population: 6 male, 6 female

ages: 19-36

AUC_i/AUC (0-inf; oral dosing; 100mg fluconazole): 46.1/21.3 

AUC_i/AUC (0-inf; oral dosing; 200mg fluconazole): 70.7/21.3 

AUC_i/AUC (0-inf; oral dosing; 400mg fluconazole): 105/21.3 
"
fluconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00196	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluconazole_inhibits_cyp3a4.html	DIKB	"06/30/2009 13:33:58
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/253	refute	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;moderate&quot; CYP3A inhibitor in vivo in it most recent guidance document. See Table 5, p22
zafirlukast_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_inhibits_cyp2c9.html	DIKB	09/24/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/263	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5550433b-8c9c-4378-058f-6bb724c4f18c	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Zafirlukast is extensively metabolized. The most common metabolic products are hydroxylated metabolites which are excreted in the feces. The metabolites of zafirlukast identified in plasma are at least 90 times less potent as LTD4 receptor antagonists than zafirlukast in a standard in vitro test of activity. In vitro studies using human liver microsomes showed that the hydroxylated metabolites of zafirlukast excreted in the feces are formed through the cytochrome P450 2C9 (CYP2C9) pathway. Additional in vitro studies utilizing human liver microsomes show that zafirlukast inhibits the cytochrome P450 CYP3A4 and CYP2C9 isoenzymes at concentrations close to the clinically achieved total plasma concentrations"
zafirlukast_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_inhibits_cyp2c9.html	DIKB	"09/24/2009 15:41:53
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/264	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5550433b-8c9c-4378-058f-6bb724c4f18c	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Drug-Drug Interactions:
...
Coadministration of multiple doses of zafirlukast (160 mg/day) to steady-state with a single 25 mg dose of warfarin (a substrate of CYP2C9) resulted in a significant increase in the mean AUC (+63%) and half-life (+36%) of S-warfarin. The mean prothrombin time increased by approximately 35%. The pharmacokinetics of zafirlukast were unaffected by coadministration with warfarin."
zafirlukast_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_inhibits_cyp2c9.html	DIKB	09/24/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/263	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5550433b-8c9c-4378-058f-6bb724c4f18c	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Zafirlukast is extensively metabolized. The most common metabolic products are hydroxylated metabolites which are excreted in the feces. The metabolites of zafirlukast identified in plasma are at least 90 times less potent as LTD4 receptor antagonists than zafirlukast in a standard in vitro test of activity. In vitro studies using human liver microsomes showed that the hydroxylated metabolites of zafirlukast excreted in the feces are formed through the cytochrome P450 2C9 (CYP2C9) pathway. Additional in vitro studies utilizing human liver microsomes show that zafirlukast inhibits the cytochrome P450 CYP3A4 and CYP2C9 isoenzymes at concentrations close to the clinically achieved total plasma concentrations"
zafirlukast_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_inhibits_cyp2c9.html	DIKB	"09/24/2009 15:41:53
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/264	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5550433b-8c9c-4378-058f-6bb724c4f18c	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"
Drug-Drug Interactions:
...
Coadministration of multiple doses of zafirlukast (160 mg/day) to steady-state with a single 25 mg dose of warfarin (a substrate of CYP2C9) resulted in a significant increase in the mean AUC (+63%) and half-life (+36%) of S-warfarin. The mean prothrombin time increased by approximately 35%. The pharmacokinetics of zafirlukast were unaffected by coadministration with warfarin."
fluvoxamine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00176	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvoxamine_inhibits_cyp2c19.html	DIKB	"05/05/2009 17:27:55
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/273	refute	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	Fluvoxamine is listed as a recommended inhibitor of CYP2C19 for in vivo studies in Table 2 (p. 19). Typically, this would qualify it as a in vivo selective inhibitor however, Table 2 also shows fluvoxamine as a recommended inhibitor of CYP1A2.
fluvoxamine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00176	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvoxamine_inhibits_cyp2c19.html	DIKB	"05/15/2009 08:52:34
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/274	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/53664f8d-3a93-9f2b-daee-380707e4062c	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"(table from section &quot;Drug Interactions&quot;)

Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also  WARNINGS for details) and limited in vitro data for the IIIA4 isozyme, it appears that fluvoxamine inhibits the following isozymes that are known to be involved in the metabolism of the listed drugs:
IA2             IIC9	        IIIA4         IIC19
Warfarin	Warfarin	Alprazolam   Omeprazole
Theophylline			
Propranolol			
Tizanidine			"
fluvoxamine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00176	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvoxamine_inhibits_cyp2c19.html	DIKB	"05/05/2009 17:27:55
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/273	refute	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	Fluvoxamine is listed as a recommended inhibitor of CYP2C19 for in vivo studies in Table 2 (p. 19). Typically, this would qualify it as a in vivo selective inhibitor however, Table 2 also shows fluvoxamine as a recommended inhibitor of CYP1A2.
fluvoxamine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00176	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvoxamine_inhibits_cyp2c19.html	DIKB	"05/15/2009 08:52:34
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/274	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/53664f8d-3a93-9f2b-daee-380707e4062c	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"(table from section &quot;Drug Interactions&quot;)

Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also  WARNINGS for details) and limited in vitro data for the IIIA4 isozyme, it appears that fluvoxamine inhibits the following isozymes that are known to be involved in the metabolism of the listed drugs:
IA2             IIC9	        IIIA4         IIC19
Warfarin	Warfarin	Alprazolam   Omeprazole
Theophylline			
Propranolol			
Tizanidine			"
paliperidone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2c9.html	DIKB				refute			
paliperidone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2c9.html	DIKB				refute			
atazanavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp3a4.html	DIKB	"06/30/2009 12:47:19
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/298	refute	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19
atazanavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp3a4.html	DIKB	"01/11/2010 15:38:56
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/299	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.1 Potential for REYATAZ to Affect Other Drugs

Atazanavir is an inhibitor of CYP3A and UGT1A1. Coadministration of REYATAZ and drugs primarily metabolized by CYP3A or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects."
risperidone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00734	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/risperidone_inhibits_cyp2c19.html	DIKB				refute			
risperidone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00734	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/risperidone_inhibits_cyp2c19.html	DIKB				refute			
perphenazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_inhibits_cyp2c19.html	DIKB				refute			
perphenazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_inhibits_cyp2c19.html	DIKB				refute			
eszopiclone_inhibits_CYP3A4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP3A4.html	DIKB				refute			
cinacalcet_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp3a4.html	DIKB				refute			
modafinil_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00745	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/modafinil_inhibits_cyp2c19.html	DIKB	"09/24/2009 12:37:09
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/349	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e16c26ad-7bc2-d155-3a5d-da83ad6492c8.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions
...
In vitro studies using human liver microsomes showed that modafinil reversibly inhibited CYP2C19 at pharmacologically relevant concentrations of modafinil. CYP2C19 is also reversibly inhibited, with similar potency, by a circulating metabolite, modafinil sulfone. Although the maximum plasma concentrations of modafinil sulfone are much lower than those of parent modafinil, the combined effect of both compounds could produce sustained partial inhibition of the enzyme. Drugs that are largely eliminated via CYP2C19 metabolism, such as diazepam, propranolol, phenytoin (also via CYP2C9) or S-mephenytoin may have prolonged elimination upon coadministration with PROVIGIL and may require dosage reduction and monitoring for toxicity."
modafinil_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00745	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/modafinil_inhibits_cyp2c19.html	DIKB	"09/24/2009 12:37:09
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/349	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e16c26ad-7bc2-d155-3a5d-da83ad6492c8.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions
...
In vitro studies using human liver microsomes showed that modafinil reversibly inhibited CYP2C19 at pharmacologically relevant concentrations of modafinil. CYP2C19 is also reversibly inhibited, with similar potency, by a circulating metabolite, modafinil sulfone. Although the maximum plasma concentrations of modafinil sulfone are much lower than those of parent modafinil, the combined effect of both compounds could produce sustained partial inhibition of the enzyme. Drugs that are largely eliminated via CYP2C19 metabolism, such as diazepam, propranolol, phenytoin (also via CYP2C9) or S-mephenytoin may have prolonged elimination upon coadministration with PROVIGIL and may require dosage reduction and monitoring for toxicity."
venlafaxine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp2c9.html	DIKB				refute			
venlafaxine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp2c9.html	DIKB				refute			
celecoxib_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp2c9.html	DIKB				refute			
celecoxib_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp2c9.html	DIKB				refute			
escitalopram_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp2c9.html	DIKB				refute			
escitalopram_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp2c9.html	DIKB				refute			
topiramate_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp2c9.html	DIKB				refute			
topiramate_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp2c9.html	DIKB				refute			
diltiazem_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00343	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/diltiazem_inhibits_cyp3a4.html	DIKB	"05/29/2007 11:43:17
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/447	refute	http://www.ncbi.nlm.nih.gov/pubmed/9146848	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"Route of administration: oral

polymorphic enzyme: NO

study duration: 3 day pretreatment with diltiazem

population: 7 male

ages: 20-22

description: 
We investigated the interaction between triazolam and diltiazem in a randomized, three-phase crossover study. Seven healthy male volunteers received orally either a single 0.25 mg dose of triazolam, a 0.25 mg dose of triazolam after a 3-day treatment of diltiazem (180 mg day-1), or a placebo. Plasma samples were collected to determine triazolam concentration over a 24 h period. The pharmacodynamic effects of triazolam were investigated using the peak saccadic velocity of eye movements (PSV), electroencephalogram (EEG), and visual analogue scale (VAS) through 8 h. RESULTS: Diltiazem pretreatment significantly increased the area under the triazolam concentration-time curve (8.0 +/- 2.4 to 18.2 +/- 3.1 ng ml-1 h; P < 0.001; mean +/- s.d.). Peak triazolam concentration was increased (2.1 +/- 0.7 to 3.6 +/- 1.0 ng ml-1, P < 0.05) and the elimination half-life prolonged (4.1 +/- 2.1 to 7.6 +/- 1.9 h; P < 0.01). The PSV, EEG, and VAS of the triazolam plus diltiazem group revealed significant differences from the triazolam alone group or the control placebo group."
citalopram_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp2c19.html	DIKB				refute			
citalopram_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp2c19.html	DIKB				refute			
montelukast_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp3a4.html	DIKB				refute			
clozapine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_inhibits_cyp2c19.html	DIKB				refute			
clozapine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_inhibits_cyp2c19.html	DIKB				refute			
amiodarone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01118	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/amiodarone_inhibits_cyp2c9.html	DIKB	"06/30/2009 12:43:42
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/482	refute	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA recommends this as a CYPC9 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19
amiodarone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01118	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/amiodarone_inhibits_cyp2c9.html	DIKB	"01/11/2010 16:39:16
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/483	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/99991CC3-7271-44FC-91C3-3CAB0BBE7645	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and CYP3A4. This inhibition can result in unexpectedly high plasma levels of other drugs which are metabolized by those CYP450 enzymes. 
amiodarone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01118	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/amiodarone_inhibits_cyp2c9.html	DIKB	"06/30/2009 12:43:42
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/482	refute	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA recommends this as a CYPC9 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19
amiodarone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01118	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/amiodarone_inhibits_cyp2c9.html	DIKB	"01/11/2010 16:39:16
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/483	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/99991CC3-7271-44FC-91C3-3CAB0BBE7645	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and CYP3A4. This inhibition can result in unexpectedly high plasma levels of other drugs which are metabolized by those CYP450 enzymes. 
celecoxib_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp2c19.html	DIKB				refute			
celecoxib_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp2c19.html	DIKB				refute			
paliperidone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2c19.html	DIKB				refute			
paliperidone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2c19.html	DIKB				refute			
voriconazole_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_inhibits_cyp2c9.html	DIKB	09/24/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/542	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Effects of Voriconazole on Other Drugs

In vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes."
voriconazole_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_inhibits_cyp2c9.html	DIKB	09/24/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/542	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Effects of Voriconazole on Other Drugs

In vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes."
rosiglitazone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2c19.html	DIKB				refute			
rosiglitazone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2c19.html	DIKB				refute			
indinavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00224	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/indinavir_inhibits_cyp3a4.html	DIKB	"06/30/2009 13:39:31
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/577	refute	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	'The FDA recommends this as a CYP3A inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19'
indinavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00224	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/indinavir_inhibits_cyp3a4.html	DIKB	"01/11/2010 16:31:55
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/578	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Indinavir is an inhibitor of the cytochrome P450 isoform CYP3A4. Coadministration of CRIXIVAN and drugs primarily metabolized by CYP3A4 may result in increased plasma concentrations of the other drug, which could increase or prolong its therapeutic and adverse effects (see CONTRAINDICATIONS and WARNINGS). Based on in vitro data in human liver microsomes, indinavir does not inhibit CYP1A2, CYP2C9, CYP2E1 and CYP2B6. However, indinavir may be a weak inhibitor of CYP2D6.
indinavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00224	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/indinavir_inhibits_cyp3a4.html	DIKB	"01/11/2010 16:59:43
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/579	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e19405d9-d9a1-4072-5b9e-40cd3ae4bf1f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Sildenafil:  The results of one published study in HIV-infected men (n=6) indicated that coadministration of indinavir (800 mg every 8 hours chronically) with a single 25-mg dose of sildenafil resulted in an 11% increase in average AUC0-8hr of indinavir and a 48% increase in average indinavir peak concentration (Cmax) compared to 800 mg every 8 hours alone. Average sildenafil AUC was increased by 340% following coadministration of sildenafil and indinavir compared to historical data following administration of sildenafil alone (see WARNINGS, Drug Interactions and PRECAUTIONS, Drug Interactions).
ziprasidone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp2c9.html	DIKB				refute			
ziprasidone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp2c9.html	DIKB				refute			
atazanavir_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp2c19.html	DIKB				refute			
atazanavir_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp2c19.html	DIKB				refute			
quetiapine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp2c9.html	DIKB				refute			
quetiapine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp2c9.html	DIKB				refute			
aripiprazole_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_inhibits_cyp2c19.html	DIKB				refute			
aripiprazole_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_inhibits_cyp2c19.html	DIKB				refute			
haloperidol_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00502	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/haloperidol_inhibits_cyp2c19.html	DIKB				refute			
haloperidol_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00502	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/haloperidol_inhibits_cyp2c19.html	DIKB				refute			
voriconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_inhibits_cyp3a4.html	DIKB	09/24/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/715	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ce3ef5cf-3087-4d92-9d94-9eb8287228db	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Effects of Voriconazole on Other Drugs

In vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes."
duloxetine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp2c9.html	DIKB				refute			
duloxetine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp2c9.html	DIKB				refute			
ketoconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01026	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ketoconazole_inhibits_cyp3a4.html	DIKB	"05/21/2007 15:16:35
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/758	refute	http://www.ncbi.nlm.nih.gov/pubmed/15114429	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_Par_Grps	"
Route of administration: oral

polymorphic enzyme: NO

study duration: 2 days ketoconazole pretreatment

population: 8 male, 13 female

ages:23-55

description: 
Plasma concentrations of midazolam, 1'OH-midazolam and 4'OH-midazolam were measured after the oral administration of 7.5 mg and 75 micro g midazolam in 13 healthy subjects without medication, in four subjects pretreated for 2 days with ketoconazole (200 mg b.i.d.), a CYP3A inhibitor, and in four subjects pretreated for 4 days with rifampicin (450 mg q.d.), a CYP3A inducer. RESULTS: After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively. No side effects were reported by the subjects taking this low dose of midazolam. Good correlations were observed between the 30-min total 1'OH-midazolam/midazolam ratio and midazolam clearance in the group without co-medication (r(2)=0.64, P<0.001) and in the three groups taken together (r(2)=0.91, P<0.0001)."
ketoconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01026	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ketoconazole_inhibits_cyp3a4.html	DIKB	"05/21/2007 15:27:20
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/759	refute	http://www.ncbi.nlm.nih.gov/pubmed/14551182	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

polymorphic enzyme: NO

study duration: 12 days

population: 17 male, 23 female

ages:18-50

description:
Forty healthy subjects were randomized to receive one of the four study drugs for 12 days in a parallel study design: fluoxetine 60 mg per day for 5 days, followed by 20 mg per day for 7 days; fluvoxamine titrated to a daily dose of 200 mg; nefazodone titrated to a daily dose of 400 mg; or ketoconazole 200 mg per day. All 40 subjects received oral midazolam solution before and after the 12-day study drug regimen. Blood samples for determination of midazolam concentrations were drawn for 24 hours after each midazolam dose and used for the calculation of pharmacokinetic parameters. The effects of the study drugs on midazolam pharmacodynamics were assessed using the symbol digit modalities test (SDMT). The mean area under the curve (AUC) for midazolam was increased 771.9% by ketoconazole..."
ketoconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01026	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ketoconazole_inhibits_cyp3a4.html	DIKB	"05/21/2007 16:08:37
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/760	refute	http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=1332	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"ketoconazole-janssen-2006-daily-med

Label date: 08/2006
Date of DIKB entry: 05/21/2007

Ambiguous statement? NO

description:
Ketoconazole is a potent inhibitor of the cytochrome P450 3A4 enzyme system. Coadministration of NIZORALï¿½ Tablets and drugs primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentrations of the drugs that could increase or prolong both therapeutic and adverse effects. Therefore, unless otherwise specified, appropriate dosage adjustments may be necessary. "
ketoconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01026	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ketoconazole_inhibits_cyp3a4.html	DIKB	"01/11/2010 17:05:33
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/761	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8ca815a8-bccb-4ee2-a042-922373329cae	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions

Ketoconazole is a potent inhibitor of the cytochrome P450 3A4 enzyme system. Coadministration of ketoconazole tablets and drugs primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentrations of the drugs that could increase or prolong both therapeutic and adverse effects. Therefore, unless otherwise specified, appropriate dosage adjustments may be necessary. "
amiodarone_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01118	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/amiodarone_inhibits_cyp3a4.html	DIKB	"01/11/2010 16:35:31
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/836	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/99991CC3-7271-44FC-91C3-3CAB0BBE7645	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions
...
Amiodarone is also known to be an inhibitor of CYP3A4. Therefore, amiodarone has the potential for interactions with drugs or substances that may be substrates, inhibitors or inducers of CYP3A4. While only a limited number of in vivo drug-drug interactions with amiodarone have been reported, the potential for other interactions should be anticipated. This is especially important for drugs associated with serious toxicity, such as other antiarrhythmics. If such drugs are needed, their dose should be reassessed and, where appropriate, plasma concentration measured. In view of the long and variable half-life of amiodarone, potential for drug interactions exists, not only with concomitant medication, but also with drugs administered after discontinuation of amiodarone."
clarithromycin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_inhibits_cyp3a4.html	DIKB	"06/05/2007 14:12:44
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/861	refute	http://www.ncbi.nlm.nih.gov/pubmed/8880291	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"
Route of administration: oral

polymorphic enzyme: NO

study duration: 5 day petreatment with clarithromycin 

population: 4 male, 8 female

ages:24-53

In an open randomized crossover study of 3 phases 12 healthy volunteers received either clarithromycin (250 mg twice a day for 5 days), azithromycin (500 mg once a day for 3 days) or no pretreatment. On the last day of antibiotic treatment they ingested 15 mg midazolam. Plasma samples were collected for midazolam analysis up to 24 h and pharmacodynamic performance measured by a series of tests up to 12 h. Pretreatment with clarithromycin caused large and statistically significant changes in both the pharmacokinetic and pharmacodynamic parameters of midazolam compared to control. For example, the AUC was increased from 248.84-888.75 hng/ml (factor of 3.57, p < 0.0001) and the mean duration of sleep increased from 135.4 min to 281.3 min (p < 0.05)."
clarithromycin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_inhibits_cyp3a4.html	DIKB	"06/30/2009 13:05:51
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/862	refute	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	'The FDA recommends this as a CYP3A inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19'
clarithromycin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_inhibits_cyp3a4.html	DIKB	"01/11/2010 16:45:51
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/863	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/aa44552c-3cfe-4111-8aa5-4251aeed9be9	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Co-administration of clarithromycin, known to inhibit CYP3A, and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug.

Clarithromycin should be used with caution in patients receiving treatment with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g., carbamazepine) and/or the substrate is extensively metabolized by this enzyme. Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored closely in patients concurrently receiving clarithromycin."
mirtazapine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_inhibits_cyp2c9.html	DIKB	"02/12/2010 17:32:18
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/29	support	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

substrate used: tolbutamide

reaction: tolbutamide hydroxylation 

Quote: 
Mirtazapine reduced the rate of the reaction by much less than 50% even at concentrations of 250micM (see Table 3).


"
mirtazapine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_inhibits_cyp2c9.html	DIKB	"02/12/2010 17:32:18
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/29	support	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

substrate used: tolbutamide

reaction: tolbutamide hydroxylation 

Quote: 
Mirtazapine reduced the rate of the reaction by much less than 50% even at concentrations of 250micM (see Table 3).


"
fluconazole_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00196	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluconazole_inhibits_cyp2c9.html	DIKB				support			
fluconazole_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00196	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluconazole_inhibits_cyp2c9.html	DIKB				support			
quetiapine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp3a4.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/76	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.
zafirlukast_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_inhibits_cyp3a4.html	DIKB				support			
ritonavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp3a4.html	DIKB				support			
duloxetine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp2c19.html	DIKB	"05/05/2009 17:40:26
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/106	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.12 Drugs Metabolized by CYP2C19

Results of in vitro studies demonstrate that duloxetine does not inhibit CYP2C19 activity at therapeutic concentrations. Inhibition of the metabolism of CYP2C19 substrates is therefore not anticipated, although clinical studies have not been performed."
duloxetine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp2c19.html	DIKB	"05/05/2009 17:40:26
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/106	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.12 Drugs Metabolized by CYP2C19

Results of in vitro studies demonstrate that duloxetine does not inhibit CYP2C19 activity at therapeutic concentrations. Inhibition of the metabolism of CYP2C19 substrates is therefore not anticipated, although clinical studies have not been performed."
paliperidone_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp3a4.html	DIKB	06102009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/109	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.
verapamil_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00661	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/verapamil_inhibits_cyp3a4.html	DIKB				support			
erythromycin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00199	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/erythromycin_inhibits_cyp3a4.html	DIKB				support			
montelukast_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp2c19.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/142	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).
montelukast_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp2c19.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/142	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).
cinacalcet_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp2c19.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/194	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions
...
An in vitro study indicates that cinacalcet is a strong inhibitor of CYP2D6, but not of CYP1A2, CYP2C9, CYP2C19, and CYP3A4."
cinacalcet_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp2c19.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/194	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions
...
An in vitro study indicates that cinacalcet is a strong inhibitor of CYP2D6, but not of CYP1A2, CYP2C9, CYP2C19, and CYP3A4."
escitalopram_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp2c19.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/199	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	in vitro enzyme inhibition data did not reveal an inhibitory effect of escitalopram on CYP3A4, -1A2, -2C9, -2C19, and -2E1. Based on in vitro data, escitalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes.
escitalopram_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp2c19.html	DIKB	"06/11/2009 16:10:21
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/200	support	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: S-mepheytoin 4'hydroxylation

Quote: 

CYP2C19. R- and S-CT were very weak inhibitors, with less than 50% inhibition of S-mephenytoin hydroxylation even at 100micM. R- and S-DCT also were weak inhibitors. R- and S-DDCT were moderate inhibitors, with mean IC50 values of 18.7 and 12.1micM, respectively. Omeprazole was a strong inhibitor of CYP2C19, as was the SSRI
fluvoxamine (see Table 2).


"
escitalopram_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp2c19.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/199	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	in vitro enzyme inhibition data did not reveal an inhibitory effect of escitalopram on CYP3A4, -1A2, -2C9, -2C19, and -2E1. Based on in vitro data, escitalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes.
escitalopram_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp2c19.html	DIKB	"06/11/2009 16:10:21
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/200	support	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: S-mepheytoin 4'hydroxylation

Quote: 

CYP2C19. R- and S-CT were very weak inhibitors, with less than 50% inhibition of S-mephenytoin hydroxylation even at 100micM. R- and S-DCT also were weak inhibitors. R- and S-DDCT were moderate inhibitors, with mean IC50 values of 18.7 and 12.1micM, respectively. Omeprazole was a strong inhibitor of CYP2C19, as was the SSRI
fluvoxamine (see Table 2).


"
citalopram_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp2c9.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/212	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data did not reveal an inhibitory effect of citalopram on CYP3A4, -2C9, or -2E1, but did suggest that it is a weak inhibitor of CYP1A2, -2D6, and -2C19. Citalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes. However, in vivo data to address this question are limited.
citalopram_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp2c9.html	DIKB	"02/12/2010 14:53:49
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/213	support	http://www.ncbi.nlm.nih.gov/pubmed/9278211	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"

route of administration: oral

study duration: a single 25 mg dose of racemic warfarin either alone or on Day 15 of a 21-day oral dosing regimen of 40 mg citalopram daily. Blood samples for pharmacokinetic analysis were obtained over a 168 h period after warfarin dosing.

population: 12 healthy males 

tested for known CYP450 polymorphisms? no

ages: 21 - 32

description:
Citalopram produced no change in the pharmacokinetics of (R)- and (S)-warfarin, indicating that citalopram does not alter the metabolism of warfarin mediated via CYP1A2, CYP3A4 and CYP2C9.


"
citalopram_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp2c9.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/212	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/62f9e5da-6215-4d6d-8601-ea01ec2655ab	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data did not reveal an inhibitory effect of citalopram on CYP3A4, -2C9, or -2E1, but did suggest that it is a weak inhibitor of CYP1A2, -2D6, and -2C19. Citalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes. However, in vivo data to address this question are limited.
citalopram_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp2c9.html	DIKB	"02/12/2010 14:53:49
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/213	support	http://www.ncbi.nlm.nih.gov/pubmed/9278211	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_RCT	"

route of administration: oral

study duration: a single 25 mg dose of racemic warfarin either alone or on Day 15 of a 21-day oral dosing regimen of 40 mg citalopram daily. Blood samples for pharmacokinetic analysis were obtained over a 168 h period after warfarin dosing.

population: 12 healthy males 

tested for known CYP450 polymorphisms? no

ages: 21 - 32

description:
Citalopram produced no change in the pharmacokinetics of (R)- and (S)-warfarin, indicating that citalopram does not alter the metabolism of warfarin mediated via CYP1A2, CYP3A4 and CYP2C9.


"
celecoxib_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp3a4.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/222	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug interactions:

In vitro studies indicate that celecoxib is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4."
duloxetine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp3a4.html	DIKB	"05/05/2009 17:38:52
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/235	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.11 Drugs Metabolized by CYP3A

Results of in vitro studies demonstrate that duloxetine does not inhibit or induce CYP3A activity. Therefore, an increase or decrease in the metabolism of CYP3A substrates (e.g., oral contraceptives and other steroidal agents) resulting from induction or inhibition is not anticipated, although clinical studies have not been performed. "
fluconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00196	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluconazole_inhibits_cyp3a4.html	DIKB				support			
zafirlukast_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_inhibits_cyp2c9.html	DIKB				support			
zafirlukast_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_inhibits_cyp2c9.html	DIKB				support			
fluvoxamine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00176	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvoxamine_inhibits_cyp2c19.html	DIKB				support			
fluvoxamine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00176	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/fluvoxamine_inhibits_cyp2c19.html	DIKB				support			
paliperidone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2c9.html	DIKB	06102009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/288	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.
paliperidone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2c9.html	DIKB	06102009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/289	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While in vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, in vivo studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance. In vitro studies have shown that paliperidone is a P-gp substrate.
paliperidone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2c9.html	DIKB	06102009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/288	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.
paliperidone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2c9.html	DIKB	06102009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/289	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While in vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, in vivo studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance. In vitro studies have shown that paliperidone is a P-gp substrate.
atazanavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp3a4.html	DIKB				support			
risperidone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00734	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/risperidone_inhibits_cyp2c19.html	DIKB	"04/25/2009 09:58:43
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/303	support	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
risperidone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00734	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/risperidone_inhibits_cyp2c19.html	DIKB	"04/25/2009 09:58:43
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/303	support	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
perphenazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_inhibits_cyp2c19.html	DIKB	"04/25/2009 10:18:23
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/304	support	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
perphenazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_inhibits_cyp2c19.html	DIKB	"04/25/2009 10:18:23
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/304	support	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
eszopiclone_inhibits_CYP3A4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP3A4.html	DIKB	11/09/2009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/306	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes."
cinacalcet_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp3a4.html	DIKB	"09/21/2009 15:20:18
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/330	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions
....

Midazolam: There were no significant differences in the pharmacokinetics of midazolam, a CYP3A4 and CYP3A5 substrate, in subjects receiving 90 mg cinacalcet once daily for 5 days and a single dose of 2 mg midazolam on day 5 as compared to those of subjects receiving 2 mg midazolam alone.  This suggests that cinacalcet would not affect the pharmacokinetics of drugs predominantly metabolized by CYP3A4 and CYP3A5."
cinacalcet_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp3a4.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/331	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions
...
An in vitro study indicates that cinacalcet is a strong inhibitor of CYP2D6, but not of CYP1A2, CYP2C9, CYP2C19, and CYP3A4."
modafinil_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00745	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/modafinil_inhibits_cyp2c19.html	DIKB				support			
modafinil_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00745	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/modafinil_inhibits_cyp2c19.html	DIKB				support			
venlafaxine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp2c9.html	DIKB	"05/14/2009 13:49:46
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/371	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	CYP2C9: Venlafaxine did not inhibit CYP2C9 in vitro. In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide. 
venlafaxine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp2c9.html	DIKB	"02/12/2010 14:23:14
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/372	support	http://www.ncbi.nlm.nih.gov/pubmed/9205822	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

reaction: tolbutamide-4-hydroxylation

Quote: 
The IC50 for venlafaxine's inhibition of the reaction was &gt; 1000micM "
venlafaxine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp2c9.html	DIKB	"05/14/2009 13:49:46
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/371	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	CYP2C9: Venlafaxine did not inhibit CYP2C9 in vitro. In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the pharmacokinetics of a single 500 mg dose of tolbutamide or the CYP2C9 mediated formation of 4-hydroxy-tolbutamide. 
venlafaxine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp2c9.html	DIKB	"02/12/2010 14:23:14
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/372	support	http://www.ncbi.nlm.nih.gov/pubmed/9205822	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

reaction: tolbutamide-4-hydroxylation

Quote: 
The IC50 for venlafaxine's inhibition of the reaction was &gt; 1000micM "
celecoxib_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp2c9.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/391	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug interactions:

In vitro studies indicate that celecoxib is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4."
celecoxib_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp2c9.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/391	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug interactions:

In vitro studies indicate that celecoxib is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4."
escitalopram_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp2c9.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/402	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	in vitro enzyme inhibition data did not reveal an inhibitory effect of escitalopram on CYP3A4, -1A2, -2C9, -2C19, and -2E1. Based on in vitro data, escitalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes.
escitalopram_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp2c9.html	DIKB	"06/11/2009 15:15:34
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/403	support	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"


Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: tolbutamide --&gt; hydroxytolbutamide

Quote: 

CYP2C9. R-CT, S-CT, R-DCT, and S-DCT were weak inhibitors of CYP2C9, represented by tolbutamide hydroxylation, with less than 50% inhibition produced even at 250micM. R-DDCT and S-DDCT produced a moderate degree of inhibition, with IC50 values of 30.7  (+/-6.3)micM and 25.7 (+/-8.0)micM, respectively. Sulfaphenazole was a strong inhibitor (IC50 1.3micM), and the SSRI fluvoxamine also was a moderately strong inhibitor (IC50 9.4micM).


"
escitalopram_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp2c9.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/402	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/13bb8267-1cab-43e5-acae-55a4d957630a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	in vitro enzyme inhibition data did not reveal an inhibitory effect of escitalopram on CYP3A4, -1A2, -2C9, -2C19, and -2E1. Based on in vitro data, escitalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these cytochromes.
escitalopram_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01175	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/escitalopram_inhibits_cyp2c9.html	DIKB	"06/11/2009 15:15:34
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/403	support	http://www.ncbi.nlm.nih.gov/pubmed/11454728	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"


Enzyme system: human liver microsomes

NADPH added: yes (a dehydrogenase generating system)

probe reaction: tolbutamide --&gt; hydroxytolbutamide

Quote: 

CYP2C9. R-CT, S-CT, R-DCT, and S-DCT were weak inhibitors of CYP2C9, represented by tolbutamide hydroxylation, with less than 50% inhibition produced even at 250micM. R-DDCT and S-DDCT produced a moderate degree of inhibition, with IC50 values of 30.7  (+/-6.3)micM and 25.7 (+/-8.0)micM, respectively. Sulfaphenazole was a strong inhibitor (IC50 1.3micM), and the SSRI fluvoxamine also was a moderately strong inhibitor (IC50 9.4micM).


"
topiramate_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp2c9.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/428	support	http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.
topiramate_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp2c9.html	DIKB	"09/22/2009 17:58:27
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/429	support	http://www.ncbi.nlm.nih.gov/pubmed/12102670	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: assumed based on the date of the article and authors

substrate used: S-warfarin

reaction: S-warfarin 7-hydroxylation

Quote:
No inhibition was found in microsomal preparations made from human livers with adequate CYP2D6 activity or with expressed CYP2D or with adequate activity of CYPs 1A2, 2A6, 2C9, 2E1, and 3A4. "
topiramate_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp2c9.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/428	support	http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=10338	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.
topiramate_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00273	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/topiramate_inhibits_cyp2c9.html	DIKB	"09/22/2009 17:58:27
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/429	support	http://www.ncbi.nlm.nih.gov/pubmed/12102670	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: assumed based on the date of the article and authors

substrate used: S-warfarin

reaction: S-warfarin 7-hydroxylation

Quote:
No inhibition was found in microsomal preparations made from human livers with adequate CYP2D6 activity or with expressed CYP2D or with adequate activity of CYPs 1A2, 2A6, 2C9, 2E1, and 3A4. "
diltiazem_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00343	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/diltiazem_inhibits_cyp3a4.html	DIKB				support			
citalopram_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp2c19.html	DIKB				support			
citalopram_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00215	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/citalopram_inhibits_cyp2c19.html	DIKB				support			
montelukast_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp3a4.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/472	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).
clozapine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_inhibits_cyp2c19.html	DIKB	"04/25/2009 10:22:07
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/475	support	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
clozapine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00363	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clozapine_inhibits_cyp2c19.html	DIKB	"04/25/2009 10:22:07
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/475	support	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
amiodarone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01118	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/amiodarone_inhibits_cyp2c9.html	DIKB				support			
amiodarone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01118	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/amiodarone_inhibits_cyp2c9.html	DIKB				support			
celecoxib_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp2c19.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/493	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug interactions:

In vitro studies indicate that celecoxib is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4."
celecoxib_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp2c19.html	DIKB	09212009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/493	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug interactions:

In vitro studies indicate that celecoxib is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4."
paliperidone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2c19.html	DIKB	06102009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/540	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While in vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, in vivo studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance. In vitro studies have shown that paliperidone is a P-gp substrate.
paliperidone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp2c19.html	DIKB	06102009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/540	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While in vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, in vivo studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance. In vitro studies have shown that paliperidone is a P-gp substrate.
voriconazole_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_inhibits_cyp2c9.html	DIKB				support			
voriconazole_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_inhibits_cyp2c9.html	DIKB				support			
rosiglitazone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2c19.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/569	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.
rosiglitazone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2c19.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/569	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.
indinavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00224	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/indinavir_inhibits_cyp3a4.html	DIKB				support			
ziprasidone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp2c9.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/583	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	An in vitro enzyme inhibition study utilizing human liver microsomes showed that ziprasidone had little inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and thus would not likely interfere with the metabolism of drugs primarily metabolized by these enzymes.
ziprasidone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp2c9.html	DIKB	"06/19/2009 17:08:33
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/584	support	http://www.ncbi.nlm.nih.gov/pubmed/10771452	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes

reaction: tolbutamide hydroxylation

The IC50 for ziprasidone inhibition of this reaction was greater than 100micM 


"
ziprasidone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp2c9.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/583	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	An in vitro enzyme inhibition study utilizing human liver microsomes showed that ziprasidone had little inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and thus would not likely interfere with the metabolism of drugs primarily metabolized by these enzymes.
ziprasidone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp2c9.html	DIKB	"06/19/2009 17:08:33
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/584	support	http://www.ncbi.nlm.nih.gov/pubmed/10771452	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes

NADPH added: yes

reaction: tolbutamide hydroxylation

The IC50 for ziprasidone inhibition of this reaction was greater than 100micM 


"
atazanavir_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp2c19.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/601	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.
atazanavir_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp2c19.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/601	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.
quetiapine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp2c9.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/615	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.
quetiapine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp2c9.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/615	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.
aripiprazole_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_inhibits_cyp2c19.html	DIKB	"04/29/2009 19:39:57
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/633	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.
aripiprazole_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_inhibits_cyp2c19.html	DIKB	"04/29/2009 19:39:57
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/633	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.
haloperidol_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00502	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/haloperidol_inhibits_cyp2c19.html	DIKB	"04/25/2009 10:21:12
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/700	support	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
haloperidol_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00502	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/haloperidol_inhibits_cyp2c19.html	DIKB	"04/25/2009 10:21:12
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/700	support	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
voriconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00582	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/voriconazole_inhibits_cyp3a4.html	DIKB				support			
duloxetine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp2c9.html	DIKB	"05/05/2009 17:37:51
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/723	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.10 Drugs Metabolized by CYP2C9

Duloxetine does not inhibit the in vitro enzyme activity of CYP2C9. Inhibition of the metabolism of CYP2C9 substrates is therefore not anticipated, although clinical studies have not been performed."
duloxetine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp2c9.html	DIKB	"05/05/2009 17:37:51
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/723	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.10 Drugs Metabolized by CYP2C9

Duloxetine does not inhibit the in vitro enzyme activity of CYP2C9. Inhibition of the metabolism of CYP2C9 substrates is therefore not anticipated, although clinical studies have not been performed."
ketoconazole_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01026	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ketoconazole_inhibits_cyp3a4.html	DIKB				support			
amiodarone_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01118	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/amiodarone_inhibits_cyp3a4.html	DIKB				support			
clarithromycin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01211	http://purl.obolibrary.org/obo/PR_000006130	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/clarithromycin_inhibits_cyp3a4.html	DIKB				support			
ziprasidone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp2c19.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/956	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	An in vitro enzyme inhibition study utilizing human liver microsomes showed that ziprasidone had little inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and thus would not likely interfere with the metabolism of drugs primarily metabolized by these enzymes.
ziprasidone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006118	modafinil-sulfone	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp2c19.html	DIKB	"06/19/2009 17:10:35
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/957	support	http://www.ncbi.nlm.nih.gov/pubmed/10771452	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"

Enzyme system: human liver microsomes

NADPH added: yes

reaction: S-mephenytoin 4'-hydroxylatoin

The IC50 for ziprasidone inhibition of this reaction was greater than 100micM 


"
ziprasidone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp2c19.html	DIKB	05142009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/956	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8326928a-2cb6-4f7f-9712-03a425a14c37	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	An in vitro enzyme inhibition study utilizing human liver microsomes showed that ziprasidone had little inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and thus would not likely interfere with the metabolism of drugs primarily metabolized by these enzymes.
ziprasidone_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00246	http://purl.obolibrary.org/obo/PR_000006118	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ziprasidone_inhibits_cyp2c19.html	DIKB	"06/19/2009 17:10:35
"	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/957	support	http://www.ncbi.nlm.nih.gov/pubmed/10771452	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"

Enzyme system: human liver microsomes

NADPH added: yes

reaction: S-mephenytoin 4'-hydroxylatoin

The IC50 for ziprasidone inhibition of this reaction was greater than 100micM 


"
atazanavir_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006120	voriconazole-N-oxide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp2c9.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/961	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.
atazanavir_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01072	http://purl.obolibrary.org/obo/PR_000006120	teriflunomide	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atazanavir_inhibits_cyp2c9.html	DIKB	01/11/2010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/961	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/165cff62-b284-4a27-a65d-9ec8a5bfcdd8	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates of CYP2C8.
cinacalcet_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/18	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions
....

Midazolam: There were no significant differences in the pharmacokinetics of midazolam, a CYP3A4 and CYP3A5 substrate, in subjects receiving 90 mg cinacalcet once daily for 5 days and a single dose of 2 mg midazolam on day 5 as compared to those of subjects receiving 2 mg midazolam alone.  This suggests that cinacalcet would not affect the pharmacokinetics of drugs predominantly metabolized by CYP3A4 and CYP3A5."
cinacalcet_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/19	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions
...
An in vitro study indicates that cinacalcet is a strong inhibitor of CYP2D6, but not of CYP1A2, CYP2C9, CYP2C19, and CYP3A4."
cinacalcet_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/18	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions
....

Midazolam: There were no significant differences in the pharmacokinetics of midazolam, a CYP3A4 and CYP3A5 substrate, in subjects receiving 90 mg cinacalcet once daily for 5 days and a single dose of 2 mg midazolam on day 5 as compared to those of subjects receiving 2 mg midazolam alone.  This suggests that cinacalcet would not affect the pharmacokinetics of drugs predominantly metabolized by CYP3A4 and CYP3A5."
cinacalcet_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/19	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions
...
An in vitro study indicates that cinacalcet is a strong inhibitor of CYP2D6, but not of CYP1A2, CYP2C9, CYP2C19, and CYP3A4."
cinacalcet_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/18	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions
....

Midazolam: There were no significant differences in the pharmacokinetics of midazolam, a CYP3A4 and CYP3A5 substrate, in subjects receiving 90 mg cinacalcet once daily for 5 days and a single dose of 2 mg midazolam on day 5 as compared to those of subjects receiving 2 mg midazolam alone.  This suggests that cinacalcet would not affect the pharmacokinetics of drugs predominantly metabolized by CYP3A4 and CYP3A5."
cinacalcet_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/19	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/45028573-13c4-4c8b-ae62-6c75bba97c81	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions
...
An in vitro study indicates that cinacalcet is a strong inhibitor of CYP2D6, but not of CYP1A2, CYP2C9, CYP2C19, and CYP3A4."
aripiprazole_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006118	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_inhibits_cyp2c19.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/40	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.
aripiprazole_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006118	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_inhibits_cyp2c19.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/40	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.
aripiprazole_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006118	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_inhibits_cyp2c19.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/40	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes. In in vivo studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.
venlafaxine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/58	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	CYP3A4: Venlafaxine did not inhibit CYP3A4 in vitro. This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.
venlafaxine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp3a4.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/59	refute	http://www.ncbi.nlm.nih.gov/pubmed/9205822	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

reaction: testosterone 6beta hydroxylation

Quote: 
The IC50 for venlafaxine's inhibition of the reaction was &gt; 1000micM "
venlafaxine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/58	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	CYP3A4: Venlafaxine did not inhibit CYP3A4 in vitro. This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.
venlafaxine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp3a4.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/59	refute	http://www.ncbi.nlm.nih.gov/pubmed/9205822	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

reaction: testosterone 6beta hydroxylation

Quote: 
The IC50 for venlafaxine's inhibition of the reaction was &gt; 1000micM "
venlafaxine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/58	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/cf2d9bee-f8e3-477a-e4b4-f0e82657b7d2	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	CYP3A4: Venlafaxine did not inhibit CYP3A4 in vitro. This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine.
venlafaxine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp3a4.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/59	refute	http://www.ncbi.nlm.nih.gov/pubmed/9205822	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

reaction: testosterone 6beta hydroxylation

Quote: 
The IC50 for venlafaxine's inhibition of the reaction was &gt; 1000micM "
duloxetine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/73	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.11 Drugs Metabolized by CYP3A

Results of in vitro studies demonstrate that duloxetine does not inhibit or induce CYP3A activity. Therefore, an increase or decrease in the metabolism of CYP3A substrates (e.g., oral contraceptives and other steroidal agents) resulting from induction or inhibition is not anticipated, although clinical studies have not been performed. "
duloxetine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/73	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.11 Drugs Metabolized by CYP3A

Results of in vitro studies demonstrate that duloxetine does not inhibit or induce CYP3A activity. Therefore, an increase or decrease in the metabolism of CYP3A substrates (e.g., oral contraceptives and other steroidal agents) resulting from induction or inhibition is not anticipated, although clinical studies have not been performed. "
duloxetine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/73	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.11 Drugs Metabolized by CYP3A

Results of in vitro studies demonstrate that duloxetine does not inhibit or induce CYP3A activity. Therefore, an increase or decrease in the metabolism of CYP3A substrates (e.g., oral contraceptives and other steroidal agents) resulting from induction or inhibition is not anticipated, although clinical studies have not been performed. "
quetiapine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp3a4.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/91	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.
quetiapine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp3a4.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/91	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.
quetiapine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp3a4.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/91	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.
celecoxib_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/94	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug interactions:

In vitro studies indicate that celecoxib is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4."
celecoxib_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/94	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug interactions:

In vitro studies indicate that celecoxib is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4."
celecoxib_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/94	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/8d52185d-421f-4e34-8db7-f7676db2a226	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug interactions:

In vitro studies indicate that celecoxib is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4."
quetiapine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006118	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp2c19.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/98	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.
quetiapine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006118	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp2c19.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/98	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.
quetiapine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006118	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp2c19.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/98	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/473a3ac4-67f4-4782-baa9-7f9bdd8761f4	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes P450 1A2, 2C9, 2C19, 2D6 and 3A4.
zafirlukast_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_inhibits_cyp3a4.html	DIKB				refute			
zafirlukast_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_inhibits_cyp3a4.html	DIKB				refute			
zafirlukast_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_inhibits_cyp3a4.html	DIKB				refute			
perphenazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006118	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_inhibits_cyp2c19.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/111	refute	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
perphenazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006118	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_inhibits_cyp2c19.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/111	refute	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
perphenazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006118	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_inhibits_cyp2c19.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/111	refute	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
ranolazine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00243	http://purl.obolibrary.org/obo/PR_000006121	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ranolazine_inhibits_cyp2d6.html	DIKB				refute			
ranolazine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00243	http://purl.obolibrary.org/obo/PR_000006121	R-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ranolazine_inhibits_cyp2d6.html	DIKB				refute			
ranolazine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00243	http://purl.obolibrary.org/obo/PR_000006121	S-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ranolazine_inhibits_cyp2d6.html	DIKB				refute			
atorvastatin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_inhibits_cyp3a4.html	DIKB				refute			
atorvastatin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_inhibits_cyp3a4.html	DIKB				refute			
atorvastatin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_inhibits_cyp3a4.html	DIKB				refute			
eszopiclone_inhibits_CYP1A2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006102	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP1A2.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/147	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes."
eszopiclone_inhibits_CYP1A2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006102	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP1A2.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/147	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes."
eszopiclone_inhibits_CYP1A2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006102	R-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP1A2.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/147	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes."
eszopiclone_inhibits_CYP1A2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006102	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP1A2.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/147	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes."
eszopiclone_inhibits_CYP1A2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006102	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP1A2.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/147	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes."
eszopiclone_inhibits_CYP1A2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006102	S-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP1A2.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/147	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes."
mirtazapine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006120	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_inhibits_cyp2c9.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/152	refute	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

substrate used: tolbutamide

reaction: tolbutamide hydroxylation 

Quote: 
Mirtazapine reduced the rate of the reaction by much less than 50% even at concentrations of 250micM (see Table 3).


"
mirtazapine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006120	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_inhibits_cyp2c9.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/152	refute	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

substrate used: tolbutamide

reaction: tolbutamide hydroxylation 

Quote: 
Mirtazapine reduced the rate of the reaction by much less than 50% even at concentrations of 250micM (see Table 3).


"
mirtazapine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006120	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_inhibits_cyp2c9.html	DIKB	02132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/152	refute	http://www.ncbi.nlm.nih.gov/pubmed/10997935	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

substrate used: tolbutamide

reaction: tolbutamide hydroxylation 

Quote: 
Mirtazapine reduced the rate of the reaction by much less than 50% even at concentrations of 250micM (see Table 3).


"
thioridazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00679	http://purl.obolibrary.org/obo/PR_000006118	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/thioridazine_inhibits_cyp2c19.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/201	refute	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
thioridazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00679	http://purl.obolibrary.org/obo/PR_000006118	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/thioridazine_inhibits_cyp2c19.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/201	refute	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
thioridazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00679	http://purl.obolibrary.org/obo/PR_000006118	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/thioridazine_inhibits_cyp2c19.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/201	refute	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
ritonavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp3a4.html	DIKB				refute			
ritonavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp3a4.html	DIKB				refute			
ritonavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp3a4.html	DIKB				refute			
chlorpromazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00477	http://purl.obolibrary.org/obo/PR_000006118	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/chlorpromazine_inhibits_cyp2c19.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/214	refute	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
chlorpromazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00477	http://purl.obolibrary.org/obo/PR_000006118	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/chlorpromazine_inhibits_cyp2c19.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/214	refute	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
chlorpromazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00477	http://purl.obolibrary.org/obo/PR_000006118	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/chlorpromazine_inhibits_cyp2c19.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/214	refute	http://www.ncbi.nlm.nih.gov/pubmed/10460810	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"Enzyme system: human liver microsomes

NADPH added: yes

reaction: omeprazole-5-hydroxylation

No k_i observed"
duloxetine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006120	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp2c9.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/215	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.10 Drugs Metabolized by CYP2C9

Duloxetine does not inhibit the in vitro enzyme activity of CYP2C9. Inhibition of the metabolism of CYP2C9 substrates is therefore not anticipated, although clinical studies have not been performed."
duloxetine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006120	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp2c9.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/215	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.10 Drugs Metabolized by CYP2C9

Duloxetine does not inhibit the in vitro enzyme activity of CYP2C9. Inhibition of the metabolism of CYP2C9 substrates is therefore not anticipated, although clinical studies have not been performed."
duloxetine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006120	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp2c9.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/215	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.10 Drugs Metabolized by CYP2C9

Duloxetine does not inhibit the in vitro enzyme activity of CYP2C9. Inhibition of the metabolism of CYP2C9 substrates is therefore not anticipated, although clinical studies have not been performed."
lansoprazole_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00448	http://purl.obolibrary.org/obo/PR_000006121	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lansoprazole_inhibits_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/224	refute	http://www.ncbi.nlm.nih.gov/pubmed/15258107	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

substrate used: bufuralol

reaction: bufuralol 1'hydroxylation

IC50 &gt; 200micM (see Table 3)

Quote:
CYP2D6 Activity. No significant effects on the formation of 1 -hydroxylated bufuralol (CYP2D6) were found, indicating that none of the five PPIs [including omeprazole, lansoprazole, pantoprazole rameprazole and esomeprazole] inhibited CYP2D6 activity in vitro (IC50 200micM). However, rabeprazole thioether inhibited CYP2D6 activity with a Ki of 12micM in HLM. "
lansoprazole_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00448	http://purl.obolibrary.org/obo/PR_000006121	R-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lansoprazole_inhibits_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/224	refute	http://www.ncbi.nlm.nih.gov/pubmed/15258107	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

substrate used: bufuralol

reaction: bufuralol 1'hydroxylation

IC50 &gt; 200micM (see Table 3)

Quote:
CYP2D6 Activity. No significant effects on the formation of 1 -hydroxylated bufuralol (CYP2D6) were found, indicating that none of the five PPIs [including omeprazole, lansoprazole, pantoprazole rameprazole and esomeprazole] inhibited CYP2D6 activity in vitro (IC50 200micM). However, rabeprazole thioether inhibited CYP2D6 activity with a Ki of 12micM in HLM. "
lansoprazole_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00448	http://purl.obolibrary.org/obo/PR_000006121	S-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lansoprazole_inhibits_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/224	refute	http://www.ncbi.nlm.nih.gov/pubmed/15258107	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

substrate used: bufuralol

reaction: bufuralol 1'hydroxylation

IC50 &gt; 200micM (see Table 3)

Quote:
CYP2D6 Activity. No significant effects on the formation of 1 -hydroxylated bufuralol (CYP2D6) were found, indicating that none of the five PPIs [including omeprazole, lansoprazole, pantoprazole rameprazole and esomeprazole] inhibited CYP2D6 activity in vitro (IC50 200micM). However, rabeprazole thioether inhibited CYP2D6 activity with a Ki of 12micM in HLM. "
atomoxetine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00289	http://purl.obolibrary.org/obo/PR_000006102	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atomoxetine_inhibits_cyp1a2.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/227	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.5  Effect of Atomoxetine on P450 Enzymes

Atomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9."
atomoxetine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00289	http://purl.obolibrary.org/obo/PR_000006102	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atomoxetine_inhibits_cyp1a2.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/227	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.5  Effect of Atomoxetine on P450 Enzymes

Atomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9."
atomoxetine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00289	http://purl.obolibrary.org/obo/PR_000006102	R-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atomoxetine_inhibits_cyp1a2.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/227	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.5  Effect of Atomoxetine on P450 Enzymes

Atomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9."
atomoxetine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00289	http://purl.obolibrary.org/obo/PR_000006102	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atomoxetine_inhibits_cyp1a2.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/227	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.5  Effect of Atomoxetine on P450 Enzymes

Atomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9."
atomoxetine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00289	http://purl.obolibrary.org/obo/PR_000006102	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atomoxetine_inhibits_cyp1a2.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/227	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.5  Effect of Atomoxetine on P450 Enzymes

Atomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9."
atomoxetine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00289	http://purl.obolibrary.org/obo/PR_000006102	S-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atomoxetine_inhibits_cyp1a2.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/227	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/309de576-c318-404a-bc15-660c2b1876fb	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.5  Effect of Atomoxetine on P450 Enzymes

Atomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9."
rosiglitazone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006120	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2c9.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/228	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.
rosiglitazone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006120	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2c9.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/228	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.
rosiglitazone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006120	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2c9.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/228	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/ec682aec-e98f-41a1-9d21-eb7580ea3a8a	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	In vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations.
montelukast_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/238	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).
montelukast_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/238	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).
montelukast_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/238	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).
montelukast_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006118	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp2c19.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/246	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).
montelukast_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006118	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp2c19.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/246	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).
montelukast_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006118	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp2c19.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/246	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/a99f55de-39d1-483a-ba88-dbda5613c6a7	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme (see Drug Interactions).
verapamil_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00661	http://purl.obolibrary.org/obo/PR_000006102	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/verapamil_inhibits_cyp1a2.html	DIKB				refute			
verapamil_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00661	http://purl.obolibrary.org/obo/PR_000006102	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/verapamil_inhibits_cyp1a2.html	DIKB				refute			
verapamil_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00661	http://purl.obolibrary.org/obo/PR_000006102	R-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/verapamil_inhibits_cyp1a2.html	DIKB				refute			
verapamil_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00661	http://purl.obolibrary.org/obo/PR_000006102	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/verapamil_inhibits_cyp1a2.html	DIKB				refute			
verapamil_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00661	http://purl.obolibrary.org/obo/PR_000006102	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/verapamil_inhibits_cyp1a2.html	DIKB				refute			
verapamil_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00661	http://purl.obolibrary.org/obo/PR_000006102	S-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/verapamil_inhibits_cyp1a2.html	DIKB				refute			
eszopiclone_inhibits_CYP3A4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP3A4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/255	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes."
eszopiclone_inhibits_CYP3A4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP3A4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/255	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes."
eszopiclone_inhibits_CYP3A4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP3A4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/255	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/fd047b2b-05a6-4d99-95cb-955f14bf329f	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor. In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone. Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes."
paliperidone_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp3a4.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/266	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.
paliperidone_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp3a4.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/266	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.
paliperidone_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp3a4.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/266	refute	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/page/structuredProductLabelMetadata/7b8e5b26-b9e4-4704-921b-3c3c0d159916	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.
propafenone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01182	http://purl.obolibrary.org/obo/PR_000006102	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/propafenone_inhibits_cyp1a2.html	DIKB				refute			
propafenone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01182	http://purl.obolibrary.org/obo/PR_000006102	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/propafenone_inhibits_cyp1a2.html	DIKB				refute			
propafenone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01182	http://purl.obolibrary.org/obo/PR_000006102	R-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/propafenone_inhibits_cyp1a2.html	DIKB				refute			
propafenone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01182	http://purl.obolibrary.org/obo/PR_000006102	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/propafenone_inhibits_cyp1a2.html	DIKB				refute			
propafenone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01182	http://purl.obolibrary.org/obo/PR_000006102	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/propafenone_inhibits_cyp1a2.html	DIKB				refute			
propafenone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01182	http://purl.obolibrary.org/obo/PR_000006102	S-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/propafenone_inhibits_cyp1a2.html	DIKB				refute			
pantoprazole_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00213	http://purl.obolibrary.org/obo/PR_000006121	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/pantoprazole_inhibits_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/279	refute	http://www.ncbi.nlm.nih.gov/pubmed/15258107	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

substrate used: bufuralol

reaction: bufuralol 1'hydroxylation

IC50 &gt; 200micM (see Table 3)

Quote:
CYP2D6 Activity. No significant effects on the formation of 1 -hydroxylated bufuralol (CYP2D6) were found, indicating that none of the five PPIs [including omeprazole, lansoprazole, pantoprazole rameprazole and esomeprazole] inhibited CYP2D6 activity in vitro (IC50 200micM). However, rabeprazole thioether inhibited CYP2D6 activity with a Ki of 12micM in HLM. "
pantoprazole_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00213	http://purl.obolibrary.org/obo/PR_000006121	R-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/pantoprazole_inhibits_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/279	refute	http://www.ncbi.nlm.nih.gov/pubmed/15258107	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

substrate used: bufuralol

reaction: bufuralol 1'hydroxylation

IC50 &gt; 200micM (see Table 3)

Quote:
CYP2D6 Activity. No significant effects on the formation of 1 -hydroxylated bufuralol (CYP2D6) were found, indicating that none of the five PPIs [including omeprazole, lansoprazole, pantoprazole rameprazole and esomeprazole] inhibited CYP2D6 activity in vitro (IC50 200micM). However, rabeprazole thioether inhibited CYP2D6 activity with a Ki of 12micM in HLM. "
pantoprazole_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00213	http://purl.obolibrary.org/obo/PR_000006121	S-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/pantoprazole_inhibits_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/279	refute	http://www.ncbi.nlm.nih.gov/pubmed/15258107	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_EX_Met_Enz_Inhibit_Cyp450_Hum_Microsome	"
Enzyme system: human liver microsomes:

NADPH added: yes

substrate used: bufuralol

reaction: bufuralol 1'hydroxylation

IC50 &gt; 200micM (see Table 3)

Quote:
CYP2D6 Activity. No significant effects on the formation of 1 -hydroxylated bufuralol (CYP2D6) were found, indicating that none of the five PPIs [including omeprazole, lansoprazole, pantoprazole rameprazole and esomeprazole] inhibited CYP2D6 activity in vitro (IC50 200micM). However, rabeprazole thioether inhibited CYP2D6 activity with a Ki of 12micM in HLM. "
modafinil_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00745	http://purl.obolibrary.org/obo/PR_000006118	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/modafinil_inhibits_cyp2c19.html	DIKB				refute			
cinacalcet_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp3a4.html	DIKB				support			
cinacalcet_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp3a4.html	DIKB				support			
cinacalcet_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01012	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/cinacalcet_inhibits_cyp3a4.html	DIKB				support			
aripiprazole_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006118	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_inhibits_cyp2c19.html	DIKB				support			
aripiprazole_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006118	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_inhibits_cyp2c19.html	DIKB				support			
aripiprazole_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01238	http://purl.obolibrary.org/obo/PR_000006118	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/aripiprazole_inhibits_cyp2c19.html	DIKB				support			
venlafaxine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp3a4.html	DIKB				support			
venlafaxine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp3a4.html	DIKB				support			
venlafaxine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00285	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/venlafaxine_inhibits_cyp3a4.html	DIKB				support			
duloxetine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp3a4.html	DIKB				support			
duloxetine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp3a4.html	DIKB				support			
duloxetine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp3a4.html	DIKB				support			
quetiapine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp3a4.html	DIKB				support			
quetiapine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp3a4.html	DIKB				support			
quetiapine_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp3a4.html	DIKB				support			
celecoxib_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp3a4.html	DIKB				support			
celecoxib_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp3a4.html	DIKB				support			
celecoxib_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00482	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/celecoxib_inhibits_cyp3a4.html	DIKB				support			
quetiapine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006118	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp2c19.html	DIKB				support			
quetiapine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006118	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp2c19.html	DIKB				support			
quetiapine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01224	http://purl.obolibrary.org/obo/PR_000006118	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/quetiapine_inhibits_cyp2c19.html	DIKB				support			
zafirlukast_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_inhibits_cyp3a4.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/104	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5550433b-8c9c-4378-058f-6bb724c4f18c	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Zafirlukast is extensively metabolized. The most common metabolic products are hydroxylated metabolites which are excreted in the feces. The metabolites of zafirlukast identified in plasma are at least 90 times less potent as LTD4 receptor antagonists than zafirlukast in a standard in vitro test of activity. In vitro studies using human liver microsomes showed that the hydroxylated metabolites of zafirlukast excreted in the feces are formed through the cytochrome P450 2C9 (CYP2C9) pathway. Additional in vitro studies utilizing human liver microsomes show that zafirlukast inhibits the cytochrome P450 CYP3A4 and CYP2C9 isoenzymes at concentrations close to the clinically achieved total plasma concentrations"
zafirlukast_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_inhibits_cyp3a4.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/104	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5550433b-8c9c-4378-058f-6bb724c4f18c	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Zafirlukast is extensively metabolized. The most common metabolic products are hydroxylated metabolites which are excreted in the feces. The metabolites of zafirlukast identified in plasma are at least 90 times less potent as LTD4 receptor antagonists than zafirlukast in a standard in vitro test of activity. In vitro studies using human liver microsomes showed that the hydroxylated metabolites of zafirlukast excreted in the feces are formed through the cytochrome P450 2C9 (CYP2C9) pathway. Additional in vitro studies utilizing human liver microsomes show that zafirlukast inhibits the cytochrome P450 CYP3A4 and CYP2C9 isoenzymes at concentrations close to the clinically achieved total plasma concentrations"
zafirlukast_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00549	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/zafirlukast_inhibits_cyp3a4.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/104	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/5550433b-8c9c-4378-058f-6bb724c4f18c	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Metabolism

Zafirlukast is extensively metabolized. The most common metabolic products are hydroxylated metabolites which are excreted in the feces. The metabolites of zafirlukast identified in plasma are at least 90 times less potent as LTD4 receptor antagonists than zafirlukast in a standard in vitro test of activity. In vitro studies using human liver microsomes showed that the hydroxylated metabolites of zafirlukast excreted in the feces are formed through the cytochrome P450 2C9 (CYP2C9) pathway. Additional in vitro studies utilizing human liver microsomes show that zafirlukast inhibits the cytochrome P450 CYP3A4 and CYP2C9 isoenzymes at concentrations close to the clinically achieved total plasma concentrations"
perphenazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006118	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_inhibits_cyp2c19.html	DIKB				support			
perphenazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006118	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_inhibits_cyp2c19.html	DIKB				support			
perphenazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00850	http://purl.obolibrary.org/obo/PR_000006118	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/perphenazine_inhibits_cyp2c19.html	DIKB				support			
ranolazine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00243	http://purl.obolibrary.org/obo/PR_000006121	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ranolazine_inhibits_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/120	support	http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10bd89e9-2d00-430c-8f55-81a37fed5fab	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.2 Effects of Ranolazine on Other Drugs

In vitro studies indicate that ranolazine and its O-demethylated metabolite are weak inhibitors of CYP3A, moderate inhibitors of CYP2D6 and moderate P-gp inhibitors. "
ranolazine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00243	http://purl.obolibrary.org/obo/PR_000006121	R-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ranolazine_inhibits_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/120	support	http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10bd89e9-2d00-430c-8f55-81a37fed5fab	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.2 Effects of Ranolazine on Other Drugs

In vitro studies indicate that ranolazine and its O-demethylated metabolite are weak inhibitors of CYP3A, moderate inhibitors of CYP2D6 and moderate P-gp inhibitors. "
ranolazine_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00243	http://purl.obolibrary.org/obo/PR_000006121	S-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ranolazine_inhibits_cyp2d6.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/120	support	http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10bd89e9-2d00-430c-8f55-81a37fed5fab	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"7.2 Effects of Ranolazine on Other Drugs

In vitro studies indicate that ranolazine and its O-demethylated metabolite are weak inhibitors of CYP3A, moderate inhibitors of CYP2D6 and moderate P-gp inhibitors. "
atorvastatin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_inhibits_cyp3a4.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/127	support	http://www.ncbi.nlm.nih.gov/pubmed/12911366	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_Par_Grps	"
Route of administration: oral

polymorphic enzyme: no

study duration: this was a matched pair study; 7 patients already take atorvastatin were matched with patients who were not taking atorvastatin or any other known CYP3A4 inhibitor. Of the patients taking atorvastatin, 5 were on 10mg/day, 1 on 20mg/day, and one on 40mg/day. All patient's received a .25mg/kg bolus of IV midazolam.

population: 14 individuals; 10 male, 4 female

ages: generally older ~61 (unfortunately ages given in mean/std dev)

AUC_i/AUC of midazolam: 889.4/629.1=1.41


"
atorvastatin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_inhibits_cyp3a4.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/127	support	http://www.ncbi.nlm.nih.gov/pubmed/12911366	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_Par_Grps	"
Route of administration: oral

polymorphic enzyme: no

study duration: this was a matched pair study; 7 patients already take atorvastatin were matched with patients who were not taking atorvastatin or any other known CYP3A4 inhibitor. Of the patients taking atorvastatin, 5 were on 10mg/day, 1 on 20mg/day, and one on 40mg/day. All patient's received a .25mg/kg bolus of IV midazolam.

population: 14 individuals; 10 male, 4 female

ages: generally older ~61 (unfortunately ages given in mean/std dev)

AUC_i/AUC of midazolam: 889.4/629.1=1.41


"
atorvastatin_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01076	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atorvastatin_inhibits_cyp3a4.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/127	support	http://www.ncbi.nlm.nih.gov/pubmed/12911366	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#EV_PK_DDI_Par_Grps	"
Route of administration: oral

polymorphic enzyme: no

study duration: this was a matched pair study; 7 patients already take atorvastatin were matched with patients who were not taking atorvastatin or any other known CYP3A4 inhibitor. Of the patients taking atorvastatin, 5 were on 10mg/day, 1 on 20mg/day, and one on 40mg/day. All patient's received a .25mg/kg bolus of IV midazolam.

population: 14 individuals; 10 male, 4 female

ages: generally older ~61 (unfortunately ages given in mean/std dev)

AUC_i/AUC of midazolam: 889.4/629.1=1.41


"
eszopiclone_inhibits_CYP1A2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006102	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP1A2.html	DIKB				support			
eszopiclone_inhibits_CYP1A2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006102	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP1A2.html	DIKB				support			
eszopiclone_inhibits_CYP1A2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006102	R-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP1A2.html	DIKB				support			
eszopiclone_inhibits_CYP1A2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006102	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP1A2.html	DIKB				support			
eszopiclone_inhibits_CYP1A2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006102	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP1A2.html	DIKB				support			
eszopiclone_inhibits_CYP1A2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006102	S-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP1A2.html	DIKB				support			
mirtazapine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006120	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_inhibits_cyp2c9.html	DIKB				support			
mirtazapine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006120	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_inhibits_cyp2c9.html	DIKB				support			
mirtazapine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370	http://purl.obolibrary.org/obo/PR_000006120	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/mirtazapine_inhibits_cyp2c9.html	DIKB				support			
thioridazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00679	http://purl.obolibrary.org/obo/PR_000006118	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/thioridazine_inhibits_cyp2c19.html	DIKB				support			
thioridazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00679	http://purl.obolibrary.org/obo/PR_000006118	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/thioridazine_inhibits_cyp2c19.html	DIKB				support			
thioridazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00679	http://purl.obolibrary.org/obo/PR_000006118	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/thioridazine_inhibits_cyp2c19.html	DIKB				support			
ritonavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/203	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19'
ritonavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/204	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2849298e-de6e-47bb-8194-56e075b33fc3	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions

Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) both in vitro and in vivo. Ritonavir also inhibits CYP2D6 in vitro, but to a lesser extent than CYP3A. Co-administration of ritonavir and drugs primarily metabolized by CYP3A or CYP2D6 may result in increased plasma concentrations of other drugs that could increase or prolong its therapeutic and adverse effects "
ritonavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/205	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2849298e-de6e-47bb-8194-56e075b33fc3	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Table 3 shows that the AUC of sildenafil increased 11-fold in the presence of ritonavir
ritonavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/203	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19'
ritonavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/204	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2849298e-de6e-47bb-8194-56e075b33fc3	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions

Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) both in vitro and in vivo. Ritonavir also inhibits CYP2D6 in vitro, but to a lesser extent than CYP3A. Co-administration of ritonavir and drugs primarily metabolized by CYP3A or CYP2D6 may result in increased plasma concentrations of other drugs that could increase or prolong its therapeutic and adverse effects "
ritonavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/205	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2849298e-de6e-47bb-8194-56e075b33fc3	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Table 3 shows that the AUC of sildenafil increased 11-fold in the presence of ritonavir
ritonavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/203	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	'The FDA recommends this as a CYP3A4/5 inhibitor for in vivo studies in it most recent guidance document. See Table 2, p. 19'
ritonavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/204	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2849298e-de6e-47bb-8194-56e075b33fc3	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions

Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) both in vitro and in vivo. Ritonavir also inhibits CYP2D6 in vitro, but to a lesser extent than CYP3A. Co-administration of ritonavir and drugs primarily metabolized by CYP3A or CYP2D6 may result in increased plasma concentrations of other drugs that could increase or prolong its therapeutic and adverse effects "
ritonavir_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00503	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/ritonavir_inhibits_cyp3a4.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/205	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/2849298e-de6e-47bb-8194-56e075b33fc3	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	Table 3 shows that the AUC of sildenafil increased 11-fold in the presence of ritonavir
chlorpromazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00477	http://purl.obolibrary.org/obo/PR_000006118	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/chlorpromazine_inhibits_cyp2c19.html	DIKB				support			
chlorpromazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00477	http://purl.obolibrary.org/obo/PR_000006118	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/chlorpromazine_inhibits_cyp2c19.html	DIKB				support			
chlorpromazine_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00477	http://purl.obolibrary.org/obo/PR_000006118	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/chlorpromazine_inhibits_cyp2c19.html	DIKB				support			
duloxetine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006120	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp2c9.html	DIKB				support			
duloxetine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006120	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp2c9.html	DIKB				support			
duloxetine_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00476	http://purl.obolibrary.org/obo/PR_000006120	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/duloxetine_inhibits_cyp2c9.html	DIKB				support			
lansoprazole_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00448	http://purl.obolibrary.org/obo/PR_000006121	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lansoprazole_inhibits_cyp2d6.html	DIKB				support			
lansoprazole_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00448	http://purl.obolibrary.org/obo/PR_000006121	R-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lansoprazole_inhibits_cyp2d6.html	DIKB				support			
lansoprazole_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00448	http://purl.obolibrary.org/obo/PR_000006121	S-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/lansoprazole_inhibits_cyp2d6.html	DIKB				support			
atomoxetine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00289	http://purl.obolibrary.org/obo/PR_000006102	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atomoxetine_inhibits_cyp1a2.html	DIKB				support			
atomoxetine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00289	http://purl.obolibrary.org/obo/PR_000006102	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atomoxetine_inhibits_cyp1a2.html	DIKB				support			
atomoxetine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00289	http://purl.obolibrary.org/obo/PR_000006102	R-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atomoxetine_inhibits_cyp1a2.html	DIKB				support			
atomoxetine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00289	http://purl.obolibrary.org/obo/PR_000006102	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atomoxetine_inhibits_cyp1a2.html	DIKB				support			
atomoxetine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00289	http://purl.obolibrary.org/obo/PR_000006102	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atomoxetine_inhibits_cyp1a2.html	DIKB				support			
atomoxetine_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00289	http://purl.obolibrary.org/obo/PR_000006102	S-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/atomoxetine_inhibits_cyp1a2.html	DIKB				support			
rosiglitazone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006120	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2c9.html	DIKB				support			
rosiglitazone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006120	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2c9.html	DIKB				support			
rosiglitazone_inhibits_cyp2c9	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00412	http://purl.obolibrary.org/obo/PR_000006120	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/rosiglitazone_inhibits_cyp2c9.html	DIKB				support			
montelukast_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp3a4.html	DIKB				support			
montelukast_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp3a4.html	DIKB				support			
montelukast_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp3a4.html	DIKB				support			
montelukast_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006118	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp2c19.html	DIKB				support			
montelukast_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006118	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp2c19.html	DIKB				support			
montelukast_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00471	http://purl.obolibrary.org/obo/PR_000006118	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/montelukast_inhibits_cyp2c19.html	DIKB				support			
verapamil_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00661	http://purl.obolibrary.org/obo/PR_000006102	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/verapamil_inhibits_cyp1a2.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/254	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;weak&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23
verapamil_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00661	http://purl.obolibrary.org/obo/PR_000006102	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/verapamil_inhibits_cyp1a2.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/254	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;weak&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23
verapamil_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00661	http://purl.obolibrary.org/obo/PR_000006102	R-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/verapamil_inhibits_cyp1a2.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/254	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;weak&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23
verapamil_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00661	http://purl.obolibrary.org/obo/PR_000006102	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/verapamil_inhibits_cyp1a2.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/254	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;weak&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23
verapamil_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00661	http://purl.obolibrary.org/obo/PR_000006102	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/verapamil_inhibits_cyp1a2.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/254	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;weak&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23
verapamil_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00661	http://purl.obolibrary.org/obo/PR_000006102	S-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/verapamil_inhibits_cyp1a2.html	DIKB	01132010	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/254	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;weak&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23
eszopiclone_inhibits_CYP3A4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP3A4.html	DIKB				support			
eszopiclone_inhibits_CYP3A4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP3A4.html	DIKB				support			
eszopiclone_inhibits_CYP3A4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00402	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/eszopiclone_inhibits_CYP3A4.html	DIKB				support			
paliperidone_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006130	beta-hydroxy-simvastatin	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp3a4.html	DIKB				support			
paliperidone_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006130	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp3a4.html	DIKB				support			
paliperidone_inhibits_cyp3a4	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01267	http://purl.obolibrary.org/obo/PR_000006130	demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/paliperidone_inhibits_cyp3a4.html	DIKB				support			
propafenone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01182	http://purl.obolibrary.org/obo/PR_000006102	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/propafenone_inhibits_cyp1a2.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/268	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;moderate&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23
propafenone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01182	http://purl.obolibrary.org/obo/PR_000006102	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/propafenone_inhibits_cyp1a2.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/268	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;moderate&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23
propafenone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01182	http://purl.obolibrary.org/obo/PR_000006102	R-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/propafenone_inhibits_cyp1a2.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/268	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;moderate&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23
propafenone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01182	http://purl.obolibrary.org/obo/PR_000006102	S-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/propafenone_inhibits_cyp1a2.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/268	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;moderate&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23
propafenone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01182	http://purl.obolibrary.org/obo/PR_000006102	dehydro-aripiprazole	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/propafenone_inhibits_cyp1a2.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/268	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;moderate&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23
propafenone_inhibits_cyp1a2	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB01182	http://purl.obolibrary.org/obo/PR_000006102	S-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/propafenone_inhibits_cyp1a2.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/268	support	http://dl.dropbox.com/u/4516186/FDA-Guidance-Drug-Interaction-Studies%E2%80%93Study%20Design-Data-Analysis-and-Implications-2006.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_Tracable_Statement	The FDA notes that this is a &quot;moderate&quot; CYP1A2 inhibitor in vivo in it most recent guidance document. See Table 6, p23
pantoprazole_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00213	http://purl.obolibrary.org/obo/PR_000006121	N-desalkylquetiapine	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/pantoprazole_inhibits_cyp2d6.html	DIKB				support			
pantoprazole_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00213	http://purl.obolibrary.org/obo/PR_000006121	R-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/pantoprazole_inhibits_cyp2d6.html	DIKB				support			
pantoprazole_inhibits_cyp2d6	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00213	http://purl.obolibrary.org/obo/PR_000006121	S-didemethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/pantoprazole_inhibits_cyp2d6.html	DIKB				support			
modafinil_inhibits_cyp2c19	inhibits	http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00745	http://purl.obolibrary.org/obo/PR_000006118	R-demethylcitalopram	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/modafinil_inhibits_cyp2c19.html	DIKB	12172009	boycer	https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/282	support	http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/e16c26ad-7bc2-d155-3a5d-da83ad6492c8.pdf	http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/DIKB_evidence_ontology_v1.3.owl#Non_traceable_Drug_Label_Statement	"Drug Interactions
...
In vitro studies using human liver microsomes showed that modafinil reversibly inhibited CYP2C19 at pharmacologically relevant concentrations of modafinil. CYP2C19 is also reversibly inhibited, with similar potency, by a circulating metabolite, modafinil sulfone. Although the maximum plasma concentrations of modafinil sulfone are much lower than those of parent modafinil, the combined effect of both compounds could produce sustained partial inhibition of the enzyme. Drugs that are largely eliminated via CYP2C19 metabolism, such as diazepam, propranolol, phenytoin (also via CYP2C9) or S-mephenytoin may have prolonged elimination upon coadministration with PROVIGIL and may require dosage reduction and monitoring for toxicity."
